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ABSTRACT
In vivo reflectance and fluorescence spectra were collected from patients with oral
lesions, as well as healthy volunteers, in order to evaluate the potential of spectroscopy to
serve as a non-invasive tool for the detection oral cancer. A total of 710 spectra were
analyzed from 79 healthy volunteers, and 87 spectra from 67 patients. Physical models
were applied to the measured spectral data in order to extract quantitative parameters
relating to the structural and biochemical properties of the tissue. Data collected from
healthy volunteers were used to characterize the relationship between the spectral
parameters and tissue anatomy. Diagnostic algorithms for distinguishing various lesion
categories were then developed using data collected from patients.
The healthy volunteer study demonstrated that tissue anatomy has a strong influence on
the spectral parameters. Anatomic sites could be easily distinguished from each other
despite the apparent overlap in their parameter distributions. In particular, keratinized
sites (gingiva and hard palate) were significantly distinct from other anatomic sites. The
results of this study provide strong evidence that a robust and accurate spectroscopic-
based diagnostic algorithm for oral cancer needs to be applied in a site specific manner.
Spectral diagnostic algorithms were developed using the data collected from patients, in
combination with the data collected from healthy volunteers. The diagnostic performance
of the algorithms was evaluated using the area under a receiver operator characteristic
curve (ROC-AUC) and the sensitivity and specificity. The diagnostic algorithms were
most successful when developed and applied to data collected from a single anatomic site
or spectrally similar sites, and when distinguishing visibly normal mucosa from lesions.
ROC-AUC values of >0.90 could be achieved for this classification. Spectral algorithms
for distinguishing benign lesions from dysplastic/malignant lesions were successfully
created for the lateral surface of the tongue (ROC-AUC =0.75) and for the combination
of the floor of the mouth and ventral tongue (ROC-AUC =0.71).
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CHAPTER 1: Overview
CHAPTER 1
Overview
In this chapter we present the epidemiology of oral cancer and how it is currently
detected, and then discuss how optical spectroscopy can impact this medical
challenge. We then detail the specific goals of this project and conclude with a
description of the organization and contents of this thesis.
CHAPTER 1: Overview
1.1 Oral Cancer
1.1.1 Epidemiology of Oral Cancer
In the United States, cancers of the oral cavity and oropharynx account for
approximately 3% of all malignancies in males, and 2% in females'. It is estimated
that 35,310 new cases of oral/pharyngeal cancer will be diagnosed in 2008, and 7,590
people will die of this disease2. Of these cases, approximately 46% are oral cancers
and 54% are pharyngeal/throat cancers3. Oral/pharyngeal cancer is most commonly
diagnosed in persons over the age of 45 years old. The median age of diagnosis is 62
years old4. Men have a higher risk than women (2:1) for developing oral cancer and
the incidence of oral and pharyngeal cancer tends to be higher among African
Americans than among whites5.
Tobacco and alcohol are well-established risk factors for oral cancer, and the
major cause for this disease in the United States. They are estimated to account for
approximately three-fourths of all oral and pharyngeal cancers in the United States6.
In one case-control study, the relative risk in current tobacco users was found to be
6.5 as compared to controls, but with cessation gradually reduced to a comparable
level after 20 years7. A synergistic effect between smoking and alcohol consumption
results in an increased risk for oral cancer, as opposed to smoking alone8 . Poor
dentition, dietary deficiencies, and human papilloma virus (HPV) infection have also
been suggested as possible causes, although there is little definitive support.
Considerable outdoor activity and resulting exposure to actinic radiation (sunlight),
has been implicated in particular for cancer of the lip.
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Early detection is critical for the successful treatment of oral/pharyngeal
cancers. The 5-year survival rate falls from 82% to 52%, when the cancer is detected
at a distant site, rather than when it is still confined to the primary site (localized) 10.
Unfortunately, only 33% of oral/pharyngeal cancers are localized at the time of
diagnosis' .
1.1.2 Detection of Oral Cancer
Currently the detection of oral cancer relies in large part on the vigilance of a
dentist or other health care professional in identifying visible signs of disease.
Alterations in surface texture (as from erosion, keratosis, induration, granularity or
fissuring), color (red, white, or mixed), and pain may be associated with oral
dysplasia or cancer. The presentation can be extremely variable or subtle, however,
particularly in the case of early disease 8' . Once a suspicious lesion is identified, a
small piece of tissue is cut and removed (biopsy), processed for histology, and
examined under a microscope. A pathologist then renders a diagnosis based on a
qualitative assessment of the tissue morphology.
This detection scheme has a number of shortcomings. First, because biopsy is
an invasive procedure, only a limited number of samples can be taken to avoid
excessive discomfort or stress to the patient. This means that the pathology results for
a biopsy taken from one area of the lesion is assumed to be representative of the
extent of the disease in the suspicious area as a whole, and often determines whether
treatment is indicated 12. Based upon his/her experience the physician selects as a site
for biopsy the area most likely to show significant disease, thus there is a risk that
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disease can be missed given the arbitrary nature of this process. Significant under-
diagnosis has been noted to occur with incisional biopsy 12,'13 .
Secondly, although the entire area of the oral cavity is exposed to the
carcinogens present in tobacco, diagnosis of cancer is often focused only on visibly
suspicious areas. Field cancerization, the concept that multiple primary tumors
develop in a field of epithelium exposed to a carcinogen, has been well described in
the oral cavity14' 15. This suggests that greater attention to the oral cavity as a whole,
and not just visibly normal areas, is important for disease detection. In support of this,
studies have demonstrated that visibly normal mucosa in heavy smokers or patients
with lesions may also exhibit pathological changes1 6,17
Finally, the usefulness of a pathologist's diagnosis is confounded by inter- and
intra-observer variability in grading, largely due to the qualitative nature of the
markers used for assessmentl8-20
One alternative method for detecting oral cancer which has been explored,
oral brush biopsy, suffers from a poor specificity 2 1. The need for a more reliable and
strategic means of diagnosing oral cancer has been highlighted in a recent review 22
1.2 Optical Spectroscopy and Cancer Diagnosis
Greater than 85% of all cancers originate in the most superficial layer of the
tissue mucosa, which is known as the epidermis. This is significant because light is
able to penetrate the epidermis, and therefore optical spectroscopy may be used to
CHAPTER 1: Overview
detect epithelial cancers. Studies investigating the use of optical spectroscopy for
cancer diagnosis have been performed in a wide variety of tissues ranging from easily
accessible tissue sites, such as the skin, oral cavity, breast, cervix, esophagus, and
lungs, to more distant sites, such as the bladder, prostate, colon, stomach, and
intestine23-37
The overall goal of these studies is to increase detection of early or localized
disease, and thus the likelihood of a favorable response to treatment. The primary
advantage of optical techniques is that they can non-invasively probe tissue, without
the need for the biopsy or the processing of the tissue specimen required for
histopathological evaluation. Research in this field is also driven by a desire to
enhance the visualization of disease, to guide the clinician in the removal of
malignant samples, and to reduce sampling errors in large, extensive lesions. These
techniques may even reveal information beyond what is currently provided by
standard detection/diagnostic methods, for example, the biochemical state of the
tissue. By extracting quantitative parameters from the spectral data, diagnostic
algorithms can be created, which may even permit cancer to be detected in real-time.
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1.3 Project Goal and Objectives
The goal of this project is to use reflectance and fluorescence spectroscopy to
non-invasively and quantitatively identify pre-cancerous or cancerous changes in the
oral cavity. In order to realize this goal, we developed the following objectives:
1) To advance the instrumentation for spectral data collection
2) To develop spectral models for the accurate modeling of reflectance and
fluorescence spectra from oral tissue and the reliable extraction of
parameters relating to tissue morphology and biochemistry
3) To collect in vivo reflectance and fluorescence spectra from healthy oral
tissue in healthy volunteers, and relate the extracted physical parameters to
tissue anatomy
4) To collect in vivo reflectance and fluorescence spectra from patients with
lesions and develop spectral diagnostic algorithms for identifying and
categorizing oral lesions
1.4 Overview of Thesis Contents
This document consists of three main sections. The introductory section,
Chapters 2-4, provides the necessary background information for understanding the
architecture of the oral cavity, as well as the spectroscopic approaches and
instrumentation that we will use to approach the detection of oral cancer. In the
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second section, Chapters 5 and 6, we describe the collection of in vivo reflectance and
fluorescence spectra. In Chapter 5 we describe our study of clinically normal tissue in
healthy volunteers, and relate the spectroscopic parameters to the tissue anatomy. In
Chapter 6 we collect spectral data from lesions in patients, and relate the
spectroscopic parameters to the disease status of the tissue. In the third section,
Chapters 7 and 8, we summarize the findings and conclusions of this investigation
and discuss future directions. We provide a comprehensive list of abbreviations used
in the subsequent chapters at the end of this thesis.
CHAPTER 1: Overview
1.5 References
1. B. W. Neville and T. A. Day, "Oral cancer and precancerous lesions," CA: A
Cancer Journal for Clinicians, 52(4), 195-215 (2002).
2. L. A. G. Ries, D. Melbert, M. Krapcho, D. G. Stinchcomb, N. Howlader, M. J.
Homer, A. Mariotto, B. A. Miller, E. J. Feuer, S. F. Altekruse, D. R. Lewis, L.
Clegg, M. P. Eisner, M. Reichman and B. K. Edwards (eds), "SEER Cancer
Statistics Review, 1975-2005," National Cancer Institute, 2008, accessed May
4, 2008
3. B. Rodu and P. Cole, "Oral cavity and pharynx-throat cancer in the United
States, 1973-2003," Oral Surgery Oral Medicine Oral Pathology Oral
Radiology andEndodontology, 104(5), 653-658 (2007).
4. "SEER Cancer Stat Fact Sheets : Cancer of the Oral Cavity and Pharynx,"
National Cancer Institute, http://seer.cancer.gov/statfacts/html/oralcav.html,
Accessed: May 3, 2008
5. L. A. G. Ries, D. Melbert, M. Krapcho, A. Mariotto, B. A. Miller, E. J. Feuer,
L. Clegg, M. J. Homer, N. Howlader, M. P. Eisner, M. Reichman and B. K.
Edwards (eds), "SEER Cancer Statistics Review, 1975-2004," National
Cancer Institute, 2007, accessed November 12, 2007
6. W. J. Blot, J. K. McLaughlin, D. M. Winn, D. F. Austin, R. S. Greenberg, S.
Prestonmartin, L. Bernstein, J. B. Schoenberg, A. Stemhagen and J. F.
Fraumeni, "Smoking And Drinking In Relation To Oral And Pharyngeal
Cancer," 48(11), 3282-3287 (1988).
7. F. Lewin, S. E. Norell, H. Johansson, P. Gustavsson, J. Wennerberg, A.
Biorklund and L. E. Rutqvist, "Smoking tobacco, oral snuff, and alcohol in the
etiology of squamous cell carcinoma of the head and neck - A population-
based case-referent study in Sweden," Cancer, 82(7), 1367-1375 (1998).
8. J. J. Sciubba, "Oral cancer and its detection - History-taking and the
diagnostic phase of management," 132(12S-18S (2001).
9. L. Dobrossy, "Epidemiology of head and neck cancer: Magnitude of the
problem," Cancer and Metastasis Reviews, 24(1), 9-17 (2005).
10. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M. J. Thun,
"Cancer Statistics, 2008," CA: A Cancer Journal for Clinicians, 58(2), 71-96
(2008).
11. E. E. Vokes, R. R. Weichselbaum, S. M. Lippman and W. K. Hong, "Medical
Progress - Head and Neck-Cancer," New England Journal of Medicine,
328(3), 184-194 (1993).
12. M. Pentenero, M. Carrozzo, M. Pagano, D. Galliano, R. Broccoletti, C. Scully
and S. Gandolfo, "Oral mucosal dysplastic lesions and early squamous cell
carcinomas: underdiagnosis from incisional biopsy," Oral Diseases, 9(2), 68-
72 (2003).
13. J. J. Lee, H. C. Hung, S. J. Cheng, C. P. Chiang, B. Y. Liu, C. H. Yu, J. H.
Jeng, H. H. Chang and S. H. Kok, "Factors associated with underdiagnosis
from incisional biopsy of oral leukoplakic lesions," Oral Surgery Oral
CHAPTER 1: Overview
Medicine Oral Pathology Oral Radiology and Endodontology, 104(2), 217-
225 (2007).
14. D. P. Slaughter, H. W. Southwick and W. Smejkal, "Field cancerization in
oral stratified squamous epithelium; clinical implications of multicentric
origin," Cancer, 6(5), 963-8 (1953).
15. F. Cianfriglia, D. A. Di Gregorio and A. Manieri, "Multiple primary tumours
in patients with oral squamous cell carcinoma," 35(2), 157-163 (1999).
16. P. J. Thomson, "Field change and oral cancer: new evidence for widespread
carcinogenesis?," International Journal of Oral and Maxillofacial Surgery,
31(3), 262-266 (2002).
17. N. Ayan, I. Ayan, C. Alatli, S. D. Guler, C. Dalkilic, F. Cinar and 0. Dogan,
"P53 overexpression in normal oral mucosa of heavy smokers," Journal of
Experimental & Clinical Cancer Research, 19(4), 525-529 (2000).
18. D. J. Fischer, J. B. Epstein, T. H. Morton and S. M. Schwartz, "Reliability of
histologic diagnosis of clinically normal intraoral tissue adjacent to clinically
suspicious lesions in former upper aerodigestive tract cancer patients," Oral
Oncology, 41(5), 489-496 (2005).
19. D. J. Fischer, J. B. Epstein, T. H. Morton and S. M. Schwartz, "Interobserver
reliability in the histopathologic diagnosis of oral pre-malignant and
malignant lesions," Journal of Oral Pathology & Medicine, 33(2), 65-70
(2004).
20. I. vanderWaal, K. P. Schepman, E. H. vanderMeij and L. E. Smeele, "Oral
leukoplakia: a clinicopathological review," Oral Oncology, 33(5), 291-301
(1997).
21. T. W. J. Poate, J. A. G. Buchanan, T. A. Hodgson, P. M. Speight, A. W.
Barrett, D. R. Moles, C. Scully and S. R. Porter, "An audit of the efficacy of
the oral brush biopsy technique in a specialist Oral Medicine unit," Oral
Oncology, 40(8), 829-834 (2004).
22. R. Tagg, M. Asadi-Zeydabadi and A. D. Meyers, "Biophotonic and other
physical methods for characterizing oral mucosa," Otolaryngologic Clinics of
North America, 38(2), 215-240 (2005).
23. S. C. Park, S. J. Lee, H. Namkung, H. Chung, S. H. Han, M. Y. Yoon, J. J.
Park, J. H. Lee, C. H. Oh and Y. A. Woo, "Feasibility study for diagnosis of
stomach adenoma and cancer using IR spectroscopy," Vibrational
Spectroscopy, 44(2), 279-285 (2007).
24. S. K. Chang, Y. N. Mirabal, E. N. Atkinson, D. Cox, A. Malpica, M. Follen
and R. Richards-Kortum, "Combined reflectance and fluorescence
spectroscopy for in vivo detection of cervical pre-cancer," Journal of
Biomedical Optics, 10(2), - (2005).
25. C. M. Krishna, N. B. Prathima, R. Malini, B. M. Vadhiraja, R. A. Bhatt, D. J.
Fernandes, P. Kushtagi, M. S. Vidyasagar and V. B. Kartha, "Raman
spectroscopy studies for diagnosis of cancers in human uterine cervix," 41(1),
136-141 (2006).
26. T. M. Breslin, F. S. Xu, G. M. Palmer, C. F. Zhu, K. W. Gilchrist and N.
Ramanujam, "Autofluorescence and diffuse reflectance properties of
CHAPTER 1: Overview
malignant and benign breast tissues," Annals of Surgical Oncology, 11(1), 65-
70 (2004).
27. A. L. Carlson, A. M. Gillenwater, M. D. Williams, A. K. El-Naggar and R. R.
Richards-Kortum, "Confocal microscopy and molecular-specific optical
contrast agents for the detection of oral neoplasia," Technology in Cancer
Research & Treatment, 6(5), 361-374 (2007).
28. M. P. L. Bard, A. Amelink, M. Skurichina, V. N. Hegt, R. P. W. Duin, H. J.
C. M. Sterenborg, H. C. Hoogsteden and J. G. J. V. Aerts, "Optical
spectroscopy for the classification of malignant lesions of the bronchial tree,"
Chest, 129(4), 995-1001 (2006).
29. P. Crow, A. Molckovsky, N. Stone, J. Uff, B. Wilson and L. M.
Wongkeesong, "Assessment of fiberoptic near-infrared Raman spectroscopy
for diagnosis of bladder and prostate cancer," Urology, 65(6), 1126-1130
(2005).
30. A. S. Haka, K. E. Shafer-Peltier, M. Fitzmaurice, J. Crowe, R. R. Dasari and
M. S. Feld, "Diagnosing breast cancer by using Raman spectroscopy,"
Proceedings of the National Academy of Sciences of the United States of
America, 102(35), 12371-12376 (2005).
31. D. C. Malins, N. L. Polissar, K. Nishikida, E. H. Holmes, H. S. Gardner and
S. J. Gunselman, "The Etiology and Prediction of Breast-Cancer - Fourier
Transform-Infrared Spectroscopy Reveals Progressive Alterations in Breast
DNA Leading to a Cancer-Like Phenotype in a High Proportion of Normal
Women," Cancer, 75(2), 503-517 (1995).
32. J. H. Ali, W. B. Wang, M. Zevallos and R. R. Alfano, "Near infrared
spectroscopy and imaging to probe differences in water content in normal and
cancer human prostate tissues," Technology in Cancer Research & Treatment,
3(5), 491-497 (2004).
33. G. Bourg-Heckly, J. Blais, J. J. Padilla, O. Bourdon, J. Etienne, F. Guillemin
and L. Lafay, "Endoscopic ultraviolet-induced autofluorescence spectroscopy
of the esophagus: Tissue characterization and potential for early cancer
diagnosis," Endoscopy, 32(10), 756-765 (2000).
34. L. D. Nunes, A. A. Martin, L. Silveira and M. Zampieri, "FT-Raman
spectroscopy study for skin cancer diagnosis," Spectroscopy-an International
Journal, 17(2-3), 597-602 (2003).
35. L. Brancaleon, A. J. Durkin, J. H. Tu, G. Menaker, J. D. Fallon and N.
Kollias, "In vivo fluorescence spectroscopy of nonmelanoma skin cancer,"
Photochemistry and Photobiology, 73(2), 178-183 (2001).
36. A. Molckovsky, L. M. W. K. Song, M. G. Shim, N. E. Marcon and B. C.
Wilson, "Diagnostic potential of near-infrared Raman spectroscopy in the
colon: differentiating adenomatous from hyperplastic polyps,"
Gastrointestinal Endoscopy, 57(3), 396-402 (2003).
37. G. Zonios, L. T. Perelman, V. M. Backman, R. Manoharan, M. Fitzmaurice, J.
Van Dam and M. S. Feld, "Diffuse reflectance spectroscopy of human
adenomatous colon polyps in vivo," Applied Optics, 38(31), 6628-6637
(1999).
CHAPTER 2: Introduction to the Oral Cavity
CHAPTER 2
Introduction to the Oral Cavity
We begin this chapter with an overview of the normal macroscopic and microscopic
architecture of the oral cavity. Next, we provide an overview of the process of cancer
development and describe commonly encountered lesions. Finally, we end with a
description of the primary treatment for oral cancer.
CHAPTER 2: Introduction to the Oral Cavity
2.1 Anatomy of the Oral Cavity
2.1.1 Macroscopic Anatomy
The oral cavity includes the lips, anterior two-thirds of the tongue, gingiva
(gums), buccal mucosa (lining inside the cheeks and lips), floor of the mouth (area
under the tip of the tongue in the anterior region of the mouth), hard palate, and
retromolar trigone (area of the gums distal to the wisdom teeth). The oropharynx
includes the soft palate, the base of the tongue, and the tonsils. Figure 2.1 depicts the
anatomic sites of the oral cavity and oropharynx'.
K
Figure 2.1 Diagram and photograph depicting the various anatomic sites of the oral cavity and
oropharynx. 1. Dorsal surface of the tongue, 2. Lateral surface of the tongue, 3. Ventral surface
of the tongue, 4. Buccal mucosa, 5. Floor of the mouth, 6. Retromolar trigone, 7. Tonsils, 8. Hard
palate, 9. Soft palate, 10. Gingiva, 11. Base of tongue, 12. Lips. Diagram modified from
http://www.3dscience.com/3D_Images/Human_Anatomy/Digestive/Open_Mouth.php
u
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Unless otherwise noted, as in the diagram used in Figure 2.1, all photographs that are
shown in this chapter are derived from samples collected during the course of our
study of the oral cavity.
2.1.2 Microscopic Anatomy
The mucosa of the oral cavity consists of two layers: an outer (most
superficial) layer of stratified squamous epithelium, and an underlying layer of
connective tissue known as the lamina propria. The two layers are separated by a
structure known as the basement membrane or basal lamina. Figure 2.2 shows a
hemotoxylin and eosin (H&E) stained specimen taken from the hard palate, showing
the normal tissue micro-architecture.
The mucosa of the oral cavity varies for different anatomic sites and is
generally divided into three categories based on specific structural features which are
related to the function of the particular site2. Lining mucosa covers the lips, buccal
mucosa (BM), soft palate (SP), ventral surface of the tongue (VT), and floor of the
mouth (FM). Lining mucosa is non-keratinized, flexible, and easily stretched.
Masticatory mucosa is keratinized [Fig. 2.2] and covers those sites which are exposed
to the intense forces of mastication: the hard palate (HP) and gingiva (GI). The dorsal
surface (anterior two-thirds) of the tongue (DT) is characterized by specialized
mucosa. Specialized mucosa consists of a mixture of keratin and surface projections
known as papillae3 .
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Epithelium
The epithelial layer protects the tissue from microbial invasion and
mechanical damage. The most inferior portion consists of a layer of actively dividing
cells, 1-2 cell layers in thickness, which are located just superficial to the basement
membrane. This zone of epithelial cells is known as the basal cell layer. Basal cells
are tightly packed and undifferentiated, and eventually progress upwards to form the
Keratin
Epithelium
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Figure 2.2 A H&E stained tissue specimen from the hard palate depicting the
epithelium with overlying keratin, the basement membrane, and the lamina
propria.
most superficial layer. The cells progressively become larger and more differentiated
as they advance towards the tissue surface. At the tissue surface, the epithelial cells
are dead, and are shed during activities such as chewing and talking. These cells are
replaced by the continuous proliferation and upward migration of the basal cell layer4.
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In keratinized epithelium (GI and HP), the basal cells produce keratin
intermediate filaments. These filaments become densely packed and the nuclear-to-
cytoplasmic ratio decreases as the cells migrate upwards, such that eventually the
cells have eliminated all their organelles. At the surface, the cells are no longer alive
and the keratin is released into the intracellular spaces2. If the nucleus is retained, this
is referred to as parakeratosis, while if absent, the pattern of keratinization is referred
to as orthokeratosis. Non-keratinized epithelium is usually thicker than keratinized
epithelium. Both keratinized and non-keratinized epithelia contain keratin.
Distinction between these two types of epithelia is based on differences in the types
of keratins present2.
The specialized mucosa of the DT possesses a number of unique features,
related to its important functions. The base of the tongue (posterior two-thirds of the
tongue) is often distinguished from the anterior two-thirds because of their unique
embryologic origin and morphology. In this thesis, we will use DT to refer to the
anterior two-thirds, and explicitly refer to the posterior portion as the base of the
tongue (BT). The DT contains four types of papillae, small protuberances, (some of
which contain taste buds) in a distinct spatial pattern. The fungiform, circumvallate,
and foliate papillae are non-keratinized, however the filiform papillae are covered by
keratinized epithelium4.
Basement Membrane
The basement membrane serves as a scaffold for regeneration of the
epithelium, influences cell proliferation and growth, and controls cell polarity5 . The
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basement membrane is composed of collagen type IV and VII, glycoproteins, and a
number of other types of fibrils2. The basement membrane is not a flat structure, but
rather undulates because the interface between the epithelium and lamina propria is
corrugated. This interface is characterized by inderdigitating epithelial ridges and
connective tissue papillae.
Lamina Propria and Submucosa
The lamina propria contains blood vessels, fat, nerves and glands, but the bulk
of this compartment is composed of collagen (mostly type I and III) produced by
fibroblasts, the most abundant cell type found in this layer. Also found within this
layer are elastin, white blood cells, macrophages, and lymphatics 3. The lamina
propria provides support for the overlying epithelium.
Deep to the lamina propria is the submucosa, which may be composed of fat
(SP, BM, and labial mucosa), muscle (lips, BM, tongue, and SP), bone (GI and
anterior portion of the HP), or glands (lips, BM, HP, SP, and tongue)3. The GI and HP
are unique in that neither contains a submucosa; but rather, the fibers of the lamina
propria are attached directly to bone4.
2.2 Oral Cavity Pathology
2.2.1 Carcinogenesis
A neoplasm ("new growth") represents a virtually autonomous mass of tissue
characterized by uncontrolled, uncoordinated growth, which is independent of normal
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growth stimuli and plays no role in the normal tissue function5. Carcinogenesis is the
multi-step process by which the original transformed cell expands and progressively
transforms into the malignant phenotype. Malignancy is characterized by features
such as accelerated growth, invasiveness, and the ability to form metastases5. Based
on a microscopic assessment of a biopsied tissue specimen, oral lesions are
commonly classified as benign, dysplastic, or malignant (cancer).
Benign lesions are characterized by changes which are abnormal, but are
considered less likely to progress to the malignant phenotype. Common benign
changes associated with oral lesions include hyperkeratosis (increased thickness of
the overlying keratin) and hyperplasia (proliferation) of keratinocytes (known as
acanthosis).
For oral lesions, epithelial dysplasia has been defined as "a pre-cancerous
lesion of stratified squamous epithelium characterized by cellular atypia and loss of
normal maturation..."6 Table 2.1 summarizes the abnormal histological features
associated with dysplasia6. The presence of dysplasia is considered an indication of
increased risk of malignant transformation as compared to non-dysplastic epithelium.
Not all dysplastic lesions will eventually become malignant, however, and some
lesions may even regress7.Dysplastic lesions are distinguished from frank cancer by
their confinement to a region superficial to the basement membrane. Dysplastic
lesions are sometimes subdivided into three categories (mild, moderate and severe),
based on whether the basal cell layer and other changes extend up to one third, two-
thirds, or greater than two-thirds, respectively, of the thickness of the epitheliums.
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Histological Criteria for Diagnosing Epithelial Dysplasia
* Nuclear hyperchromatism (increased nuclear staining)
* Cellular and nuclear pleomorphism (variation in nuclear shape and size)
* Enlarged nuclei
* Irregular epithelial stratification
* Increased number of mitotic figures
* Mitotic figures that are abnormal in form
* The presence of mitotic figures in the superficial half of the epithelium
* Loss of polarity of basal cells
* Increased nuclear-cytoplasmic ratio
* Drop-shaped rete ridges
* Loss of intercellular adherence
* The presence of more than one layer of cells having a basaloid appearance
* Keratinization of single cells or cell groups in the prickle cell layer
Table 2.1 A description of the major histological features associated with dysplasia.
Epithelial cancer (also known as squamous cell carcinoma (SCC)) develops
once the neoplastic cells penetrate the basement membrane and invade the underlying
stroma. Approximately 92% of all oral cancers are SCCs9. A term used to describe an
intermediate stage in which there is uncontrolled growth of epithelial cells throughout
the full thickness of the epithelium, but without stromal invasion, is known as
carcinoma in situ (CIS)6.
Figure 2.3 shows a series of microscopic specimens obtained from the floor of
the mouth showing the histological changes with progression from mild dysplasia to
cancer.
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Figure 2.3 H&E stained microscopic specimens from the floor of the mouth showing (a) mild
dysplasia, (b) moderate dysplasia, (c) severe dysplasia, and (d) cancer. The progression of dysplasia is
characterized by proliferation and expansion of the actively dividing cells of the basal cell layer to more
superficial regions of the epithelium. Finally, with cancer, the rapidly proliferating cells breech the
basement membrane (note the loss of this structure) and invade the underlying stroma, where they
continue to proliferate.
Figure 2.4 shows photographs of 2 different regions of the epithelium of a dysplastic
lateral tongue lesion demonstrating the nuclear and cellular pleomorphism [Fig.
2.4(a)] and presence of mitotic figures in the superficial region of the epithelium [Fig.
2.4(b)].
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Figure 2.4 Two photographs of a H&E stained microscopic specimen showing a dysplastic lesion
from the lateral tongue. (a) The basal cells and the epithelial-stromal junction. The variation in the size
and shape of the nuclei and cells (pleomorphism) can be appreciated. (b) Superficial region of the
epithelium. The presence of actively dividing cells near the tissue surface is evidenced by the presence
of mitotic figures (2 are indicated by the arrows). This represents an abnormal maturation pattern.
The tongue is the most common location of cancer development in the oral
cavity and oropharynx, followed by the floor of the mouth'0 . In a study of a series of
200 patients with oral SCC, 26% had a primary tumor on the lateral border of the
tongue, 17% in the ventral tongue/floor of mouth region, and 15% solely in the floor
of mouth". The most common sites of metastasis of oral cancers include the
mediastinal lymph nodes, lungs, liver, and bones5 . Invasive lesions can be described
as poorly, moderately or well-differentiated based on the degree of keratinization
(poor indicating the least amount of keratinization). In addition to histological
grading, the TNM system has been used for staging oral lesions. Using this
classification, the tumor size (T), status of the lymph nodes with respect to metastasis
(N), and the presence or absence of distant metastases (M) are evaluated'2
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2.2.2 Lesions of the Oral Cavity
There are two lesions commonly encountered in the oral cavity: leukoplakia
("white plaque") and erythroplakia ("red plaque").
Leukoplakia
Leukoplakia, the most commonly observed suspicious lesion found in the oral
cavity, is a clinical term which refers to a predominantly white lesion of the oral
mucosa that cannot be wiped off or attributed to any specific disease etiology 13. Non-
idiopathic causes of white lesions include candidiasis (fungal infection by Candida
albicans) and lichen planus (an inflammatory disease often producing lesions on the
oral mucosa) 14. Under microscopic examination, white lesions can range in
appearance from benign areas of hyperkeratosis, to dysplasia, or frank cancer. The
white appearance of the plaque is due to the keratin filaments, which scatter all
wavelengths of light. Upon microscopic evaluation, most cases of leukoplakia show
only benign changes. In a study of 3,256 biopsied leukoplakias, 80.2% showed
benign changes, particularly hyperkeratosis and hyperplasia. Of the remaining cases,
16.7% showed dysplasia/CIS and 3.1% were diagnosed as infiltrating SCC1 .
Interestingly, the frequency of disease findings for white lesions was found to vary
among different sites in the mouth. The sites with the highest incidence included the
floor of the mouth (42.9%), tongue (24.2%), lip (24%), and palate (18.8%).
Reports vary widely on the rate of transformation of benign leukoplakia to
SCC. In a study of 257 patients with leukoplakia studied for an average of 7.1 years,
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45 patients (17.5%) with an initial diagnosis of benign hyperkeratosis subsequently
developed squamous cell carcinomas in an average time of 8.1 years16. The
transformation rate for leukoplakia, however, varies widely across studies, ranging
from 0.9% to 17.5%'.
Erythroplakia
Erythroplakia is a less commonly observed lesion, and presents as a red,
velvety, flat or slightly depressed lesion. This lesion has a prevalence between 0.02%
and 0.83% 17. Like leukoplakia, this term is simply a clinical description of the lesion.
The description is replaced once the diagnosis is rendered. The diagnosis at the time
of initial biopsy of erythroplakia tends to be far more severe than that for leukoplakia.
In a study by Shafer and Waldron of 65 cases of erythroplakia, all of the cases
showed the presence of dysplasia (49%) or invasive SCC (51%)18. Under the
microscope these red lesions frequently display a superficially eroded epithelium, an
intense inflammatory reaction within the stroma with vascular dilation and signs of
early or late cancerous changes5. The red color of these lesions is due to increased
vascularity and inflammation. Erythroplakia is commonly found on the soft palate
and floor of the mouth' 7. Some red lesions are mixed with white areas of keratosis
and are referred to as erythroleukoplakias.
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2.3 Treatment for Oral Cancer
Surgical excision is the primary means of treating oral cancer 19. Overall
disease-free survival at 5 years is 58%20. Successful treatment has been found to be
significantly affected by the histopathological grade at the time of diagnosis and the
stage of disease (according to the TNM classification system)20. There is a relatively
high recurrence rate for oral lesions and surgical excision does not reduce this risk' 9.
In addition, the development of second (metachronous) primary tumors is common,
particularly within the first twelve months of treatment21 .
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CHAPTER 3
Introduction to Spectroscopy:
Methods and Models
We begin this chapter by describing the advantages and motivation for using optical
techniques to detect malignancy. Following this, we introduce the major optical
spectroscopy, imaging, and microscopy modalities that have been applied to the oral
cavity. For each technique, we briefly summarize the relevant literature on the
application of the technique to the evaluation of normal or diseased oral tissue. The
results of other investigators will be described in further detail and compared with our
own findings in the ensuing chapters. Finally, we introduce the two physical models
we use to analyze the spectral data and extract physical parameters related to tissue
morphology and biochemistry: Diffuse Reflectance Spectroscopy (DRS) and Intrinsic
Fluorescence Spectroscopy (IFS). Light Scattering Spectroscopy (LSS), a technique
previously used by our laboratory will also be discussed.
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3.1 Spectroscopy and Cancer Diagnosis: Motivation
A number of structural and metabolic changes are associated with the
development of dysplasia and cancer that significantly alter the normal architecture
and biochemical properties of tissue' 7. Many of the same tissue components affected
by the disease process also interact with light through processes such as scattering,
absorption, and fluorescence. Therefore, as these components are altered, we expect
the impact of disease to produce changes in the light emitted from the tissue.
There is an extensive body of literature describing spectroscopic changes
associated with disease (i.e. dysplasia, cancer) in epithelial tissue8-14. Table 3.1
provides an overview of the findings associated with benign, dysplastic, and
malignant lesions, and how these changes can produce differences in the
spectroscopic properties of the tissue. The actual spectroscopic changes observed
with carcinogenesis will represent a combination of the individual (or dominant)
changes listed, and depend on factors such as the tissue under study, and the methods
and instrumentation used to probe the tissue. Frequent findings reported in the
literature with regard to the spectral changes associated with disease include
increased hemoglobin absorption and nicotinamide adenine dinucleotide in the
reduced form (NADH) fluorescence, and a decrease in the magnitude of the scattering
and collagen fluorescence9, 13'15
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Changes Associated with Spectroscopic Signature
Benign/Dysplastic/Malignant Lesions
Hyperplasia, nuclear crowding Increased scattering by small particles
Increased nuclear/cytoplasm ratio Increased scattering by small particles
Degradation of extracellular matrix (collagen) Decreased scattering from collagen
Decreased fluorescence from collagen
Loss of basement membrane (collagen) Decreased scattering from collagen
Decreased fluorescence from collagen
Angiogenesis Increased hemoglobin absorption
Decreased hemoglobin oxygenation (hypoxia) Oxyhemoglobin absorption peaks
decrease, deoxyhemoglobin absorption
peaks increase, (increased tissue
hemoglobin oxygenation)
Increased metabolic activity Increased NADH fluorescence
Decreased FAD fluorescence
Inflammation Increased hemoglobin absorption
Hyperkeratosis Increased scattering
Table 3.1 The morphological and biochemical changes associated with benign,
dysplastic, and malignant lesions and their spectroscopic correlate. NADH: reduced
nicotinamide adenine dinucleotide, FAD: flavin adenine dinucleotide.
There are a variety of methods to detect these optical contrasts, and the major
techniques and approaches will be described in the subsequent section.
3.2 Optical Techniques and their Application to the Oral
Cavity
Upon irradiating tissue with light, several types of optical signals are
generated from interactions within the tissue; however, three important types are
scattering, absorption, and fluorescence. These processes form the basis for the
spectroscopic and imaging techniques used to non-invasively investigate oral tissue.
In the following subsections we review the major optical techniques and give a brief
overview of their application in the oral cavity specifically. We focus primarily on
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studies that have been done in vivo in humans, as they are most relevant to the work
described in this thesis.
3.2.1 Diffuse Reflectance Spectroscopy: Elastic Scattering and Absorption
Diffuse reflectance spectroscopy (DRS) examines the changes in the
properties of light due to the interplay of elastic scattering and absorption within a
medium. This technique provides information about the bulk architecture of a small
volume of tissue. Broad bandwidth light is delivered to the tissue and the re-emitted
light is collected (both usually with an optical fiber probe). The returned light is then
dispersed by a spectrograph and detected by a CCD. The simple, inexpensive
instrumentation is one of the major advantages of diffuse reflectance spectroscopy. In
addition, the measurements can be performed very rapidly.
Elastic Scattering
Elastic scattering occurs when the path of light is redirected as a result of
variations in the refractive indices of cellular and extracellular constituents within the
tissue, with respect to their surrounding medium. The refractive index is defined as
the ratio of the velocity of light as it travels through a vacuum relative to the velocity
as it travels through a medium. In elastic scattering, the scattered light ray has the
same energy as the incident ray. Scattering particles present within tissue include
nuclei, mitochondria, collagen, elastin, and keratin16 . The extent to which light is
scattered is a function of the density of particles, the sizes of the particles relative to
the wavelength of the light, and the ratio of the refractive indices of the particles
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relative to that of the surrounding medium. The pattern of the scattered light largely
reflects those structures that have the highest refractive index mismatch compared to
their surrounding. However, because of the complex mixture of components present
within tissue (and thus inhomogeneities in refractive index), many structures
ultimately contribute to the scattering.
Light that enters tissue can be re-emitted after undergoing only a single
scattering event or after multiple scattering events. In principle, evaluation of singly-
scattered light, Light Scattering Spectroscopy (LSS), can provide in depth
information about specific structures localized in the most superficial layers of a
tissue (Section 3.3.3). Diffusely scattered light refers to elastic scattering in which the
incident light undergoes multiple scattering events to such an extent that it becomes
randomized in direction. Because the measured signal represents light that has
sampled a variety of paths and depths within the tissue, the diffuse reflectance
spectrum represents an average measure of the properties over a volume of tissue.
Specular reflectance can occur if the incident light rays encounter a microscopically
smooth surface (i.e. a mirror). In this case, the light rays are not reflected in a broad
range of directions as in diffuse reflectance.
Absorption
Molecules and atoms can absorb incident light at specific energies, converting
the light's energy into internal energy and ultimately, heat. The structure of the
molecule determines which incident frequencies will be absorbed. When tissue is
irradiated, the process of absorption causes a reduction in the amount of the incident
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light which returns to the surface to be collected. Table 3.2 lists the major tissue
absorbers in the ultraviolet (UV) and visible regions of the spectrum16-1
In the UV region of the spectrum, nucleic acids and amino acids are the major
absorbers. Of the amino acids, tryptophan exhibits the most intense absorption. Light
is readily absorbed in the UV region and thus is able to penetrate only one or two cell
layers deep into the tissue. Hemoglobin is the principal absorber in tissue in the
visible region of the spectrum and strongly absorbs blue light. The removal of the
blue component from the beam of incident white light results in its characteristic red
color. Melanin and n-carotene are additional absorbers in the visible region. Visible
light typically penetrates tissue to a depth of 0.5-2.5 mm20. In the wavelength region
from 600-1500 nm, known as the 'diagnostic window', scattering prevails over
absorption, and light can penetrate as deep as 8-10 mm before being collected20.
Diffuse Reflectance Studies in the Oral Cavity
There have been relatively few reports describing the use of diffuse
reflectance spectroscopy in vivo in humans for the detection of oral malignancy 9,21-23
Absorber Absorption Peak(s) / Range inmi
Nucleic Acids: DNA ,RNA 258
Amino acid: Tyrosine 275
Amino acid: Tryptophan 280
Amino acid: Phenylalanine 260
Oxyhemoglobin 415, 542,576
Deoxyhemoglobin 433, 556
O3-Carotene <300nm, -450
Melanin 400-700
Table 3.2 Summary of the major absorbers present in tissue and their absorption maxima or
absorption range.
CHAPTER 3: Introduction to Spectroscopy: Methods and Models
In one study, a preliminary examination of this technique was presented and the data
included only 6 people22 . In another, the researchers compared ex vivo tissue data
from patients with in vivo data from healthy volunteers23. Sharwani et al. conducted
an in vivo study in which they collected 25 white light spectra from 25 patients with
leukoplakia and analyzed the data from 340-800 nm21. Their system used an optical
fiber probe to convey light from a xenon-arc lamp to the tissue and also the emitted
light to the CCD-based detection system. The data included 4 normal sites, 10 benign
sites, 10 dysplastic sites, and 1 carcinoma in-situ (CIS). Using linear discriminant
analysis followed by leave-one-out cross-validation, they obtained a sensitivity and
specificity of 72.7% and 75%, respectively, for separating normal from dysplastic
sites. Recently, Amelink et al. compared clinically normal versus cancerous sites in
31 patients using an optical fiber probe designed to capture the returned signal
specifically from a superficial layer of the tissue (-350 jpm) 9. Using a model-based
approach to extract physical parameters, they found that the cancerous sites
demonstrated decreased scattering and oxygen saturation values, and increased blood
content and scattering slope. A study by de Veld et al. examined diffuse reflectance
spectra from oral tissue in combination with fluorescence from 172 oral lesions and
70 healthy volunteers24. They analyzed the spectra from 400-700 nm using principal
component analysis (PCA), after applying various normalization methods. Multiple
classification algorithms were also tested for distinguishing various subsets of the
data. They found that lesions could successfully be distinguished from healthy tissue,
and the best separation for distinguishing benign lesions from dysplastic/malignant
lesions yielded a sensitivity and specificity of 69% and 77%, respectively.
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3.2.2 Raman Spectroscopy
A small fraction of the light which interacts with tissue undergoes a scattering
event that causes a change in the energy (frequency) of the incident light, a process
known as inelastic scattering. Raman scattering is a specific type of inelastic
scattering. In Raman scattering, the change in the energy of the incident light occurs
because a portion of the energy is transferred from the photons to the molecules of the
material, where it excites vibrational energy states (Stokes scattering), or, to a lesser
extent, from the molecules of the material to the photons (anti-Stokes scattering) 25.
Figure 3.1 shows an energy level diagram depicting the processes by which Stokes
and anti-Stokes Raman scattering occur.
Excited State
hvo hvo
Fig 3.1 Illustration showing the processes
which Stokes Raman and anti-Stokes Ram
scattering occur. In Stokes Raman scatteri
by
lan
ng,
the incident photon excites a molecule into a
higher vibrational state excited state and only
a portion of the energy is released as the
molecule returns to a lower energy state. In
anti-Stokes Raman scattering, a photon
interacts with a molecule in a higher
vibrational energy state. When the molecule
transitions to a lower energy state, a portion
of the absorbed energy is transferred to the
photon, such that the emitted photon has
Stokes Anti-Stokes more energy than the incident photon.
By analyzing a Raman spectrum, a plot of the scattered light intensity as a
function of the change in energy between the incident and scattered photon in
wavenumbers (Raman shift), the relative contributions of various statistical, chemical,
or morphological components can be quantitatively extracted and used to develop
diagnostic algorithms26. There are a number of Raman active biological molecules
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including nucleic acids, proteins (e.g. collagen and elastin) and lipids27. In most tissue
applications, near-infrared light is used as the excitation source in order to avoid the
strong interference from tissue fluorescence at shorter wavelengths26.
A major advantage of Raman spectroscopy is its molecular specificity. In
addition, molecular vibrations are influenced by the microenvironment of functional
groups, and thus this technique provides information about molecular interactions.
Several considerations and challenges in the application of Raman spectroscopy to
tissue diagnostics are related to the inherent weakness of the Raman signal. Ensuring
an adequate signal-to-noise ratio (SNR) (which is also dependent on the tissue under
study) can be difficult, and therefore powerful sources and sensitive detectors are
required. The need for low or no ambient light (lights turned off) to prevent artifacts
in the signal may not be possible in all clinical settings. In addition, Raman spectra
require extensive processing, including the removal of the significant background
fluorescence in the measured signal16. Despite these challenges, a number of
researchers have successfully applied this technique in in vivo studies in tissue28,29
Raman Spectroscopy Studies in the Oral Cavity
Most Raman spectroscopy studies of the oral cavity have been limited to ex
vivo frozen tissue samples, formalin-fixed samples, or animal models30-33
Venkatakrishna et al. examined 49 malignant and normal tissue samples in saline
within 30 minutes of resection 34. The tissue was excited with 785 nm light. The
authors observed that the spectra from normal tissue displayed more lipid features
than those from malignant samples. A total of 140 spectra were analyzed using PCA
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to extract quantitative parameters and classified by applying a threshold on the
Mahalanobis distance (to determine similarity and thus likelihood of membership)
calculated for each sample compared to the model set of malignant spectra. Using this
approach they obtained a sensitivity and specificity of 85% and 90%, respectively.
3.2.3 Optical Coherence Tomography (OCT)
Optical Coherence Tomography (OCT) is an imaging modality which
measures backscattered light and provides high resolution (1-15 pm), cross-sectional
images in real-time 16. The technique, based on the Michelson interferometer,
compares the backscattered light collected from the sample arm (tissue) to that from
the reference arm (mirror) with a known pathlength in order to extract distance and
microstructural information. Figure 3.2 shows a diagram depicting the basic
components of a Michelson interferometer35. A light source is split into two beams,
each of which is directed to one arm of the interferometer. The signal measured from
the two arms recombine at the beam splitter, and the intensity of this signal is
measured'". In OCT a low coherence light source is used therefore an interference
pattern is produced only when the reflected light from both beams have traveled the
same optical distance. The tomogram is generated by performing rapid axial
measurements of backscattered light (by scanning the reference mirror) along
successive transverse positions on the tissue28,29,36
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Figure 3.2 Basic components of a Michelson interferometer. The signals
from the input (Ein), output (Eout), reference (Erefence) and sample (Esample)
arms are shown. Modified from Tomlins et al.
Although OCT is equivalent in principle to ultrasound cross-sectional (B-
mode) imaging, it provides far greater resolution. This technique can also be applied
using a fiber-based geometry, which enables tissue sites that are only accessible by an
endoscope or catheter to be studied. Some limitations are that the penetration can be
severely limited in the presence of significant absorption or scattering, its sensitivity
to tissue movement, and the difficulty of training needed for the identification and
interpretation of structures in the images.
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OCT Studies in the Oral Cavity
In an early study by Feldchtein et al. of 5 volunteers with healthy tissue, they
found marked differences between anatomic sites with non-keratinized and
keratinized epithelia 37. They noted that the presence of keratin resulted in a reduction
in their ability to see deeper structures. They were able to note features such as the
epithelium, lamina propria, muscle, bones, glands and vessels; however, the extent to
which they were able to distinguish various features varied from site to site. In a
more recent study of 41 adults, the investigators examined normal, benign, and
malignant oral cavity and oropharynx tissue sites during surgical endoscopy in order
to characterize normal structural components38 . They compared the OCT images to
standard images from histopathology. Using 1.31 jgm light, they were able to image
up to 1.6 mm in depth with a lateral and axial resolution of 15 and 10 jIm,
respectively. From their images, they were able to identify overlying keratin, the
epithelium, the basement membrane, lamina propria, glands and vessels. Furthermore,
they could observe transitions from areas of normal to cancer based on the
elimination of the basement membrane and loss of normal tissue microstructures. One
challenge they highlight for the application of OCT in the oral cavity is the need for
the patient to remain motionless (as during a surgical procedure when patients are
under general anesthesia). However, this can be overcome as the speed of data
acquisition continues to increase.
37
CHAPTER 3: Introduction to Spectroscopy: Methods and Models
3.2.4 Fluorescence Spectroscopy
Fluorescence arises when a molecule absorbs light with the appropriate energy
to undergo an electronic transition from the ground state, dissipates a portion of the
energy through non-radiative processes, and then emits light at a lower energy.
Fluorophores are highly sensitive to their surroundings and thus may be used to
identify changes in the tissue microenvironment relevant to cancer development
perhaps not yet identifiable by gross or microscopic inspection. Factors such as the
presence of quenchers (i.e. 02,), the solvent, the pH, and nearby chromophores with
which energy transfer, complex formation, or reactions can occur, greatly impact the
characteristics of the emitted light39. A variety of fluorophores have been identified
which are native to the tissue, including molecules related to metabolism and energy
transport (NADH, flavin adenine dinucleotide (FAD)), structural proteins (collagen,
elastin, and keratin), amino acids (tryptophan), and porphyrins (e.g. protoporphyrin
IX (PPIX), Zn protoporphyrin, coproporphyrin)40 -43. Table 3.3 lists the excitation and
emission maxima or range for a variety of tissue fluorophores17'44
Fluorophore Excitation Maximum Emission Maxima [nm]
Inmn
Collagen crosslinks 325 400
Elastin crosslinks 325 400
NADH 290, 340 440, 450
FAD 450 515
Tryptophan 280 350
Porphyrins 405 630, 690
Table 3.3 Excitation and emission properties of some endogenous tissue fluorophores
Fluorescence spectroscopy provides both metabolic and morphological information
about the tissue. Additionally, the use of exogenous fluorophores permits enhanced
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contrast and targeting of specific molecules of interest (e.g. to monitor their dynamics
or localization, or treatment purposes, as in photodynamic therapy). One disadvantage
is that fluorescence emission can be affected not only by the fluorophores and their
local environment, but also by the processes of absorption and scattering.
Fluorescence Spectroscopy Studies in the Oral Cavity
Fluorescence spectroscopy has been extensively investigated as a tool for oral
cancer detectionl 2' 24'30' 42' 45-65. Most studies collect information about the spectral
profile (wavelength dependence) of the fluorescence emission. A variety of
excitations between approximately 200 and 600 nm have been utilized in these
studies. The quantitative spectral parameters are usually extracted using methods such
as intensity ratios, area under the curve values, principal component analysis (PCA)
and neural networks. Discrimination between clinically normal healthy tissue and
malignant or dysplastic/malignant has been investigated in most studies and shown to
be highly successful. The ability to distinguish between benign and
dysplastic/malignant lesions has been less frequently investigated66.
A few studies have performed time-resolved measurements, in which the
timing of the fluorescence decay is analyzed67. The advantages of this technique
compared to steady-state measurements, is that fluorophores whose emission spectra
overlap spectrally, may be resolved temporally, and the decay is less sensitive to
variables such as the instrumentation and intensity of the excitation wavelength. In
one study by Chen et al., clinically normal and pre-malignant lesions in the oral
cavity were excited with 410 nm light and the amplitude and decay time at 633 nm
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emission were extracted67. They could successfully distinguish members of three
groups, normal, epithelial hyperplasia and verrucous hyperplasia (a type of benign
white lesion), and dysplasia, respectively, into three categories using Fisher's
discriminant analysis with an accuracy of 100, 75, and 93%, respectively. One of the
2 components in the exponential decay model was hypothesized to be PPIX, however
the source of shorter lifetime component could not be definitively assigned based on
the available literature. The authors note that the technique was time-consuming,
taking approximately 30 s per measurement in order to acquire a sufficient number of
photons.
3.2.5 Microscopy Techniques
Multi-photon Microscopy (MPM)
Multi-photon microscopy in a nonlinear technique in which fluorescence is
generated by near-simultaneous absorption of two or more low energy photons that
sum to the energy needed to excite an electronic transition68 . The use of longer
wavelength (infrared) light to excite fluorescence permits deeper light penetration, by
reducing the probability of scattering and absorption. Unlike traditional 1 photon
fluorescence, pulsed laser light (femtoseconds-attoseconds in between the two pulses
in two-photon excitation) is used and the spot is focused to a small volume to increase
the intensity and likelihood of a multi-photon event. This beam is then scanned to
image the entire sample. Limiting the fluorescence to a small volume decreases
photobleaching, and increases axial depth discrimination as compared to 1 photon
fluorescence techniques' 6 . Photodamage can occur, however, in the focal volume.
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Another advantage is that the excitation spectrum is entirely resolved from the
emission spectrum, such that the former can be completely filtered without substantial
loss in the measured intensity. One disadvantage is that the quality of the image
(contrast and resolution) can be greatly diminished if there is significant scattering of
the fluorescence excitation or emission light, as occurs in tissue . MPM has not been
studied in vivo in humans for oral cancer detection, but has been applied in animal
models for oral cancer69' 7 .
Confocal Reflectance Microscopy (CRM)
Confocal reflectance microscopy (CRM) examines the backscattered light
from tissue captured through an aperture which matches that of the delivery light,
enabling a plane of focus to be selectively imaged. Some disadvantages of confocal
microscopy include the small field view and limited penetration depth.
An in vivo confocal reflectance microscopy study by White et al. examined
healthy mucosa from the lip and tongue with a video-rate CRM system71. The lateral
resolution of the system was 0.5-1.0 jpm and the axial resolution 3-5pm. They
achieved imaging depths up to 490 and 250 Lpm in the lip and tongue, respectively.
Imaging depth was limited by superficial scattering, especially for keratinized sites.
Their system generated horizontal (en face) images, as compared to the normal
transverse view of histopathology. Only anterior portions of the oral cavity could be
assessed because of the need for a bulky tissue stabilizer to minimize motion artifacts
during their measurements, which took several seconds per site. Their images
permitted greater cellular detail to be appreciated than that of a corresponding
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histological section taken from the same site. Interestingly, they calculated several
quantitative parameters related to the tissue architecture (i.e. epithelial thickness,
cellular and nuclear diameters of epithelial cells) and found statistically significant
differences when these values were compared to the same metrics calculated from
histological sections, which may be due to artifacts during processing of tissue
specimens.
3.3 Spectroscopic Models
In the present study, we focus on the detection of oral cancer using two
spectroscopic modalities: Diffuse Reflectance Spectroscopy (DRS) and Intrinsic
Fluorescence Spectroscopy (IFS). Our laboratory has developed physical models
which we apply to the measured spectral data in order to extract quantitative
parameters. In this section we provide a detailed description of these models. Light
Scattering Spectroscopy (LSS) is a third modality, which was also developed by our
laboratory and previously used in the analysis of clinical data. In the course of the
present work, new findings related to this technique were discovered and we discuss
why this technique is no longer applied to the clinical data.
3.3.1 Diffuse Reflectance Spectroscopy
Most models describing the propagation of scattered light in tissue are based
on the steady-state diffusion approximation to the radiative transfer equation72 . The
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radiative transfer equation describes the transport of energy through a medium
containing particles and has been applied to a variety of scattering phenomena 72'73
The radiative transport equation treats light as a collection of photons and neglects the
field properties of light. While the radiative transport equation can only be solved
numerically (there is no closed form solution), the diffusion equation can be solved
analytically. The diffusion approximation assumes that light transport is dominated
by scattering, as is often the case for tissue, such that photons are scattered uniformly
in all directions and engage in what can be thought of as a random walk through the
medium.
Diffuse Reflectance Models
In the diffusion-based description of reflectance there are two key parameters
for describing the interaction of light with scatterers and absorbers: the reduced
scattering coefficient (ks') and absorption coefficient (pa), respectively. These
parameters are wavelength dependent and the inverse of these values represents the
average distance (step-size) traveled by a photon before encountering a
scatterer/absorber. The reduced scattering coefficient is calculated as follows:
p/, (A)= P, -(l-g), [mm ]  (3.1)
where p.8 is the scattering coefficient, and g, is the anisotropy parameter. Because
light is not isotropically scattered in tissue (an equal probability of scattering in all
directions), but instead is strongly forward-directed, the anisotropy parameter, g,
applies a correction enabling the scattering to be treated in a manner equivalent to the
isotropic case, which is one of the requirements for the diffusion approximation. The
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anisotropy parameter is wavelength-dependent and represents the average cosine of
the scattering angle. An equation for spatially-resolved diffuse reflectance in the
radial direction, Rd(r), has been derived by Farrell et al. based on this
74.
approximation74:
R 1 1 e - 1 , 1 ) (3.2)
Rd(r) • ,  + 2 ; +2zb "e 2 '4r, r2 2
where,
r1 = [Z 02 +r
2 2
,
r2 = [(zo +2zb2 2  ]1/2,
a 
PS
[Ps +Pa 1'
1
ef l
z b = 2 AD,
l+y
A--
1
-y
y = -1.44nre -2 + 0.710nre -1 + 0.0636ne, + 0.668.
The quantities ri and r2 are related to the boundary conditions, which specify that the
fluence at the interface must be zero. The term zo is equal to 1/jtt'. The quantity a' is
the transport albedo and teff denotes the effective attenuation coefficient. To account
for the mismatch in refractive index at the tissue-surface interface, the parameter A
describes the internal reflection at the interface and is calculated using y as described.
The term nrel is the relative refractive index. Similar to Fick's 1st Law of Diffusion, the
diffuse photons are characterized by a diffusion coefficient, D, where
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D= 1 (3.3)
3[,us+ pa ]
In the case where light is delivered to and collected from the tissue via an
optical fiber probe, R& must be integrated over the area of the delivery and collection
fibers, respectively. The model of Farrell et al. assumes a semi-infinite medium and
describes the diffuse reflectance collected at the tissue surface for a single scatterer
source.
The values for the scattering and absorption coefficients can be extracted by
modeling the reflectance data. With an increasing number of scattering/absorption
events within a medium, each parameter increases in value. The diffusion
approximation is valid when g' >> p. and breaks down in highly absorbing samples
or very dilute samples, in which photons do not sample the medium to any great
extent, and thus are not sufficiently randomized. This model also becomes inaccurate
at small source-detector separations, where the collected signal represents light which
has traveled only very short distances within the tissue and has not experienced
sufficient scattering events to become diffusive.
Our laboratory has developed a simple analytical DRS model, based on the
model of Farrell et al., which is specific for our probe configuration13 . The diffuse
reflectance is once again characterized by the reduced scattering coefficient and
absorption coefficient. The tissue is considered to be a homogenous, semi-infinite
medium in which the re-emitted signal corresponds to the diffusely scattered light
which escapes after losses in intensity due to absorption. The equation developed by
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Zonios et al. for the wavelength-dependent diffuse reflectance collected from the
probe, RmCas, is expressed as follows:
p I-o(1+jA).jo eCA' 4 e-A2 (3.4)
R (A))= , s e - o +e (1+-A).zo
meas 3S +a r r2
e pr* r2
where,
Zo 1/(p,' + ha)
rl= [(z02 + rcr'2]1/2 , and
r2= [zo2(l+ (4/3)-A)2 + r 2]1/2.
The properties of the probe are taken into account, as in the full model described by
Farrell et al., but a few additional simplifications are included. First, the delivery
radius of the probe, rd, is neglected (treated as a point source). Second, the collection
radius of the probe, re, is modeled by a single term, re', which corresponds to an
effective radius of collection. This latter term is an empirical value derived by
calibrating the probe with a phantom, a simple tissue model with known scattering
and absorption properties. Based on a calibration of our probe using a solution of
beads with known reflectance properties, we use a value of 0.36 mm for r,' in our
analysis (the reduced scattering coefficient and absorption coefficient are expressed in
units of mm-1). These assumptions reduce the double integral in the original form of
the equation to a single integral with a simple analytical solution. We use a value of
1.4 for nel, so that A = 3.213
Modeling the Reduced Scattering Coefficient
In our study of oral tissue, the reduced scattering coefficient was constrained
to follow a double power law, such that
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(3.5)
P; = A + C .[mm-'
Here, the wavelength, X, is expressed in units of microns, and X0 = 1 pun. This power
law description (with and without the second term) has been widely used to model the
wavelength-dependence of the scattering coefficient parameter in studies of both cells
and tissue7s-78. From modeling this parameter we extract three scattering parameters
that describe the tissue, A, B, and C76,77.
The A parameter is a scaling parameter related to the overall magnitude of
scattering. In a study of skin, the collagen fibers of the dermis were shown to be the
major source of light scattering- contributing mostly to scattering from larger
particles (Mie scattering), and to a lesser extent, scattering by small particles
(Rayleigh scattering)79. Mourant et al. showed that when modeling scattering from
suspended cells with a Gaussian distribution, the exponent of the power law was
sensitive to the standard deviation (width of the size distribution) and increased until
reaching a value of 4 (the Raleigh limit) as the size of the scatterers decreased. They
also found that the exponent is particularly sensitive to the smaller particles in the
distribution75. The C term represents the magnitude of scattering by Rayleigh
particles.
Modeling the Absorption Coefficient
The absorption coefficient was modeled as the sum of the contributions from
two absorbers, hemoglobin and 0-carotene:
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P a () =aHb (A) + a C () [mm 1] (3.6)
Plots of the extinction spectra for Hb, HbO2, and p-carotene are shown in Figure 3.3.
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Figure 3.3 A plot of the extinction spectrum, &, for three
absorbers found in oral tissue: (a) Hb (dotted black line) and
HbO2 (solid black line) (b) O-Carotene.
Hemoglobin absorption was modeled using a correction for vessel packaging
previously described in the literature8082. In our analysis, we adopt the formulation of
the model developed by Svaasand et al., and also presented by van Veen et aP'82 .
Vessel packaging accounts for alterations in the shape and intensity of the
hemoglobin absorption peaks as a result of the absorber being confined to discrete
finite-sized blood vessels, rather than homogeneously distributed throughout the
tissue. This model assumes that there is a single-sized vessel distributed uniformly
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throughout the tissue. We further impose a lower limit on the fitted vessel radius of
2.5 pm, since the minimum diameter of a capillary is on the order of 5-7 pm83 .
Using this model, the absorption coefficient of hemoglobin is represented by
the product of the absorption coefficient of hemoglobin in whole blood, 9ablood , a
wavelength-dependent correction factor which alters the shape of the absorption
spectrum, K, and the volume fraction of blood sampled, v. The absorption coefficient
for hemoglobin was described as follows:
Pa b (A) = K(A) .v Pa blood (A) [m m 1 - (3.7)
The correction factor K is calculated by the following equation,
I - exp[-2 -p blood (A).R ]
K(A) = ex() (3.8)
where R is the effective vessel radius in units of millimeters and the absorption
coefficient of blood, 9ablo0d(,) is in units of mm -1.The volume fraction, v, is described
by the following ratio:
v = cHb /150, (3.9)
where cHb is the extracted concentration of hemoglobin in units of mg/mL. The
concentration of hemoglobin in whole blood was assigned a value of 150 mg/mL. The
equation for 1ablodis given by
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pblood (A) = 0.1 -ln(10) 150[a - Hbo2 (A) + (1- a). EHb()] , [ 1m-] (3.10)
where a is the oxygen saturation, s is the extinction coefficient in units of
1/[cm-(mg/mL)], HbO 2 denotes oxyhemoglobin, and Hb denotes deoxyhemoglobin1 9.
The dramatic effect of the correction factor, K, on the lineshape and intensity of the
absorption coefficient of hemoglobin is shown in Figure 3.4.
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Figure 3.4 A plot of the absorption
coefficient of hemoglobin in the
absence of vessel packaging R= 0
[lm and for three different vessel
radii: 3, 5.5, and 7 gLm, respectively.
550 600 650
Figure 3.5 shows synthetic diffuse reflectance curves generated with the model of
Zonios et al. Parameters consistent with those obtained from clinical data collected
from the oral cavity were used to calculate Ps' and p~. Figure 3.5(a) shows the effect
of varying cHb while the vessel radius, R, is held constant. The plot shows that the
depth of the 420 nm and 540/580 nm hemoglobin peaks increases with increasing
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hemoglobin concentration. Figure 3.5(b) shows the effect of varying the vessel radius,
R, while cHb is held constant. In this case, the intensity of the 420 nm absorption
peak decreases relative to that of the 540/580 nm peaks, while the latter peaks remain
essentially unchanged.
(a)
Figure 3.5 Synthetic diffuse reflectance
data generated using the model of Zonios
et al. based on scattering and absorption
parameters consistent with those
obtained from clinical data. In each plot,
the dashed curve represents the curve for
the minimum value of the varied
parameter and the arrow represents the
(b) Wavelength [nm] direction of increasing value for the
varied parameter. (A). Reflectance
curves generated for hemoglobin
concentrations varying between 0 and 2
mg/mL, while the vessel radius was held
constant. (B) Reflectance curves
generated for vessel radii between 2.5
and 20 pmun, while the hemoglobin
concentration was held constant.
K0
Wavelength [nm]
The absorption coefficient for p-carotene was modeled as follows:
0af (A) = .1.- n(10)-cfiC. (2), [mm -'] (3.11)
where cPC denotes the concentration of p-carotene in units of mg/mL, and Ejc is the
extinction coefficient p-carotene in units of 1/[cm-(mg/mL)] 18. The complete
description of the absorption coefficient was as follows:
a (A) = K(A) -v -p',ood (A) + 0.l- ln(lO) -cfiC -cc(A) . [m m -1] (3.12)
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3.3.2 Intrinsic Fluorescence Spectroscopy
Intrinsic fluorescence spectroscopy (IFS) is a technique that was developed by
our laboratory to extract the fluorescence emitted by molecules native to the tissue
(autofluorescence) from the measured fluorescence, without alterations in intensity
and lineshape due to scattering and absorption8 4 '85. Intrinsic fluorescence, unlike the
measured fluorescence, represents a linear combination of the individual fluorophores
present within the tissue.
Fluorescence photons undergo scattering and absorption between the path of
origin and detection, which can cause significant distortions in the detected lineshape
and intensity. These distortions prevent the quantitative extraction of the specific
biochemical tissue components. Because fluorescence and reflectance photons
undergo approximately the same scattering and absorption events, the alterations in
the measured fluorescence can be accounted for and corrected, using a reflectance
spectrum that is collected from the same location. Extracting the intrinsic
fluorescence is particularly important for ensuring that changes in absorption (in
particular due to hemoglobin) and scattering do not affect the fluorescence parameters
and lead to misinterpretation of the data. The intrinsic fluorescence, fxm, can be
calculated as follows:
S=xm
Psx 1I x JS R, Rom
,= e
fi - 1
f = S(1 - g)
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The subscripts x and m refer to the dependence of the quantities on the excitation and
emission wavelengths, respectively. Fxm is the measured fluorescence and Ro is the
measured reflectance in the absence of absorption. The constant 1, has units of length,
and is related to the effective depth from which the fluorescence is collected by the
probe and is determined by the medium, as well as the delivery-collection geometry
of the probe. The parameter S represents a probe-specific constant, and g is the
anisotropy parameter. In our analysis, we use values obtained from studies of skin as
a reasonable approximation for g.
This method was developed based on the photon migration model, which
describes photons traveling through a turbid medium along paths with discrete nodes,
at which a scattering or absorption event occurs85'86. At each node, a portion of the
light is lost due to absorption and a fraction is scattered and continues to travel
through the medium. In this picture, the reflectance is related to the product of the
fraction of unabsorbed photons at each interaction event (albedo), and the probability
that a photon entering the medium and undergoing y scattering events will escape and
be collected. An analytical expression for the escape probability, Pn, was determined
based on Monte Carlo simulations by Wu et al. and modified by Zhang et al., such
that the reflectance, R, in the absence of absorption can de described as follows:
Si. -a -exp(-fP) (3.14)
R(2) = .,a np, =
y=1 1-a exp(-fi)
where
p, = a exp(-fpn)
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= S(1-g),
K= eR(4),
s = exp(p) 
-1,
a = ps/(s +Ra)
The parameter S is a constant related to the probe, g is the anisotropy parameter, and
a is the albedo.
To extend the picture to incorporate fluorescence, the fluorescence is
considered to occur at the (i+1) th node, after an initial i scattering events at the
excitation wavelength. After being absorbed by the fluorophore, the fluorescence
photon undergoes y-i-1 scattering events at the emission wavelength, where y is the
total number of scattering events. The measured fluorescence can then be defined in a
similar manner as the reflectance as follows:
Co y-l f -i-(3.15)
Fxm x a X aJx m Y ni p
y=l i=O fsx
where
fxm vIX 1 -'Ixmhvm (3.16)(hvX )
Pi =(axam)/2 "exp[-fx(i+1)exp[-- (y-i-)],
The intensity is denoted by I and the absorption coefficient of the fluorophore as jtf,.
The energy per the photon is calculated as the product of Planck's constant, h, and the
frequency of the light, v. The quantum yield of the fluorophore is denoted by <, and 1,
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as before is a probe-specific constant. The quantity fxm is defined as the intrinsic
fluorescence. By inserting the terms p, and pni into the equations for R(X) and Fxm,
we obtain the formula for the intrinsic fluorescence derived above (Eq. 3.13). This
model assumes a homogeneous medium and does not account for subsequent
secondary absorption of fluorescence that occurs within the medium, although these
are not expected to be significant effects.
In order to apply the IFS model, we need to compute the reflectance in the
absence of absorption at the excitation and emission wavelengths, Rox and Rom,
respectively. To do this we first used the scattering parameters extracted from the
modeled fit to the reflectance spectrum to calculate the wavelength-dependence of .s'
(Eq. 3.5). Rox and Rom are then calculated by setting la(X) to zero, inputting g,'(Q) into
the model of Zonios et al. (Eq. 3.4), and evaluating the equation either at each of the
ten excitations wavelengths (Rox), or for the entire range of emission wavelengths
(Rom). The Rx term in the IFS model is calculated by evaluating the equation of
Zonios et al., using the hemoglobin concentration extracted from the fit to the diffuse
reflectance data to calculate the input pL(Q). Rm was obtained directly from the
calibrated reflectance. Based on experiments with tissue phantoms, the constant S was
set to 1 and the constant I was set to 220 gm.
3.3.3 Light Scattering Spectroscopy
Light scattering spectroscopy (LSS) studies the spectral variation of singly-
scattered elastic light from the most superficial layers of tissue. This signal is
attributed to scattering from epithelial nuclei. The reflectance signal collected from
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tissue represents both singly and diffusely scattered light. Our laboratory developed a
novel method for separating the much weaker singly-scattered light signal from the
large diffusive background using a model-based approach87'". In this approach, the
light scattering signal is obtained by subtracting the modeled diffuse scattering
component (DRS fit, Section 3.3.1) from the measured reflectance. By modeling the
amplitude and frequency of this residual signal, which corresponds to the light
scattering signal, the nuclear density and size distribution were then extracted.
After an in depth investigation of this model, a number of findings were
discovered that provided strong evidence that this technique is not reliable. While the
initial studies and development of this technique were based on work with cells, it
was found that in tissue, imperfect modeling of hemoglobin absorption using the DRS
model resulted in hemoglobin absorption features in the residual signal. This was
particularly the case when vessel packaging was not taken into account in the DRS
model. Figure 3.6 shows an example of a reflectance spectrum collected from the oral
cavity, and the modeled fit with the DRS model either with or without taking vessel
packaging into account [Fig. 3.6(a)]. The LSS residual signals extracted using the
data with each of the respective fits in Fig. 3.6(a) are shown in Fig. 3.6(b). The
hemoglobin features are clearly visible in the LSS residual obtained from the fit in
which vessel packaging was not taken into account. The imperfect fit alters both the
amplitude and frequency of the oscillations.
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Figure 3.6 (a) A plot of a
reflectance spectrum collected
from the lateral surface of the
tongue (black line), and the
modeled fit without vessel
packaging (red line), and with
vessel packaging (green line).
(b) The LSS residual signal
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The amplitude of the LSS signal was found to be on the order of 5%, as
shown in Figure 3.6(b). In an analysis performed on esophageal tissue, hemoglobin
features were visible and oscillatory amplitudes as great as 20% were observed1 0' 89. In
contrast to these results, we recently performed a numerical simulation to predict the
expected amplitude of the LSS signal in tissue and it was found to be <2%89. Given
that the typical noise in the clinical measurements is on the order of 5%, we expect
this to also contribute significantly to the residual obtained after subtracting the fit to
the data. Therefore, reliably extracting LSS parameters from this signal may be more
difficult.
As another test, we generated numerical (synthetic) reflectance data using
parameters consistent with those obtained from clinical data as inputs into the Zonios
reflectance model. The scattering coefficient was calculated using Eq. 3.5 and the
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absorption for hemoglobin was modeled either with vessel packaging (Eq. 3.7) or
without vessel packaging (equivalent to Eq. 3.10 without the factor of 150). Random
Gaussian noise was added to all the spectra in the amounts typically found in clinical
data measured from the oral cavity. In the first series of reflectance spectra, vessel
packaging effects were included in the model and each parameter (A, B, C, cHb, a,
the effective vessel radius, the wavelength-dependence (shape) of the noise, and
magnitude of the noise) was systematically varied, while the others were held
constant. The resulting numerical reflectance data were fit over the range of 380-700
nm using the Zonios model, but without including vessel packaging in modeling the
absorption. LSS parameters were extracted from the residual spectra using the
published method 87. All reflectance and residual data were fit over the range of 380-
700 nm. Since the numerically generated data was fit without vessel packaging,
hemoglobin absorption features were clearly visible in the residual spectra. If we
apply the model of Perelman et al., we extract values for the mean diameter (- 11-14
pm) and standard deviations of the nuclei (-0-5 ptm) that are consistent with those
obtained from pathology even in the absence of nuclear scattering. Furthermore, the
extracted LSS parameters were significantly affected by the wavelength range used in
the LSS analysis, the concentration of hemoglobin present, and the magnitude and
wavelength-dependence (shape) of the noise. For example, when the analysis range
was changed from 350-700 nm to 390-700 nm, the values for the extracted mean
diameter and the percentage of enlarged nuclei shifted by 3 ptm and 40%,
respectively.
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Previous studies in our laboratory combined all three modalities, DRS, LSS,
and IFS, a technique known as Tri-modal spectroscopy (TMS)'1 '1 2. However, from
the compelling evidence mentioned above, it was decided that the LSS technique was
not a robust method and the signal generated using the model-based approach was
unlikely to be due to epithelial nuclei. Therefore only DRS and IFS were used in the
present work.
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CHAPTER 4
Instrumentation and Data Analysis
In this chapter, we first present a detailed description of the instrumentation and
software used to collect the spectroscopic data. Following this, we describe the
methods used to calibrate and model the data in order to obtain quantitative
parameters relating to the tissue morphology and biochemistry. Finally, we conclude
with a description of the statistical methods that we employ in the analysis of the
clinical data.
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4.1 Instrumentation and Software
4.1.1 Basic Description of the FastEEM Clinical Instrument
Our laboratory has developed a portable, clinical device known as the Fast
Excitation Emission Matrix (FastEEM)'. The FastEEM collects diffuse reflectance
and fluorescence spectra in a fraction of a second under standard room illumination.
A xenon arc flash lamp and a 308 nm XeCl excimer laser serve as the excitation light
sources for the reflectance and fluorescence measurements, respectively. A
nhotogranh of the FastEEM in the
clinical setting is shown in Figure
4.1.
Light is delivered to the
tissue and collected via an optical
fiber probe, which is placed in gentle
contact with the tissue. The light
returned from the tissue is focused
onto the entrance slit of a diffraction
spectrometer, dispersed onto an
intensified CCD, and stored by a
computer. The operation of the
instrument and data acquisition is
controlled by a custom-designed
software program.
Figure 4.1 A photograph of the FastEEM in the
clinic.
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4.1.2 Generation of Excitation Light
A schematic diagram showing the major hardware components of the
FastEEM is shown in Figure 4.2.
rioer SMA To
Figure 4.2 Diagram showing the major hardware components of the FastEEM. The Xe flashlamp and XeCl
excimer laser are used to generate the excitation light for the reflectance and fluorescence measurements,
respectively. The excitation light is coupled into the delivery fiber of the optical fiber probe. The returned
light is directed through the filter wheel, to the spectrograph, and CCD. A photograph of the dye cell wheel
shown in the schematic on the left (boxed area) is shown on the right.
The flashlamp (60 W, L7684, Hamamatsu, Bridgewater, NJ) generates
broadband white light over the wavelength range of approximately 300-800 nm. The
XeCl excimer laser (OPTEX, Lambda Physik, Ft. Lauderdale, FL), provides
fluorescence excitation light at 308 nm and nine additional wavelengths, by pumping
a series of dyes with emission wavelengths ranging from 340-460 nm. Table 4.1 lists
the nine dyes used to generate the fluorescence excitation light, their emission
wavelengths, and the full width at half maximum (FWHM) of the signal. The dyes are
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contained within cylindrical cuvettes (d = 22 mm, path length = 12.5 mm) situated on
a rotating wheel (dye wheel). The dye wheel rotates at -3 Hz. The cuvettes are made
of optically transparent Spectrosil Quartz (Starna Cells, Inc., Atascadero, CA). In
order to generate each excitation wavelength, the laser beam is directed by a series of
mirrors and focused to a point, such that as the dye wheel rotates, each dye is
successively brought into the path of the beam and excited during the collection
period. For 308 nm fluorescence excitation light, a cylindrical lens is positioned on
the dye wheel (no cuvette is present) and the output from the excimer laser is
conveyed directly to the delivery fiber of the optical fiber probe. The FWHM of the
308 nm excitation light is 8.5 nm.
Laser Dye Solvent Emission X inm] FWHM [nm]
p-Terphenyl (PTP) p-dioxane 341.6 5
PBD p-dioxane 360.0 5
Exalite 384 p-dioxane 383.6 6
Exalite 398 p-dioxane 400.0 6
LD 425 p-dioxane 407.2 12
Stilbene 420 methanol 425.7 8
Coumarin 440 methanol 441.0 10
Coumarin 460 methanol 461.5 10
Coumarin 480 methanol 483.1 9
Table 4.1 Properties of the dyes used to generate the nine fluorescence excitation
wavelengths.
Emission light generated from the reflectance and fluorescence sources,
respectively, are focused into two separate ends of a Y-fiber coupler. The fibers from
the two excitation sources are merged and form the central delivery fiber of the
optical fiber probe. The flashlamp and excimer laser are both pulsed sources. The
pulse duration of the flashlamp and excimer laser is 2.9 gps and 8 ns, respectively, at
FWHM. The collection of a complete data set entails the sequential excitation and
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collection of the reflectance and fluorescence data and takes -0.3 s. Figure 4.2
summarizes the specifications for the two light sources.
Property Flash Lamp Excimer Laser
Repetition Rate (s-) 6 30
Radiant Energy (pulse') 1 pJ 1 -10 p.
Pulse Width (FWHM) 2.9 ps 8 ns
Irradiance per Pulse (kW/cm 2) 0.03 184-1,840
Fluence per Pulse (mJ/cm2) 0.17 0.17-1.7
Table 4.2 Summary of the specifications for the two light sources preent on the
FastEEM, the Xe arc flashlamp and XeCl excimer laser.
4.1.3 Optical Fiber Probe
A i l fIb . i
used to deliver the excitation
light from the two sources, as
well as to convey light emitted
from the tissue to the detection
components. The probe consists
n1 oLtCa Ler •pro• as
A.
of a central delivery fiber, into 'I [,C
Figure 4.3 (a) Diagram of the optical fiber probe showing
which the excitation light is front and side view (b) Photograph showing the tip of ti
optical fiber probe, which is placed in contact with the tissu
coupled, surrounded by 6
collection fibers in a closest-packed configuration. The fiber core is composed of
fused silica and has a diameter of 200 gtm (Numerical Aperture (NA) = 0.22). With
the cladding, the diameter of each fiber is 220 glm. The entire 3 m length of the probe
is enclosed in Teflon tubing for protection. At the probe tip, the fibers are exposed
a
he
e.
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from the cladding, fused, embedded in a protective silver epoxy, and surrounded by a
protective sheath. A 1.5 mm long quartz shield is placed at the very tip to create a
reproducible geometry when in contact with the tissue. With the cladding and
protective sheath, the probe tip has a diameter of approximately 1.4 mm. The tip of
the probe is polished to an angle of approximately 170 to prevent specular reflections
from entering the probe and producing artifacts in the measured signal. Figure 4.3
shows a schematic of the probe geometry [Fig 4.3a] and a photograph of the probe
[Fig 4.3b]. The diameter of the delivered excitation light is approximately 480 glm.
At the distal end of the probe, the 6 collection fibers separate from the source
fiber and couple to the detection components via a set of 6 SubMiniature version A
(SMA) connectors. Similarly, the distal end of the delivery fiber is coupled to the
excitation sources via a separate SMA connector.
4.1.4 Detection System
The six collection fibers are aligned vertically, focused, and directed through a
filter on a second rotating wheel (filter wheel). The filter wheel and dye wheel are
coupled so that they rotate in parallel and the appropriate long pass filter for the
particular excitation light in the sequence is in place. The filter wheel contains 10
filters which specifically block back-reflected excitation light for each fluorescence
excitation wavelength.
After passing through the filter, the collected light is directed through the slit
of the spectrograph (Spectra Pro 150 Acton Research, Acton, MA, 300 grooves/mm
with 500 nm blaze, center wavelength 550 nm), where it is dispersed and then
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detected by an intensified CCD (PIMAX 1024RB Roper Scientific, Princeton, NJ).
The dimensions of the chip are 256x1024 pixels. The rapid gated detection of the
intensified CCD minimizes motion artifacts and enables data to be acquired in the
presence of ambient light. The CCD is cooled to -200 C by Peltier (thermoelectric)
cooling to reduce noise from the dark current (thermally generated charge) and
improve the signal-to-noise ratio. The wavelength resolution of the system based on
the FWHM is approximately 5.3 nm.
4.1.5 Timing and Triggering
The timing of the data acquisition is controlled by a National Instruments
timer/counter board (PCI-6602, National Instruments, Austin, TX). A ring of metal
pins attached to the dye wheel are positioned to sequentially interrupt a beam of light
between two optical sensors (Omron Photomicrosensors EE-SX770, Schaumburg, IL)
as each dye (or blank position) is rotated into the path of the laser. When a pin passes
through the beam, the constant voltage signal generated between the two sensors
decays, generating a trigger signal that is read by the timer board. The timer board
then sends an appropriate trigger signal to the flash lamp or the laser. A second ring
of pins on the dye wheel controls the gating of the CCD via a second set of optical
sensors.
CHAPTER 4: Instrumentation and Data Analysis
4.1.6 Software
A custom-designed software program created using LabView 7.0 (National
Instruments Corporation, Austin, TX) is used to control the hardware components and
coordinate the timing of the initiation and termination of data collection. The software
was developed by engineers in our laboratory. The program is operated through a
graphical user (GUI) interface on the FastEEM's computer. Using the GUI, various
settings can be controlled including the gain on the CCD and the number of spectra to
be averaged for each measurement. Real-time analysis of the collected diffuse
reflectance and fluorescence data using the mathematical models described in Chapter
3 can also be performed by the software in combination with MATLAB (The
MathWorks, Inc. Natick, MA).
A complete set of data consists of two diffuse reflectance spectra and an
excitation-emission matrix (EEM), which contains fluorescence intensities as a
function of the excitation and emission wavelengths. As described earlier, a single
data set can be collected in -0.3 s. Because we typically average 5 sets of reflectance
and fluorescence data for each saved measurement, the collection time is on the order
of -1.5 s. For each measurement, the standard deviation of the 5 spectra as a function
of the emission wavelength is also recorded.
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4.1.7 Advances in Instrumentation
Reliable Measurement of Diffuse Reflectance
At the beginning of this project, we worked extensively to identify the source
of an artifact present in the reflectance data. Unlike earlier data, recent data began to
show a large deviation in the red region, starting at approximately 600 nm (see Fig.
4.4(a)), between the modeled reflectance spectrum and in vivo data. The data
measured by the FastEEM systematically indicated higher amounts of reflected light
than the modeled data in this wavelength regime. In order to elucidate the source of
this artifact, we carried out studies with physical tissue models (solutions of
polystyrene beads and hemoglobin in water with known scattering and absorption
parameters), so that the actual data could be compared with the theoretical modeled
reflectance spectrum.
Early steps in the investigation of the source of this problem involved testing
several hypotheses to explain the extra counts including the following: 1) Limitations
in the resolution of the spectrophotometer resulted in broadening of peaks and the
distribution of extra counts into a wide range of wavelengths, and 2) The additional
counts were due to second order light generated from the diffraction grating.
To test the first hypothesis, we took a background spectrum in which we
shone the probe light into a black cup of water. We then directed light from a laser
pointer (630-680 nm) into the probe and examined the collected light. If our first
hypothesis were true we would expect to see an increase in the background counts on
either side of the laser line due to scattering of this light into other wavelengths,
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compared to a spectrum collected when the laser light was absent. The results showed
no difference in the backgrounds.
Second-order light corresponds to a higher order diffraction pattern of the
signal from the shorter wavelengths, produced at exactly twice the original
wavelength. Because of the spatial overlap of this signal with the true reflectance
measured at the longer wavelengths, the counts recorded by the CCD would represent
a combination of the two signals. To test the possibility that second order light from
the grating was contributing to the observed signal, we collected spectra from
phantoms after placing a 335 nm, 365 nm or, no long-pass filter in front of the flash
lamp. We expected less deviation at the higher wavelengths with the filters present
because they would cut off the transmission of the first order light, and furthermore,
the most improvement would be seen in the case of the 365nm long-pass filter. Figure
4.4 shows the results from this experiment. The abnormal rise in the reflectance at the
longer wavelengths is clearly apparent in Figure 4.4(b). With the 335 nm long pass
filter the rise does not occur until -650 nm which is approximately twice the
wavelength at which this filter begins to transmit light. Similarly, the 365 nm long
pass filter further suppresses the rise in the reflectance until -720 nm.
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Figure 4.4 (a) Calibrated reflectance for a tissue phantom taken with no filter present (blue dotted
line), with a 335 nm long-pass filter (grey line), or with a 365 nm long-pass filter (black line) placed in
front of the flash lamp. (b) A close-up of the reflectance spectra from (a) at longer wavelengths.
This experiment confirmed that the problem was due to second order light.
Our system is particularly affected by this artifact because data is collected over a
broad wavelength range (300 - 800 nm).
After isolating the source of the problem, we set out to characterize the
magnitude of the second order effect. An experiment was carried out in which a series
of fluorescent solutions were excited by the laser, thus providing well-defined
fluorescence emission peaks. The peak emission wavelengths of the dyes ranged from
approximately 350nm to 380 nm. We were able to observe a second well-defined
peak with a smaller magnitude at longer wavelengths with a center wavelength at
approximately twice the center wavelength of the sample's fluorescence peak as
shown in Figure 4.5.
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Figure 4.5 Plot of the measured signal from a fluorescent dye with an emission
peak at -360nm. The second order light results in a second peak at approximately
twice the peak wavelength. The inset shows a zoomed in view of the fluorescence
signal detected at longer wavelengths.
By aligning the signal of the second order light on the scale of the first order
light, [Figure 4.6(a)], and dividing the second order light by the first order light, we
developed a wavelength-dependent correction curve. By combining the ratios
obtained from the various fluorescence emission peaks, the correction factors for a
wide range of wavelengths could be fit by a linear equation (R2 = 0.97) as shown in
Figure 4.6(b).
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Figure 4.6 (a) Plot of the first order light and the second order light (plotted at half the actual
wavelength at which it was detected). Both signals were normalized to the peak. (b) Plot of the
correction factor, the ratio of the second order light to the first order light. A linear fit is also
shown.
The introduction of the second order light in the reflectance signal was caused
by a switch to UV grade optics, which allowed shorter wavelength light from the
flash lamp (down to -160 nm) to be transmitted through the system. Since the flash
lamp produces light as far down as -270 nm, second order light was generated
beginning at -540 nm.
Our next experiments tested whether the linear correction function ("second
order equation") could be used to fix previously collected data. We compared
phantoms taken without the filter in front of the flashlamp and fixed using the second-
order equation, to the signal measured from the same phantom after placing a 400 nm
long pass filter in front of the flash lamp. This filter would block all second order
light generated below -760 nm. Figure 4.7 shows the results for one phantom, the
results of which confirmed that the two methods are equivalent.
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As a permanent solution, we created a hardware fix for the problem. In a
single data acquisition, the reflectance measurement is performed twice in order to
correct for second-order light from the spectrograph that contributes to the diffuse
reflectance signal measured by the detector.
In the first reflectance measurement, the filter wheel slot is empty, therefore
the entire measured reflectance signal enters the spectrograph. In this case, the signal
from shorter wavelengths is reliable, but at longer wavelengths (>550 nm), the
second-order light generated by the grating of the spectrograph also contributes to the
signal measured by the CCD. For the second measurement, the filter wheel contains a
435 nm long-pass filter, which prevents transmission of the signal at shorter
wavelength from being transmitted to the spectrograph. As a result, the measured
reflectance at the longer wavelengths represents the true measured signal from the
tissue. In the preprocessing of the collected reflectance, the data from the 2
reflectance measurements are merged. The merging process involves first correcting
the second (filtered) measurement for the transmission properties of the filter, and
then scaling it to overlap with the measurement from the first (unfiltered)
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Figure 4.7 Reflectance from a
phantom taken with a 400 nm
long pass filter (black solid
line), without the filter (blue
dotted line), and without the
filter, and without the filter,
but corrected by the second
order fix equation (dashed
grey line).
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measurement. The final spectrum contains the signal measured from the unfiltered
reflectance data at shorter wavelengths and the counts from the filtered reflectance
data at longer wavelengths.
4.2 Data Preprocessing and Analysis
4.2.1 Artifact in the Measured Data
In the course of analyzing the clinical data, we observed a signal in the
fluorescence data which was not consistent with the fluorescence of known
fluorophores, and also appeared in the fluorescence at every excitation without any
shift in wavelength. It was discovered that the white light emitting source worn by the
physician ("headlight") and the overhead lights in the operating room which were
shone directly on the tissue during data collection, were diffusing into the tissue and
being collected by our probe. Unlike ambient room light which is weak and not
focused directly on the tissue, these light sources are directed on the tissue in a more
focused manner. We devised a means of correcting both the reflectance and
fluorescence signal for this artifact as follows. First we identified a fluorescence
excitation at which the measured fluorescence excitation signal was negligible or
weak (often 425 or 440 nm excitation). Because the measured signal for this
excitation would not be due to fluorescence, it provided a means of isolating the stray
light signal. By correcting this stray light spectrum for the transmission properties of
the long-pass filter used for this specific excitation light, we obtained the true
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spectrum of the stray light. The reflectance spectra were corrected by subtracting
these counts from the measured spectrum. The measured signals at the remaining
fluorescence excitations were then corrected by subtracting this spectrum from the
measured signal at the excitation after multiplying the stray light spectrum by the
transmission properties of the filter used at the particular excitation, since the
measured signal must pass through the filter (on the filter wheel, Section 4.1.4))
before it is detected.
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Figure 4.8 (a) Measured fluorescence signal for 5 fluorescence excitations, which contains the stray
light (b) Examples of the stray light signal isolated from the reflectance and 3 fluorescence
excitations after correcting for the transmission properties of the filters (fluorescence only) (c)
application of second order light correction (merging of unfiltered and filtered spectra) (blue line),
and stray light correction (black line), to calibrated reflectance (red line).
Figure 4.8(a) shows the measured fluorescence counts after correcting for the
background signal for 5 fluorescence excitations, with clearly visible signs of stray
light. Figure 4.8(b) shows the isolated stray light signal to correct the measured
reflectance, as well as the correction for 3 fluorescence excitations. Because the stray
light signal isolated from each of the fluorescence excitations has been corrected for
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the transmission properties of the respective filters, the spectra all overlap. Figure
4.8(c) shows the uncorrected calibrated (original) reflectance data, and the effect of
the stray light correction. In addition the second order correction was performed by
merging the data. The aforementioned correction was used to correct data which had
already been collected. Once this was recognized, extra light sources other than room
lights were turned off prior to each measurement. For a large number of samples, the
fluorescence spectra excited at the longer wavelengths were imperfectly corrected
(overcorrection was frequently noted), likely due to the fact that the fluorescence
emission and stray light overlap to a greater extent, and the presence of absorption
features in the stray light, which would remove rather than add light to the measured
signal. This meant that the measured signal for most of the 10 fluorescence
excitations were unreliable. As a result, only the 308 nm and 340 nm excitations were
analyzed in the work described in this thesis as their emission was reliable.
4.2.2 Calibration and Modeling of the Reflectance Data
All data were corrected for background reflectance and fluorescence by
measuring a spectrum from water in a black container and subtracting these counts
from the signal measured from the tissue and calibration spectra. The calibrated
diffuse reflectance spectrum, Rcal(X), was generated by dividing the measured
spectrum, Rmeas(,), by a spectrum measured from a Spectralon (LabSphere, Inc.,
North Sutton, NH) 20% reflectance standard, R-td(X), as follows:
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R,7a (A) = SR (A) -[R.R, (A) - Rbg (A)] /[R,,d (2) - Rbg (2)]. (4.1)
SR (k) denotes the fraction of the light reflected by the spectralon reflectance standard
and is an intrinsic property of the material. The values for SR (k) were provided by the
manufacturer. Rbg refers to the background reflectance counts. As shown in the
equation, all of the quantities are wavelength dependent. Calibration of the measured
reflectance corrects for the spectral profile of the flashlamp and the wavelength-
dependence of the detector response.
A non-linear least-squares fitting algorithm was used to fit the calibrated
reflectance data to the model of Zonios et al. described in the previous chapter. The
function minimizes YA, the error between the modeled fit, Rft, and RcIa, where
S= [(Rt () -Rca()) 2 / R() 2] (4.2)
The standard deviation of Rcal, aRcal, was calculated by propagating the error
(standard deviation) in each of the measured spectra used to calculate the calibrated
data according to the following equation:
S (A) = S aR 2+ aRcal +2 (Rea 21
aR ) bg aR (4.3)
The standard deviations are denoted by a. All values of a are in units of counts
except for 5Rcal, which is in calibrated reflectance units The standard deviation for
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each measurement is derived from the 5 individual spectra which are averaged to
produce a single recorded measurement. Based on the previous equation, the error in
the calibrated reflectance (in reflectance units) was computed as follows:
S_______[ 2+(D 2 (R R ')221 1/2 (4.4)
'RC, (A) SR= R g- R•Rstd - Rbg ) R.  + (R, - Rst, )2" 2 + ( bg - meas d 201 2  
4.2.3 Calibration and Modeling of the Fluorescence Data
The fluorescence emission measured by the system at a specific excitation
wavelength, Fmes(Xx,,), is a function of the laser intensity, I,, detector response,
Ssystem, and the intensity of the fluorescence emitted by the fluorophore, Ffl:
F..e (AX, A) = I (A) -F(2 x,2) Se. (). (4.5)
The dependence of these quantities on the excitation wavelength and/or emission
wavelength is indicated by x. and X, respectively. Because we do not measure the
intensity of the laser during data collection and variations from day to day can affect
the measured fluorescence, we calibrate the fluorescence intensity using a standard
solution of rhodamine 610 dye (Exciton Dayton, OH) in ethylene glycol. Rhodamine
has a single emission peak at 580 nm and can be excited by all the excitation
wavelengths. The goal of the rhodamine calibration procedure is to isolate the
intensity of the fluorescence emitted by the tissue from the intensity of the excitation
light generated from the laser and dyes, as well as other variations in the system. This
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calibration also serves as a means of relating the intensity of the excitation light for
the different excitation wavelengths.
By measuring the fluorescence emission profile of the rhodamine solution
using a fluorimeter, we determined the true relative fluorescence intensities for each
excitation wavelength. We then normalized the intensity values measured at each
excitation wavelength by the intensity measured at 308 nm excitation. Each day of
data collection, we measure the same rhodamine solution on the FastEEM, determine
the maximum peak intensity for each excitation wavelength, and then apply the same
normalization process. Using the normalized intensity ratios obtained from the
fluorimeter, Sreerence, and the set of normalized ratios derived from the measurement
with the FastEEM, Serhod, we apply a correction factor to the measured fluorescence
and obtain the calibrated fluorescence. For each excitation wavelength, the calibrated
fluorescence, Fcal, is calculated according to the following equation:
Fcat ( x, ) = [Fme~ ( ~x,, ) F A (22) 2x,2)] [( (2X) / Sfod ()]. (4.6)
The background fluorescence is denoted by Fbg. Although the rhodamine
fluorescence standard corrects the fluorescence intensity and enables the comparison
of the intensity across different excitation wavelengths, despite different output
energies from the dyes, it does not correct for distortions in the measured
fluorescence lineshape.
The extraction of the intrinsic fluorescence is achieved using the IFS
algorithm presented in Chapter 3.3. The spectra of the component fluorophores (basis
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spectra) for each excitation wavelength were then extracted from the intrinsic
fluorescence using multivariate curve resolution (MCR) and in some cases, a
spectrum collected from the pure chemical. The intrinsic fluorescence spectrum
extracted for each excitation wavelength was modeled as a linear combination of the
component fluorophores using a linear least squares fitting algorithm in order to
obtain the contribution of each fluorophore. The component fluorophores for each
excitation wavelength are shown in Table 4.3, where an "x" denotes the component is
included in the model.
Excitation Wavelength Inm] Tryptophan Collagen NADH
308 x x ix
340 x x
Table 4.3 Summary of the fluorophores excited at each excitation
wavelength analyzed in the clinical studies.
4.2.4 Wavelength Calibration
An emission spectrum from a mercury argon lamp (HG-1, Ocean Optics,
Dunedin, FL) was recorded each day of data collection. Because the wavelengths of
these peaks are known, we can determine the relationship between pixel number and
wavelength by fitting a second-order polynomial to a plot of the wavelength of each
peak versus the pixel number of the peak.
CHAPTER 4: Instrumentation and Data Analysis
4.3 Statistical Methods
4.3.1 Logistic Regression
Logistic regression is a classification method in which one or more
independent predictor variables (spectral parameters, in our case) are used to predict
the probability (dependent variable), of a sample's membership to one of two classes
(binary outcome)2. The probability, p, as a function of the independent variables,
X,...X,, is modeled according to the following equation:
pIn(IPP= a+f iX 1 8+2X2 + 183 3x..3,xn, (4.7)
where a is a constant, and PI... n represent fit coefficients for each independent
variable. The values of these quantities are obtained by applying the method of
maximum likelihood estimation (MLE) on a set of training data in which the class
membership is known. MLE maximizes the likelihood function, the joint probability
or likelihood of obtaining the observed data, in order to extract a and the coefficients
for each of the parameters3. The MLE function is solved iteratively by a computer. In
order to obtain p, this equation can be rearranged as follows:
1 (4.8)
1 + e- (a+p'x ' +p2X2 -f3X3"-- nX,)
The value ofp indicates the probability of a positive (e.g. diseased) outcome. A more
in depth description of logistic regression can be found in the following source3
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4.3.2 Identification of Significant/Diagnostic Parameters
While we extract a number of spectral parameters from the reflectance and
fluorescence spectra, not all of these parameters contribute significantly to the
separations of interest or provide diagnostic information. In order to identify the most
relevant parameters to be used for constructing the spectral models, we employ the
likelihood ratio test (also known as the log likelihood ratio test). The test is based on a
comparison of a measure of the "badness of the fit" for the logistic regression models
developed from two different sets of parameters. This measure is known as the
deviance, D, and is related to the maximum likelihood value of a fitted model, Li, as
follows:
D = -2 -InL, (4.9)
The deviance is an output obtained from the numerical calculation performed by the
computer to maximize the likelihood function. The log likelihood ratio test (LLR) is
calculated as the difference in the deviances for two models, or equivalently, using
the following ratio:
LLR = -2 -(L (4.10)
LI represents the maximum likelihood value for the reduced or simpler model, and L2
the value for the full model. For this test, the two models L1 and L2 must be nested,
meaning that the parameters in the reduced model are a subset of those in the full
model.
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The LLR tests the null hypothesis that the parameter omitted in the simple
model has a coefficient of 0 in the logistic regression model. The higher the value of
the LLR, the more significant the omitted parameter. A non-significant likelihood
ratio test indicates no difference between the full and reduced models; therefore, the
specific regression coefficient(s) being tested can be omitted. The LLR approximately
follows a chi-squared distribution with degrees of freedom equal to the difference in
the number of parameters present in the full model and reduced model. Based on the
values of the LLR, all the parameters can be ranked in terms of their importance in
contributing to the model; however, only those parameters for which the test statistic
exceeds the critical chi-squared value at the 5% significance level are considered
statistically significant.
4.3.3 Leave-one-out Cross Validation and Receiver Operator Characteristic Curves
In order to assess the effectiveness with which various diagnostic parameter
combinations and algorithms separate two classes (discrimination), we used leave-
one-out cross-validation (LCV). LCV is a method applied in cases in which the
number of samples available for constructing a training set and test set for the
evaluation of the performance of a classifier is limited. LCV is performed by
partitioning the total number of samples, n, into two groups: a single test case, and a
training set comprised of the remaining n-l samples. The diagnostic algorithm
developed from the training set is then applied to the test case, and this procedure is
then repeated so that each of the n samples are sequentially omitted and treated as the
test case.
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One set of measures of the discriminatory power or accuracy of a diagnostic
algorithm is the sensitivity and sensitivity4. The sensitivity indicates the percentage of
correctly classified positive (diseased) cases. Sensitivity does not take into account
false positive cases. In contrast, specificity represents the percentage of correctly
predicted negative (non-diseased) cases. By summing the number of true positive
(TP), true negative (TN), false positive (FP), and false negative (FN) results for the
classification of the final point across all the n samples, the sensitivity and specificity
can be calculated according to the following equations:
Sensitivity = TP / (TP + FN), (4.11)
Specificity = TN / (TN + FP). (4.12)
TP corresponds to the number of positive (diseased) samples that were correctly
classified by the diagnostic algorithm as positive, while FN is the number of times in
which a positive sample was incorrectly classified as negative (non-diseased). TN is
the number of negative samples correctly classified by the diagnostic test as negative,
while FP is the number of negative samples which were incorrectly classified as
positive by the test. A perfect separation, as could be achieved for two non-
overlapping groups, would have a sensitivity and specificity of 100% and 100%,
respectively.
By computing the sensitivity and specificity based on the LCV results for each
value of the p (probability threshold), we can generate a receiver operator
characteristic (ROC) curve in which the sensitivity (true positive rate) is plotted
against 1-specificity (false positive rate)4. This curve depicts the trade off between the
sensitivity and specificity for various thresholds inp. Each point along the ROC curve
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corresponds to the sensitivity and specificity for a specific threshold. The optimal
sensitivity and specificity, or combination, for the specific application is chosen and
used to report the accuracy of the diagnostic algorithm. The final decision line/surface
for diagnosis would then represent the solution to the logistic regression equation
(determination of the coefficients of the independent variables) calculated at the
specific p value corresponding to this point. A new test case which produces a p
greater than this value would be considered a positive test result.
In addition to the sensitivity and specificity, a diagnostic test can also be
evaluated in terms of the positive predictive value (PPV) and negative predictive
value (NPV). The PPV represents the probability of disease among people who test
positive, and the NPV, the probability of the absence of disease among people who
test negative. They can be calculated according to the following equations:
PPV = sensitivity -prevalence (4.13)
sensitivity -prevalence + (1 - specificity) . (1 - prevalence )
NPV = specificity. (1 - prevalence ) (4.14)(1 - sensitivity) prevalence + specificity . (1 - prevalence )
The PPV and NPV provide a measure of the usefulness of the test given the prior
probability of disease in the population before the test was administered5.
Using the ROC curve, another measure of the accuracy of a diagnostic test can
be extracted by calculating the area under the curve (ROC-AUC)6 . The ROC-AUC
corresponds to the probability that a positive sample would exhibit a higher classifier
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score than that of a negative sample, if a random pair of samples is selected from the
positive and negative groups4. A value of the ROC-AUC equal to 0.5 indicates that
the test produces diagnostic results equivalent to what would be observed due to
chance alone. At the other extreme, a value of 1.0 indicates no overlap in the
distributions and thus a perfect separation. The higher the ROC-AUC value, the better
the diagnostic accuracy. This measure characterizes the overall accuracy of the model
across the entire range of thresholds, and thus is more comprehensive than the
sensitivity and specificity, which are determined from a single point. The quality of
the ROC curve, and thus the ROC-AUC, increases with the number of thresholds
tested (step size) and with increasing size of the test sets4. An example of an ROC
curve is shown in Figure 4.9. Curves depicting an ROC-AUC of 0.5 and 1.0,
respectively, as well as a typical ROC curve for a diagnostic test are shown.
1
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Figure 4.9 Examples of ROC curves. The dotted line represents
the ROC curve that would result for a test which produces a
classification result equivalent to what would be observed due to
chance (ROC-AUC = 0.5). The thick solid line shows the ROC
curve for a test which produces a perfect separation (ROC-AUC =
1.0). The dashed line shows a typical curve for a classification test
with a ROC-AUC of >0.70.
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4.3.3 Interquartile Range (IQR) Exclusion Criteria
On method of identifying outliers in data is based on the interquartile range
(IQR) criteria. In order to understand the IQR exclusion criteria, it is helpful to
introduce the box plot. A basic box plot summarizes the following properties of a set
of data: the median, the lower limit (minimum), upper limit (maximum), the lower
quartile (median of the lower half of the data), and upper quartile (median of the
upper half of the data)7. In some box plots, notches are also displayed, which
represent the approximate confidence interval about the median. The IQR is defined
as the difference between the value of the upper quartile (Q3) and the lower quartile
(Q1). The IQR represents the middle 50% of the data points, since a quartile
corresponds to the range within which 25% of the data points lie. The length of a box
plot is equivalent to the IQR. Figure 4.10 shows an example of a box plot with the
major components labeled.
* 4- Outliers
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Figure 4.10 Example of a box
plot. The major components of
this plot are labeled, including
the median, upper and lower
limits, upper and lower quartiles,
notches, outliers, and IQR.
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According to the IQR exclusion criteria, data points which exceed Q3 by 1.5-IQR, or
fall below Q1 by 1.5-IQR are considered outliers (red plusses in Fig. 4.10). These
criteria can be summarized as follows:
Outliers > Q3 + 1.5.(Q3-Q1) (4.15)
< Q1 - 1.5"(Q3-Q1) (4.16)
4.3.4 K-means Clustering
K-means clustering is one of several types of unsupervised classification
methods. The goal of an unsupervised classification method is to find natural
groupings (category labels) for a set of data without any labels, based on patterns in a
similarity measure . The clustering algorithm examines multiple partitions of the
parameter(s) into k clusters in order to determine the optimal partition, such that the
patterns in a cluster are more similar to each other than to patterns in different
clusters. The optimum partition for a given value of k represents the solution which
minimizes the sum of the within cluster variations totaled for all k clusters. The
variation between each member of a specific cluster and the cluster center or centroid
can be characterized by various distance measures, such as the Euclidean or squared
Euclidean distance, and Mahalanobis distance.
For k-means cluster analysis, the number of clusters and the initial cluster
centers need to be specified. One method to determine the initial clusters, which was
used in our analysis, is to randomly divide the data into the specified number of
clusters and then determine the centroid of each cluster. The final results of this
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analysis are a unique cluster assignment for each sample of the data. Other variations
on this technique, such as fuzzy k-means, assigns to each sample a degree of
membership into the k clusters.
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CHAPTER 5
In Vivo Clinical Study: Healthy Volunteers
In this chapter we investigate the impact of tissue anatomy on the spectral parameters
and relate the physical parameters we derive to the known tissue properties. We begin
by outlining the motivation and goals for this work. Following this we describe the
study protocol and methods. Finally, we end with a discussion of the results and the
conclusions.
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5.1 Motivation and Goals
Reflectance and fluorescence spectroscopy have been widely investigated as
non-invasive tools for detecting oral cancer, and a number of studies have reported
differences in spectral parameters when comparing malignant and normal tissues.'1-5 A
critical step in applying these techniques to the detection of oral malignancy is to first
develop an understanding of the spectral distinctions among anatomic sites (i.e. the
gingiva, buccal mucosa, etc.) in the oral cavity. Many studies focus on detecting
cancer in multiple sites without taking into account this natural source of variation.
This can lead to spectral differences that are incorrectly attributed to malignancy. 5-8
Only a few studies relate spectral variations to anatomic differences. In a
study by Kolli et al., fluorescence spectra were collected from the buccal mucosa and
dorsal surface of the tongue of 21 healthy volunteers, in addition to patients.9 For the
normal sites, analysis of the ratio of fluorescence emission at 450 nm when excited at
335 and 375 nm, respectively, revealed that the intensity ratio was statistically
different between the buccal mucosa and dorsal surface of the tongue. Differences in
the fluorescence peak intensities at 337, 365, and 410 nm excitation were also noted
by Gillenwater et al. in a study of 9 sites in the oral cavity of 8 healthy volunteers.10
Another small study of 10 healthy volunteers by Dhingra et al. noted differences
among sites." Although these three studies provide support for the fact that
differences based on anatomy exist, they lack a detailed description of the differences
and only examine a few sites.
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In a larger study by de Veld et al., 9295 fluorescence spectra were collected
from 97 subjects to determine whether differences in the mucosa in various sites of
the mouth resulted in changes in the fluorescence intensity and lineshape. 12 A total of
7 fluorescence excitations between 350-450 nm were evaluated and emission light
from 455-867 nm was analyzed. In this study both classification and clustering
methods were used to identify differences by site. The authors found that the dorsal
surface of the tongue and vermilion border of the lip were most consistently
distinguished among the 13 sites in the mouth studied; however, significant
differences in total fluorescence intensity between almost all the different sites were
noted at multiple wavelengths. In this large study, the authors tested the class overlap
between each of 11 anatomic sites (dorsal surface of the tongue and vermilion border
of the lip were excluded because they were significantly different from rest) against
the remaining 10 sites. Because the larger group consisted of multiple sites with small
differences in their means and standard deviations, the resultant distribution has a
large spread and is more likely to overlap with the single site against which it is
compared. This would diminish the ability to observe differences. There may be
added value in separating certain sites, as small changes with cancer would be more
easily distinguished for narrow distributions (i.e. increased power of a diagnostic
test). The authors concluded that all sites could be combined because of their
considerable overlap, except the dorsal surface of the tongue and vermilion border of
the lip. As shown below, we reach a different conclusion based on our own analysis.
None of the four studies cited above used a physical model of tissue
fluorescence, in which the spectral features are modeled by parameters relating to
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specific tissue components. Therefore, it is difficult to directly interpret or provide an
explanation for the observed differences in fluorescence emission. Additionally, to
the best of our knowledge, no studies examining differences in sites based on
reflectance parameters have been performed.
In the present study, we use a physical model to extract parameters from both
diffuse reflectance and intrinsic fluorescence spectra which are related to the
morphological and biochemical properties of the tissue. 13 We compare the extracted
parameter distributions for various tissue types and also relate the physical spectral
parameters to the anatomic features of the tissue sites. K-means clustering is then
performed in order to identify and classify groups of sites that share similar or distinct
spectral properties.
Understanding the normal spectral variations in the oral cavity is essential for
guiding the analysis and interpretation of data collected from lesions, and the
development of robust spectroscopic-based algorithms for diagnosing oral cancer.
5.2 Materials and Methods
5.2.1 In Vivo Data Collection
Healthy volunteers (HVs) were recruited at Boston Medical Center (BMC)
and at the Massachusetts Institute of Technology (MIT). The protocol for in vivo data
collection was approved by the institutional review board at BMC and the Committee
on the Use of Humans as Experimental Subjects at MIT. Written informed consent
was obtained from all participants to indicate their willingness to participate in the
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study. Relevant background information was obtained from each volunteer, such as
their smoking history, alcohol consumption, and history of lesions in the upper
aerodigestive tract. Study participants without a prior history of a lesion of the oral
cavity, larynx, or esophagus (benign or malignant) were considered healthy
volunteers, regardless of their smoking status. Smokers were included as HVs
because in our patient study we have found that those presenting with oral lesions
represent a mixture of smokers and non-smokers. Less than 1% of the subjects had a
history of alcohol abuse.
Reflectance and fluorescence spectra were collected using the Fast Excitation
Emission Matrix (FastEEM) instrument (Chapter 4). The optical fiber probe was
disinfected with CIDEX OPA (Advanced Sterilization Products, Irvine, CA) before
each session according to the manufacturer's specifications. Each measurement was
acquired in approximately 1.5 s and represented the average of 5 sets of reflectance
and fluorescence data. For each measurement, the standard deviation of the 5 spectra
was also recorded. For each site of data collection, 3-5 measurements were acquired.
We examined the raw spectra for all samples in each set of measurements for a site
and excluded those with poor overlap or large standard deviations. If all the
measurements in a set were inconsistent, all the data for that site was excluded.
5.2.2 Model-Based Analysis
The spectra were calibrated and the modeled fit obtained as described in
Chapters 3.3 and 4.2. The diffuse reflectance spectra were fit over the range of 380-
700 nm. From the reflectance spectra we derive 7 parameters: A, B, C, concentration
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of hemoglobin (cHb), the oxygen saturation (a), effective vessel radius, and
concentration of 0-carotene (c|3C).
Parameters were extracted from the fluorescence spectra in the subsequent
data analysis in one of two ways, which we refer to as non-normalized fluorescence
spectra or area-normalized fluorescence spectra. In the case of the non-normalized
data, the basis spectrum of each fluorophore at a given excitation wavelength was
normalized to the peak, such that each component had a maximum value of unity.
Following this step, these basis spectra were then used to fit the intrinsic fluorescence
spectrum for the sample. For area-normalization, the individual basis spectra were
divided by the total area under their respective curves. This same process was applied
to the intrinsic fluorescence spectrum for the sample. The resultant intrinsic
fluorescence curve for the sample was then fit with a linear combination of the basis
spectra. In a final step, the extracted contribution of each fluorophore derived from
the fit was then divided by the total sum of the contributions for all the components at
the specific excitation wavelength. The extracted contribution for each fluorophore
therefore represents the fraction of the total area under the emission curve contributed
by the specific fluorophore, at the specific excitation wavelength.
The fluorescence excited at 308 nm was modeled by a linear combination of
tryptophan, collagen, and reduced nicotinamide adenine dinucleotide (NADH) over
the range 370-600 nm. The fluorescence excited at 340 nm over the emission range
380-600 nm was modeled as a linear combination of NADH and collagen. These 2
excitations correspond to those which could be analyzed reliably from the data
collected from patients (Section 4.2.1).
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5.2.3 Outlier Removal and K-means Cluster Analysis
Outliers for each of the parameters were identified for each site separately
based on the interquartile range (IQR) criterion (Section 4.3.3)14. Because each
parameter was evaluated separately, the number of exclusions varied for each
parameter. The percentage of data excluded for any one parameter was <13%.
Following this procedure, we performed k-means cluster analysis in order to partition
the entire data set into groups without assuming that each anatomic site was distinct.
The analysis was performed using MATLAB (Mathworks, Natick, MA). Clustering
analysis was performed after the removal of outliers in order to prevent skewing of
the cluster centroid and to maximize the accuracy of the results. Analysis was
performed for each parameter separately for k = 2, 3, and 4 clusters using a random
initial clustering assignment and the city-block distance measure. Each separation
entailed 20 replicate runs of the clustering algorithm. For each iteration, the distance
from all samples to its assigned centroid was calculated and the final result of the
function represented the iteration which produced the minimum sum of all the
distances. For each k-means separation (i.e. k = 2, 3 or 4), the percentage of each site
within each of the clusters was identified after subtracting the probability of a site
being assigned to a cluster purely due to chance (i.e. 25% for k=4). We define A as
the difference between the maximum percentage of a given site assigned to a cluster
and the percentage that would be expected to be assigned due to chance. All sites for
which the value for A for all three separations or at least two separations exceeded
30.0% were identified for each parameter. These selection criteria for A were used to
identify sites displaying significant clustering. For each parameter, sites meeting these
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criteria were either clustered together or separately based on the whether they shared
the same or unique cluster assignments.
5.2.3 Impact of Probe Contact
The impact of probe pressure was tested in various sites in the oral cavity by
positioning the probe on the tissue and taking three to four measurements in which
the applied pressure was successively increased in between successive measurements.
The probe was kept in place after each measurement. Similarly, the effect of repeat
measurements (repositioning the probe in the same place) was tested by collecting
three to four separate measurements in which the probe was removed and replaced in
the same location in between each measurement.
5.3 Results and Discussion
5.3.1 General Description of the Data
The complete set of HV data consisted of 781 spectra. Due to instrumentation
error, evidence of movement (large variations in the set if 3-5 spectra collected from
each site), or too few spectra collected from a given anatomic site, 9.1% of the spectra
were excluded. The final set of healthy volunteer data included 710 spectra from 79
subjects. The average age (± standard deviation) of the volunteers was 41.5±16 years.
Data were collected from the following nine sites in the oral cavity: buccal mucosa
(BM), dorsal surface of the tongue (DT), floor of the mouth (FM), gingiva (GI), hard
palate (HP), lateral surface of the tongue (LT), retromolar trigone (RT), soft palate
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(SP), and ventral surface of the tongue (VT). These sites were chosen because most of
the data collected from patients were measured from these sites and because of their
accessibility to the probe. Table 5.1 summarizes the number of spectra collected from
each site within the oral cavity for the entire data set. Fewer spectra were collected
from sites such as the HP, RT, and SP because the architecture of the oral cavity in
some volunteers made these areas less accessible to the probe.
Total Data Calibration Data Validation Data
Site Number of Spectra
BM 100 88 12
DT 124 110 14
FM 112 98 14
GI 58 38 20
HP 54 32 22
LT 112 101 11
RT 33 24 9
SP 43 30 13
VT 74 63 11
Total 710 584 126
Table 5.1 Summary of the number of spectra collected from each of the nine
sites in the oral cavity for the calibration, validation, and total data sets. BM:
buccal mucosa, DT: dorsal surface of the tongue, FM: floor of the mouth, GI:
gingiva, HP: hard palate, LT: lateral surface of the tongue, RT: retromolar
trigone, SP: soft palate, VT: ventral surface of the tongue.
A comparison of the data from each site for people who had never smoked
and people who had either quit or were current smokers did not demonstrate
substantial differences.
106
CHAPTER 5: In Vivo Clinical Study: Healthy Volunteers
5.3.2 Modeling the Reflectance and Fluorescence Spectra
Modeling the Reflectance
Figure 5.1(a-b) shows representative examples of the excellent quality of the
fits to the reflectance spectra. In order to fully capture the major spectral features
necessary for accurately modeling the reflectance and fluorescence analysis of
healthy oral tissue, we incorporated the absorber p-carotene. Although p-carotene has
not been previously noted in reflectance measurements of the oral cavity, there are
numerous reports in the literature of its presence in oral cells/tissue as well as in
plasma. 15-17 This absorber is found at much lower concentrations than hemoglobin,
but its extinction coefficient is greater than 200 times that of hemoglobin at 450 nm. 8
Distortions of the hemoglobin spectrum due to vessel packaging effects were also
taken into account in the reflectance model. This correction has been used in other
investigations studying tissue reflectance. 19' 20
Examples of how the quality of the modeled fit can deteriorate when either 3-
carotene or vessel packaging are not accounted for are shown in Figs. 5.1(a) and
5.1(b), respectively. p-carotene has a prominent absorption peak at approximately
450 nm and a secondary peak at 478 nm. The latter absorption peak is especially
prominent in the spectrum in Fig. 5.1(a). The vessel packaging model predicts that the
differences in the depth of the 420 nm hemoglobin peak as compared to the 540 and
580 nm peaks will diminish as the size of the effective vessel radius increases. The
uncorrected hemoglobin absorption spectrum underfits the 540 and 580 nm peaks.
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Figure 5.1 (a) Plot of a reflectance spectrum measured from the buccal mucosa (thick black line)
and the modeled fit excluding p-Carotene (dashed grey line). The solid grey line demonstrates the fit
when 3-Carotene is included as an absorber, (b) Plot of a reflectance spectrum measured from the
lateral surface of the tongue (thick black line). The grey lines show the modeled fit excluding the
effect of vessel packaging (dashed grey line) and including vessel packaging (solid grey line), (c)
Plot of the intrinsic fluorescence at 308 nm excitation (black line) and the modeled fit (grey line) for
a DT site, (d) Plot of the intrinsic fluorescence at 340 nm excitation (black line) and the modeled fit
(grev line) for a HP site.
Modeling the Fluorescence
Figure 5.1(c-d) shows examples of the fluorescence data and fit at 308 and
340 nm excitation, respectively. Figure 5.2(a) shows the spectra of tryptophan,
collagen, and NADH, the three components used to fit the spectra at 308 nm
excitation. A preliminary examination of the data revealed that 3 basis spectra were
needed to account for the fluorescence at 340 nm excitation for the entire data set. To
determine if keratin contributed to the measured fluorescence, we separated the
keratinized sites (GI, HP, DT) from the non-keratinized sites and performed MCR
108
40C
(C)
450 500 550 0 e 050 700
Wavelength [nm]
550 600
" ' ' ' I I I I I I D
[1
CHAPTER 5: In Vivo Clinical Study: Healthy Volunteers
analysis separately on these two groups. We found that the extracted basis spectra
were identical for both groups. We therefore attributed the fluorophores to
collagen(s), likely in combination with elastin. The necessity for two distinct collagen
spectra may result from differences in the types of collagen being excited, the layered
architecture, depth-related effects (which can shift the proportions of light penetrating
to the basement membrane or stromal layers), or a combination thereof. Figure 5.2(b)
shows a plot of the two spectral components used to fit the spectra at 340 nm
excitation in addition to NADH. We refer to the two extracted collagen components
as Co11401 and Co11427, where the number represents the wavelength at which the
peak emission occurs. Figure 5.3 shows an example of the deviation in the fit to the
fluorescence data at 340 nm excitation that was systematically observed throughout
the data when only 2 basis spectra were used to fit the data [Figure 5.3(a)]. Figure
5.3(b) shows the fit quality when NADH, Co11401, and Co11427 were used to fit the
data.
To determine if the two fluorophores we extracted could be due to different
types of collagen we collected the fluorescence emission with the FastEEM from dry
collagen IV (Sigma-Aldrich C9879) and collagen I (Sigma-Aldrich C5533), the major
forms present in the basement membrane and stroma, respectively. 21 ,22 Figure 5.2(c)
shows the fluorescence emission excited at 340 nm. The peaks for collagen IV and
collagen I occur at -422 and -409 nm, respectively.
109
CHAPTER 5: In Vivo Clinical Study: Healthy Volunteers
Wavelength [nm]
/ Cdl IV
L ca,,v
400 450 500 550 600
Wavelength [nm]
Figure 5.2 Basis spectra used to fit the fluorescence spectra (a) Plot of the basis spectra used at
308 nm excitation: tryptophan, Collagen, and NADH (b) Plot of the two fluorescence spectra
extracted at 340 nm excitation using multivariate curve resolution, Co11401 (solid black line)
and Co11427 (dotted black line), and NADH (shaded grey line). The fluorescence peaks occur at
approximately 401 nm and 427 nm, respectively. These three components were used to model
the intrinsic fluorescence spectra at 340 nm excitation. (c) Plot of the fluorescence emission
from collagen I (solid line) and collagen IV (dotted line) chemicals at 340 nm excitation. The
fluorescence peaks occur at approximately 409 nm and 422 nm, respectively.
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(a)
Figure 5.3 (a) Example of
the deviation in the fit at
340 nm excitation observed
when only 2 basis spectra
were used to fit the data.
(b) Improvement in the
quality of the fit when three
400 450 500 550 600 basis spectra are used
Wavelength [nm] (NADH, Co11401, and
(b) Co11427). In each plot the
data is shown in black and
the fit in red.
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The spectra collected from the two collagens show that collagen IV (major
type in the basement membrane) has a different emission profile from collagen I
(major type in the stroma)23. This supports the fact that variations in the collagen
signal exist, although the emission of the extracted spectral components and
chemicals do not appear to be equivalent. A study of freshly excised ex vivo cervical
tissue by Chang et al. found that the stromal fluorescence differed greatly among
various specimens and that data from their large patient data set was best modeled
using a linear combination of three separate collagen fluorescence spectra24. The
authors attributed two of the components to different types of collagen crosslinks, as
they are the structural components responsible for collagen fluorescence. Differences
between the spectra of the pure chemicals and the results from MCR are likely due to
the inability of the dry chemical to recapitulate the actual protein in situ and the
influence of the tissue microenvironment, the contribution of other types of collagen,
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and fluorophores such as elastin and possibly keratin, which strongly overlap in
emission.
The following 6 fluorescence ratios were examined based on the analysis of
the non-normalized data: NADH/Collagen (308 nm), NADH/Tryptophan (308 nm),
NADH/Coll401 (340 nm), NADH/Coll1427 (340 nm), NADH/Total collagen (340
nm), and Co11401/Co11427 (340 nm). The number in parentheses indicates the
excitation wavelength. Total collagen refers to the sum of Co11401 and Co11427.
Analysis of the area-normalized intrinsic fluorescence yielded 6 additional
parameters: Tryptophan (308 nm), Collagen (308 nm), NADH (308 nm), NADH
(340 nm), Co11401 (340 nm), and Co11427 (340 nm).
5.3.3 Model-based Analysis Parameter Distributions
Table 5.2 summarizes the mean, standard deviation (a), and the relative
standard deviation (RSD) ([cr/mean]* 100) for all the parameters examined for each of
the 9 individual sites, as well as when all sites are combined into a single group. In
each case the statistical measures were calculated after applying the IQR exclusion
criteria. No clear trend was noted among the excluded samples, therefore effects such
as probe contact (i.e. slipping of the probe against the tissue, probe pressure, etc.) and
tissue movement likely are the cause of these outliers.
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Parameter BM DT FM GI HP LT RT SP VT Combined
A
n 95 120 109 55 51 108 33 42 72 685
Mean 1.7 1.4 1.5 1.5 1.4 1.5 1.7 1.6 1.5 1.5
a 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2
olMean[%] 8.6 8.8 14 12 11 7.9 11 9.4 9.1 12
B
n 100 124 110 51 52 110 33 43 74 697
Mean 0.4 0.3 0.2 0.6 0.6 0.1 0.4 0.3 0.2 0.3
a 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.2
o/Mean [% 47 48 65 20 28 69 48 54 68 64
C
n 98 121 110 55 51 109 33 42 74 693
Mean 0.010 0.012 0.02 0.004 0.002 0.018 0.008 0.009 0.02 0.013
a 0.006 0.007 0.01 0.004 0.002 0.006 0.008 0.005 0.01 0.009
a/Mean [% 61 62 53 96 112 32 96 59 46 72
cHb
n 88 113 103 53 48 102 32 38 72 649
Mean 1.2 1 2 0.6 0.4 3 1.0 0.6 2 1
o 0.6 1 1 0.3 0.1 1 0.8 0.3 1 1
alMean [%] 45 70 80 58 29 55 81 48 61 82
n 99 123 111 56 53 112 33 42 74 703
Mean 0.6 0.7 0.6 0 .6 0.7 0.7 0 0. 0.7 0.6 0.6
a 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.2
a/Mean [%] 24 20 32 16 13 22 25 21 29 24
Vessel Radius m]
n 96 115 106 51 49 106 32 39 74 668
Mean 0.004 0.005 0.005 0.0032 0.0028 0.006 0.004 0.0030 0.006 0.005
a 0.001 0.002 0.002 0.0006 0.0002 0.002 0.002 0.0003 0.002 0.002
a/Mean [%1 31 40 46 18 7 33 44 11 36 44
cDC
n 96 123 107 55 53 106 31 43 73 687
Mean 0.003 0.002 0.003 0.0012 0.0014 0.003 0.002 0.004 0.003 0.003
a 0.001 0.001 0.002 0.0008 0.0008 0.001 0.001 0.002 0.002 0.002
a/Mean [%] 45 71 57 64 58 46 50 48 54 65
NADHICollagen 308 nm)
n 100 120 102 56 46 105 33 41 73 676
Mean 0.4 0.39 0.6 0.34 0.40 0.39 0.3 0.5 0.5 0.4
a 0.1 0.09 0.1 0.08 0.06 0.09 0.1 0.1 0.1 0.1
o/Mean [%] 30 23 17 24 15 23 36 24 21 29
NADWHTryptophan (308 nm)
n 98 119 110 51 52 107 33 39 72 681
Mean 0.22 0.14 0.4 0.08 0.12 0.18 0.13 0.25 0.3 0.2
a 0.08 0.05 0.1 0.03 0.04 0.06 0.07 0.08 0.1 0.1
o/Mean [%] 36 39 30 38 31 32 59 30 38 58
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Parameter BM DT FM GI HP LT RT SP VT Combined
NADHIColl401 (340 nm)
n 100 118 109 54 51 109 33 41 73 688
Mean 0.6 0.8 0.8 1.1 1.3 0.4 0.5 0.8 0.7 0.8
a 0.2 0.3 0.2 0.6 0.4 0.2 0.2 0.2 0.2 0.4
ca/Mean [%] 32 36 27 53 29 44 46 29 27 49
NADH/Coll427 (340 nm)
n 98 120 106 52 49 108 31 42 71 677
Mean 0.6 0.6 0.6 0.7 0.8 0.5 0.6 0.6 0.5 0.6
a 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2
olMean [%] 43 37 38 22 22 42 30 27 25 38
NADHITotal Collagen (340 nm)
n 99 117 109 58 49 109 32 42 70 685
Mean 0.3 0.4 0.3 0.4 0.5 0.22 0.2 0.4 0.28 0.3
a 0.1 0.1 0.1 0.2 0.1 0.09 0.1 0.1 0.06 0.1
I/Mean [%] 36 31 31 36 23 42 39 28 22 40
Co11401Co11427 (340 nm)
n 96 120 106 57 50 111 30 42 71 683
Mean 0.9 0.8 0.8 0.7 0.6 1.1 1.2 0.8 0.8 0.8
a 0.2 0.3 0.2 0.3 0.1 0.3 0.3 0.1 0.1 0.3
cr/Mean [%] 27 34 25 41 19 29 25 16 19 34
Tryptophan (308 nm
n 100 120 109 51 54 108 3 39 72 686
Mean 0.28 0.35 0.20 0.46 0.39 0.30 0.37 0.25 0.23 0.3
a 0.06 0.07 0.04 0.06 0.06 0.05 0.09 0.05 0.06 0.1
clIMean [%1 23 20 19 12 14 17 24 19 25 32
Collagen (308 nm)
n 91 114 103 55 49 104 32 39 70 657
Mean 0.43 0.40 0.43 0.37 0.37 0.44 0.42 0.42 0.44 0.42
a 0.04 0.03 0.03 0.03 0.02 0.03 0.03 0.03 0.03 0.04
crMean [%] 8.8 8.2 7.9 7.2 5.3 7.6 7.1 8.1 5.7 9.5
NADH (308 nm)
n 100 121 106 56 52 109 33 38 74 689
Mean 0.28 0.24 0.36 0.19 0.23 0.26 0.21 0.31 0.32 0.27
a 0.06 0.05 0.05 0.06 0.04 0.05 0.07 0.05 0.06 0.08
l/Mean [%] 22 22 13 31 19 20 36 15 20 28
NADH (340 nm)
n 100 118 106 58 49 109 32 42 73 687
Mean 0.29 0.34 0.32 0.37 0.40 0.23 0.27 0.32 0.28 0.31
a 0.08 0.07 0.06 0.08 0.05 0.08 0.07 0.06 0.05 0.08
alMean [%] 27 21 19 23 13 33 27 19 18 27
Co11401 (340 nm)
n 100 122 111 58 52 110 32 39 74 698
Mean 0.32 0.28 0.29 0.25 0.22 0.38 0.39 0.30 0.30 0.30
a 0.05 0.06 0.04 0.09 0.04 0.07 0.07 0.03 0.04 0.07
cr/Mean [%] 16 23 14 35 18 19 19 11 15 25
Co11427 (340 nm)
n 92 118 103 54 54 104 32 43 71 671
Mean 0.37 0.38 0.39 0.38 0.37 0.37 0.34 0.37 0.41 0.38
0 0.06 0.07 0.06 0.04 0.05 0.05 0.05 0.04 0.04 0.06
a/Mean [%] 16 18 16 11 13 13 14 10 10 15
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Table 5.2 (Continued from previous page) Summary of the mean, standard deviation, and relative
standard deviation for each parameter for each of the nine sites, as well as the combined group of sites.
BM: buccal mucosa, DT: dorsal surface of the tongue, FM: floor of the mouth, GI: gingiva, HP: hard
palate, LT: lateral surface of the tongue, RT: retromolar trigone, SP: soft palate, VT: ventral surface of
the tongue.
Scattering Parameters
For the A parameter, most of the sites showed very similar mean values, with
the exceptions of the BM and RT. The BM and RT exhibited a mean which was
significantly higher than all other sites based on a test of multiple corrections
(p<0.05), but not from each other. The HP and DT demonstrated slightly lower mean
values which were significantly different from all other sites except the GI.
The GI and HP both exhibited values of B of 0.6, which is significantly larger
than for other sites. Three groups were easily distinguished for the C parameter. The
FM, LT, and VT formed one group, demonstrating the largest values of C. The BM,
DT, RT, and SP form another group with intermediate values of the C parameter. At
the other extreme, the keratinized GI and HP are easily distinguished by a small C
parameter. Figure 5.4(a) shows an example of a box plot showing the C parameter
distribution for each of the 9 sites.
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Figure 5.4 (a) Example of the distribution for the C parameter obtained for each of the 9 sites.
The brackets indicate the 3 groups of sites which are similar in their mean values. (b) A box
plot which shows the result of combining the individual sites shown by the brackets into three
site groups. The asterisks indicate a significant difference between two groups.
It is clearly seen that both the median and spreads in the distribution vary among the 9
sites, however, there are approximately 3 distinct groups of sites (site groups) and the
members of each group share similar properties. When the members of each of the
three site groups are combined in their respective group, the resultant distributions are
shown in Figure 5.4(b). The means between all three site groups are statistically
different from one other.
Absorption Parameters
The GI, HP, and SP demonstrated very low concentrations of hemoglobin as
compared to other sites. In the case of the former two sites, these results may indicate
that keratin prevents light from reaching the underlying stroma where the blood
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vessels are located. During data collection from the GI, visible blanching was often
observed when the probe contacted the tissue, which may also contribute to the lower
cHb values obtained for this site. The FM, LT, and VT, sites with relatively thin
epithelia as compared to other sites, demonstrated the highest cHb. The mean oxygen
saturations were comparable across all 9 sites and the combined set of sites had a
mean value of 60%. The mean effective vessel radius for the nine sites ranged from
approximately 3-6 jgm. The mean effective vessel radius was largest for areas on the
tongue (DT, VT, LT) and the FM. Blood vessels are easily observable at the
macroscopic level on the VT and FM and the tongue has a very high density of
vessels.
Because f3-carotene is present in adipose tissue and in blood, we would expect
the sites which demonstrated a large cHb and contain submucosal fat to contain the
largest concentration of this absorber. The highest concentration was found in the SP,
which meets both these criteria. The FM, LT, and VT and BM were tied for the next
highest value. The former three sites were those which displayed the highest cHb and
the BM and FM both contain adipose tissue in the submucosa. Similar to the results
for cHb, the GI and HP exhibit the lowest concentration of the absorber.
Fluorescence Parameters
For the NADH/Tryptophan and NADH/Collagen fluorescence ratios at 308
nm excitation, the FM was significantly different from all other sites. At 308 nm
excitation, light does not penetrate deeply into tissue because of absorption, and the
emission signal will be heavily influenced by superficial components. The FM
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displayed a mean value significantly higher (p<0.05) than all the other sites for the
NADH/Tryptophan (308 nm) and NADH/Collagen (308 nm) ratios, as well as the
NADH (308 nm) and Tryptophan (308 nm) parameters. The FM is distinguished by a
very thin epithelium (190 ± 40 pm), as compared to 580 ± 90 gtm for the BM, and 310
± 50 Pm for the HP21. The GI and HP displayed the two lowest mean Collagen (308
nm) values.
Of the two collagen fluorophores excited at 340 nm excitation, the
contribution of fluorescence emission peaking at 427 nm was slightly higher than the
contribution from the peak at 401 nm for all of the sites except the LT and RT. The
site with the largest values for the ratio of NADH to Co11401, Co11427, and the Total
collagen contribution was the HP. The GI had the second highest value for the former
two ratios, but was tied for second with the DT and SP for the latter ratio. These
ratios are affected by a complex mixture of epithelial and stromal characteristics. The
GI and HP demonstrated the lowest mean Co11401/Co11427 ratio of all the sites. In a
study by Collier et al. examining cervical tissue by confocal microscopy, the authors
found that keratin (which can be present both in normal and precancerous tissue)
introduces a significant source of variability in the depth penetration of the incident
light, and therefore the extent to which scattering from different layers contribute to
the observed signal.25 Although the collagen content in the deeper stroma (mostly
collagen type I) is significantly higher, this is offset by the higher probability of light
reaching and returning from more shallow structures, such as the collagen IV present
in the basement membrane. Most sites display Co11401/Co11427 ratios less than one,
indicating that emission from Co11427 is preferentially collected over Co11401. The
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presence of keratin on the GI and HP likely further reduces penetration of light to the
deeper stroma thus resulting in the low Co11401 (340 nm) values, and as a result,
mean Coll401/Coll427 values.
General Trends
The detailed summary of the parameters provided in Table 5.2 reveals a
number of findings relating the extracted parameters to the structural characteristics
of the sites. The GI, DT, and HP are sites which are normally keratinized, however
only the GI and HP display unique features as compared to the non-keratinized sites.
The keratinized sites are distinguished by large values for B, Tryptophan (308 nm),
and NADH (340 nm), and low C, cHb, effective vessel radius, cl3C, Co11401/Co11427,
NADH/Total collagen, Collagen (308 nm), and NADH (308nm) values. The large B
value for the GI and HP may reflect strong scattering by the superficial keratin layer,
resulting in a rapid fall in the scattering as a function of wavelength. In their depth-
resolved studies of fluorescence from epithelial tissue, Wu et al. observed a similar
trend in the fluorescence intensity.26 Unlike for non-keratinized tissues, they found
that the presence of keratin caused the fluorescence intensity to rapidly decay with
increasing sampling depth. The DT, which is only partially keratinized, exhibited a B
value comparable to the non-keratinized sites.27 The presence of keratin appears to
diminish signals from small, more superficial cellular scatterers, resulting in small C
values for the HP and GI.
The relative standard deviation varies widely across sites for a given
parameter even among sites with similar means. For 16 of the 19 parameters, the RSD
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for the combined group of sites exhibits a value which ranks among the highest 3
values for a given parameter. Figure 5.5 shows examples of the distributions for two
parameters, the effective vessel radius and NADH/Coll1427 (340 nm). The HP was
frequently shown in Table 5.2 to have a relatively small RSD compared to the other
sites, and the combined group to have among the largest values.
(a) (b)
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Figure 5.5 (a) Example of the distributions for the effective vessel radius for the HP (blue
line), BM (green line), and the combination of 9 sites (red line). (b) Example of the
distributions for the NADH/Coll427 ratio for the HP (blue line) and the combination of 9
sites (green line).
In fact for most parameters, HP and, to a lesser extent the SP, were also
unique in that the spread in the distribution for the samples was significantly smaller
than for most other sites. This may be due to the relatively small number of
samples/subjects for these sites as compared to other sites as there may be inter-
subject variability. Another possible reason is that these sites are relatively hard and
non-compressible and therefore less prone to error from variations in probe pressure.
The fluorescence parameters extracted from the area-normalized fluorescence
may be more useful in future studies focused on disease detection, as they exhibited
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smaller spreads in their distributions than for the parameters extracted from the non-
normalized fluorescence spectra.
In addition to the natural variation across various sites as a result of the
architecture of the mucosa, regional variations in the morphology within a given site,
poor accessibility with the probe (i.e. the RT, some locations along the palate), the
intrinsic movement of the tissue (i.e. in the case of the tongue), and the highly
compressible nature of the softer tissue sites also contribute to the spread in the data.
Analysis of data collected at different points along the palate and tongue
demonstrated not only the variation within a site, but also that transition areas
between sites can produce either gradual or marked shifts in a parameter, depending
on its sensitivity to the specific structural differences present between the two sites.
These transitions can be appreciated based on the clinical appearance and through
microscopic examination of the oral cavity.21
The sources of the variations in the data will be discussed in further detail in
the subsequent discussion of results for the validation data test (Section 5.3.5 and
5.3.6).
5.3.4 K-means Cluster Analysis
K-means clustering (Section 4.3.4) was used to determine if there were
specific sites with unique properties without assuming a priori that the 9 individual
sites were well-defined groups (unsupervised classification). This analysis provided
an objective and quantitative means of identifying and determining the magnitude of
similarities and differences among sites based on the data summarized in Table 5.2.
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In applying this method, all of the samples used to generate the data summarized in
Table 5.2 were inputted into the algorithm. The algorithm assigned each of the
samples to a specific cluster based on the parameter value, such that samples with
similar parameter values are grouped together. The algorithm does not incorporate
any information about the specific anatomic site from which the sample was derived.
We then determined what percentage of the samples from each anatomic site were
assigned to each cluster and applied the specific criteria for A (Section 5.2.3) to
identify similar and dissimilar groups of sites. The various site clusters are shown in
Table 5.3. For each parameter, we list the site(s) meeting the criteria for A and the
range of values for A for each cluster. For those sites meeting these criteria, each row
represents a separate clustering assignment; therefore, sites which were assigned to
the same cluster are listed together, while those assigned to a separate cluster are
listed in different rows. The sites which are not listed for a given parameter are not
necessarily all assigned to the same cluster.
For all but one parameter, oxygen saturation, there is at least one site or group
of sites that form a well-defined cluster. For 15 of the 19 parameters studied, the HP
was identified as being distinct from the majority of the other sites, either alone or in
combination with another site(s). The next site to most frequently demonstrate
significant clustering was the GI (10 parameters). For 8 of the 19 parameters, the HP
was assigned to the same cluster as the GI. Only in the case of one parameter
(NADH/Tryptophan (308 nm)), did the DT group with these sites. The FM displayed
unique properties for all of the non-normalized fluorescence parameters at 308 nm
excitation, and 2 of the 3 area-normalized fluorescence parameters. The sites least
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likely to show significant clustering were the BM and DT. Each of these sites met the
criteria for A only for a single parameter.
Sites meeting this criteria exhibit a very narrow distribution about their mean
and/or a very distinct mean value as compared to the rest of the sites. In support of
this, the HP, as shown in Table 5.2 exhibits small RSDs and mean parameter values
which are frequently at the extreme of the range for the 9 sites. Although the GI and
HP frequently cluster together, the DT only displays significant clustering with these
sites for a single parameter (NADH/Tryptophan (308 nm)). In addition to differences
in the extent of keratinization, the DT is distinct from the GI and HP because it
contains muscle in the submucosa rather than bone. It can be noted from the range of
values for A observed for a number of parameters, that the degree of clustering can be
very significant.
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Parameter Sites Range for A [%]
A BM 30.9-38.4
B GI,HP 36.5-56.1
LT,VT 30.4-44.5
C GI,HP 38.6-66.7
cHb GI,HP,RT,SP 34.4-75.0
BM 30.7-40.9
a No distinct sites
Vessel Radius BM,GI,HP,SP 32.3-75.0
cpC GI,HP 38.4-48.2
NADH/Collagen (308nm) GI 30.4-41.1
HP 31.5-34.1
FM 32.4-48.0
NADH/Tryptophan (308nm) DT,GI,HP,RT 34.9-69.1
FM 36.7-43.6
NADH/Coll401 (340nm) HP 42.2-47.5
LT,RT 34.8-42.7
NADH/Co11427 (340nm) LT,VT 30.6-39.8
NADHITotal Collagen (340nm) HP 39.8-50.5
LT 33.6-38.1
Coll401/ColI427 (340nm) HP 48.0-53.7
RT 40.0-41.7
Tryptophan (308nm) GI,HP 35.2-65.2
FM,SP,VT 30.8-63.9
Collagen (308nm) GI,HP 46.4-56.5
NADH (308nm) HP 34.6-34.6
GI 37.5-47.0
FM 40.1-53.5
SP 34.2-40.8
NADH (340nm) HP 39.8-50.3
LT 30.9-36.5
Co1401 (340 nm) HP 48.1-57.1
RT 34.4-40.6
ColI427 (340nm) VT 34.3-35.9
Table 5.3 Summary of the results from the k-means clustering analysis. For each
parameter, cases in which A exceeded 30.0% for all three separations (k=2, k=3, and
k=4) or at least two separations are listed. For sites meeting these criteria, those
assigned to the same cluster are listed together, while sites assigned to different
clusters are listed separately. In the last column, the range of values for A observed
for a specific cluster is provided. BM: buccal mucosa, DT: dorsal surface of the
tongue, FM: floor of the mouth, GI: gingiva, HP: hard palate, LT: lateral surface of
the tongue, RT: retromolar trigone, SP: soft palate, VT: ventral surface of the
tongue.
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The results from the K-means cluster analysis provided in Table 5.3 provide a
rapid means of determining which parameters would be expected to play a significant
role in distinguishing a certain site or group of sites from one another. In Figure 5.4
we showed that there were several groups of sites which displayed similar properties
for the C parameter. In Table 5.3 the GI and HP were found to cluster significantly
(met the criteria for A) for this parameter and are listed as belonging to the same
cluster. The sites in the remaining two groups have large spreads, and therefore were
not found to cluster significantly according to the established criteria.
Based on the information provided in Table 5.3, the BM and FM would be
expected to show some degree of separation based any of the following parameters:
A, cHb, vessel radius, NADH/Collagen (308 nm), NADH/Tryptophan (308 nm),
Tryptophan (308 nm), and NADH (308 nm). In each case either the BM and/or FM
met the criteria for A, and if both meet the criteria, they were assigned to separate
clusters. Figure 5.6 shows box plots for two of the parameters, A and
NADH/Tryptophan (308 nm). A shift in the medians for the 2 sites is apparent for
both parameters.
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Table 5.6 Boxplots showing the distributions for each of the 9 sites for (a) the A parameter,
and (b) NADH/Tryptophan (308 nm).
Figure 5.7(a) shows a binary scatter plot demonstrating a clear separation for
these sites based on these two parameters. Decision lines were generated using
logistic regression and the sensitivity and specificity were evaluated using leave-one-
out cross validation. The sensitivity and specificity for separating the BM from the
FM using only the 2 parameters (NADH/Tryptophan (308 nm) and A) were 81% and
83%, respectively (ROC-AUC=0.89). Similar results could also be obtained using
either Tryptophan (308 nm) and A (sensitivity and specificity of 87% and 79%,
respectively) or NADH (308 nm) and A (sensitivity and specificity of 83% and 78%,
respectively).
126
CHAPTER 5: In Vivo Clinical Study: Healthy Volunteers
Figure 5.7 Binary scatter plots
Sensitivity: 81%
Specificity 83%
ROC-AUC: 0.89
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Another binary plot comparing the DT and VT is shown in Figure 5.7(b) for
NADH/Tryptophan (308 nm) versus c0C. The two different aspects of the tongue
can be differentiated based on NADH/Tryptophan (308 nm) and cpC with a
sensitivity and specificity of 92% and 78%, respectively (ROC-AUC=0.90). As
expected from Table 5.3, NADH/Tryptophan (308 nm) contributed to the separation
to a greater extent than the c3C. Using the parameters extracted after area-
normalization, similar results were demonstrated. A sensitivity and specificity of 92%
and 81%, respectively, was obtained using cPC and Tryptophan (308 nm). A
sensitivity and specificity of 89% and 79%, respectively, was obtained using c3C and
NADH (308 nm).
Figure 5.7(c) shows a similar binary scatter plot of cHb versus B for the GI
and HP. Both of these sites were found to cluster significantly and were assigned to
the same cluster for these two parameters. As the plot shows, the two sites overlap
considerably (ROC-AUC=0.53).
Despite the large RSD values and apparent overlap among the sites, clear
separations based on anatomy can occur.
Figure 5.8 shows the similarity of the GI and HP histology [Figs. 5.8(a) and
5.8(b)], and their contrast to the thicker, non-keratinized epithelium of the BM [Fig.
5.8(c)]. A multiple comparison test revealed that the BM and GI were significantly
different for 15/19 parameters, and the BM and HP were significantly different for
16/19 parameters. With only two parameters (cHb and A), the BM and HP could be
distinguished with a sensitivity and specificity of 89% and 95%, respectively (ROC-
AUC = 0.93).
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Although the separation between specific sites may be small for a single
parameter, the combination of several parameters can enhance their individual effects
and produce a considerable separation. By combining C with A and Tryptophan (308
nm), a sensitivity and specificity of 94% and 80%, respectively, can be achieved in
discriminating between the BM and FM (ROC-AUC = 0.88 versus ROC-AUC =
0.84). As another example, the FM and VT are poorly distinguished (sensitivity and
specificity of 80% and 47%, respectively) based on the A parameter and Tryptophan
(308 nm) (ROC-AUC = 0.68). However, with the addition of NADH (340 nm), a
sensitivity and specificity of 72% and 72%, respectively, can be achieved (ROC-AUC
= 0.73).
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Figure 5.8 Photos showing the
normal microscopic architecture
of the HP (a) and the GI (b), sites
which were frequently found to be
spectroscopically similar to each
other. The contrasting architecture
of the BM is shown in (c).
Overlying keratin is indicated by
the letter, k.
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5.3.5 Validation of Normal Tissue Discrimination
In order to evaluate how accurately we have captured the parameter
distributions for normal tissue ("normal limits") for each site and can use the results
in Table 5.2 to characterize unknown data, we divided the full data set into two
groups: a calibration data set, and a validation data set. The calibration data set
consisted of 584 spectra collected from 65 subjects and was used to derive the normal
limits for each parameter for each site based on the 95% confidence interval (C.I.).
The IQR exclusion criterion was applied to the calibration data in a similar manner as
for the previous analysis of the full data set. The validation data was comprised of
126 spectra collected from the remaining 14 subjects. This data set was used to test
the reliability of the calibration data to correctly categorize normal tissue by
determining if each parameter extracted for a given site fell within the 95% C.I. for
that parameter for that specific site. The average age (± standard deviation) for
subjects in the calibration and validation data was 41.0±16 and 43.8 ±18 years,
respectively. Table 5.1 provides a summary of the number of spectra collected from
each site in both data sets. The percentage of all the samples in the validation data
falling within the normal limits developed from the calibration data set (after applying
the IQR outlier criterion) is shown in Table 5.4. The number of correctly classified
samples in the validation data for each site and for each parameter was determined.
We then totaled the sums across all the sites for each parameter and divided by the
total number of samples to determine the percentage of correctly classified samples.
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Extracted Parameter Percentage of Data within 95% C.I.
A 95.2
B 93.7
C 93.7
cHb 88.1
Oxygen Saturation 95.2
Vessel radius 92.1
cl3C 88.1
NADH/Collagen (308 nm) 96.8
NADH/Tryptophan (308 nm) 93.7
NADH/Coll401 (340 nm) 92.1
NADH/Col1427 (340 nm) 88.9
NADH/Total Collagen (340 nm) 92.9
Co1401/Col1427 97.6
Tryptophan (308 nm) 93.7
Collagen (308 nm) 93.7
NADH (308 nm) 96.0
NADH (340 nm) 94.4
Coll401 (340 nm) 95.2
Co11427 (340 nm) 96.8
Table 5.4 Summary of the percentage of the 126 spectra in the validation data
collected from healthy volunteers in which the listed parameters fell within the
95% confidence interval ('normal limits') for a specific parameter for a given
site. The normal limits were developed based on the results of the calibration
data set.
We obtained excellent results, with few false positives (abnormal results),
indicating that we have successfully captured the distributions for each parameter. All
of the fluorescence parameters except (NADH/Coll1427) demonstrate excellent
accuracy in classifying normal tissue. The concentrations of hemoglobin and 13-
carotene are somewhat less accurate for identifying normal tissue. This is not
surprising in that within any given site, (particularly those in which vessels may be
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located non-uniformly throughout the site), the probe may sample more or less
hemoglobin or O-carotene depending on the proximity and density of the blood
vessels.
5.3.6 Impact of Probe Contact
There are a number of factors that contribute to the spread observed for a
given site for the extracted parameters. These include variations among and within
individuals, variations in the anatomy within a site, as well as probe-related factors.
Since the healthy volunteer data were collected from a large number of subjects, the
effect of probe contact likely contributes to the observed spread for each site. In order
to examine the impact of the probe we collected sets of 3-4 measurements in 13
people in which we either repeated a measurement in the same location, or increased
the pressure on the probe in between measurements. Nine sets of data from the BM,
DT, FM, LT, and VT were collected in which the probe pressure was varied (29
spectra total). Twelve sets of data were collected from the BM, DT, FM, GI, HP, and
LT in which the probe was repositioned in the same site in between successive
measurements (36 spectra total). We applied the 95% CI criteria (normal limits)
developed from the data summarized in Table 5.2 to test whether the parameters
derived from the data in each of these 2 tests were classified as normal tissue. The
comparison against the normal limits was performed in a site specific manner. The
results are shown in Table 5.5.
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Parameter Repeat Measurements I%1 Pressure Varied [%]
A 91.7 96.6
B 94.4 100.0
C 91.7 96.6
cHb [mg/mL] 72.2 100.0
a 94.4 86.2
Vessel radius [mm] 88.9 100.0
cO3C 80.6 93.1
NADH/Collagen (308 nm) 80.6 100
NADH/Tryptophan (308 nm) 97.2 100
NADH/Coll401 (340 nm) 94.4 82.8
NADH/Coll427 (340 nm) 100 100
NADH/Total Collagen (340 nm) 100 82.8
Coll401/ Coll427 (340 nm) 100 86.2
Tryptophan (308 nm) 91.7 96.6
Collagen (308 nm) 83.3 89.7
NADH (308 nm) 91.7 100.0
NADH (340 nm) 100.0 86.2
Coll401 (340 nm) 100.0 86.2
Co11427 (340 nm) 100.0 100.0
Table 5.5 Percentage of measurements falling within the 95% confidence intervals developed
using data collected from normal tissue for repeat measurements in the same site and when
the pressure was varied.
The impact of probe pressure is particularly pronounced for the fluorescence
parameters, particularly at 340 nm excitation, while repeating a probe measurement in
the same location produces misclassifications mostly for reflectance parameters and
for fluorescence parameters at 308 nm excitation. For 8/9 sets, NADH/Co11427 (340
nm), NADH/Total collagen (340 nm), Tryptophan (308 nm), and NADH (340 nm)
consistently decreased, and NADH (308 nm) increased as the pressure was increased.
There were no clear trends in the changes with repeat measurements. Because the
probe was repositioned in the same location for repeat measurement, in addition to
slight changes in position, there may also be slight differences in the pressure applied
during a given measurement. The poor result for cHb is surprising, as it would be
expected that pressure would have a greater effect. Clearly the probe contact can
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affect the measurements, however, the results for the complete set of data capture the
effects of these variations reasonably well.
We did not attempt to quantify the percent change in the parameters or signal
intensity as these probe properties were varied because these variables were not
studied in a rigorous manner. Changes in lineshape and intensity could be appreciated
both in the reflectance and fluorescence measurements. In the case of varying the
pressure, highly compressible sites (BM, VT, FM) tended to be more strongly
affected than less compressible sites (i.e. DT, LT).
5.4 Conclusions
The assessment of the natural variation of healthy oral tissue is a crucial step
in developing a spectroscopic-based tool for cancer diagnosis. Because the oral cavity
is complex, in that it includes several different anatomic sites, the goal of this work
was to characterize the natural variations. In this study we employed reflectance and
intrinsic fluorescence spectroscopy to characterize 9 sites in the oral cavity with a
physical-based model. In comparing the parameters among various sites, we have
shown that there are significant differences in the mean and spread for various sites
and therefore spectroscopy is influenced by anatomy. Our findings also demonstrate
the strong correlation between the parameters and the physical properties of the
tissue. Keratinized sites (HP, GI) were distinct from non-keratinized sites based on
cluster analysis, as well as the model-based parameters. We have identified which
parameters are affected by this feature and how the parameters are affected. Even
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among non-keratinized sites, certain sites could be distinguished with >80%
sensitivity and specificity with only 2 parameters. Results from the clustering give an
indication of which sites are similar or dissimilar and display unique spectral
properties. In addition, we have developed thresholds for the range of normal values
for each parameter for each site.
Our understanding of the impact of keratin on the spectral parameters will be
valuable in our assessment of patient data, as many lesions (benign, dysplastic, or
malignant) exhibit hyperkeratosis (leukoplakia). Using the thresholds for the range of
normal values for each parameter for each site, we have the potential to determine
whether we can detect malignancy in the absence of visible findings (Chapter 6).
The findings in this work also highlight a number of major points to be
considered in the application of spectroscopy to the detection of oral cancer. First,
differences in the distribution of white (keratinized) lesions among benign, dysplastic,
and cancerous data sets could be interpreted mistakenly as evidence of a separation
between benign and malignant tissue. This is shown by the frequent separation
between the HP and GI and other non-keratinized sites. This would have a
particularly pronounced impact when data collected from healthy volunteers are
directly compared to data collected from patients with lesions, as oral lesions are
often white (leukoplakia). When small numbers of benign samples are grouped with
large numbers of samples collected from healthy volunteers without visible lesions,
this effect is also likely to occur.
Second, this work also emphasizes that by combining several anatomic sites,
differences in anatomy can skew distributions, such that in comparing malignant
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tissue samples to benign/healthy samples, each of which are comprised of different
proportions of each site, a separation that is completely unrelated to malignancy may
arise. We demonstrated cases in which sensitivities and specificities of 280% were
achieved in separating different anatomic sites.
Finally, combining sites that have statistically different mean values can result
in a larger spread in each parameter, and this makes it more difficult for a change that
occurs with cancer to become significant. The combination of a site with a large
spread with a site with a smaller spread would also make it more difficult to
appreciate changes with disease for the site with the smaller spread. These effects are
clearly demonstrated by the group statistics for the combination of 9 sites as
compared to a single site.
Because we have fully characterized how various sites compare to one another
for the various parameters, for future studies of lesions we may be able to combine
certain sites with similar properties. The number of biopsy cases demonstrating
dysplasia or cancer is usually limited, and combining sites would increase the number
of samples from which a diagnostic algorithm could be developed, and also extend
the number of sites to which it could be applied. The disadvantage is that this may
incur a decrease in sensitivity and specificity for cancer due to an increase in the
overall spread for the distributions by combining sites.
This work provides an important foundation for guiding our analysis of the
patient data and the development of spectroscopic-based diagnostic algorithms for
oral cancer.
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CHAPTER 6
In Vivo Clinical Study: Patients
In this chapter we describe the development of spectral diagnostic algorithms using
data collected from patients with lesions. We first use the healthy volunteer data to
identify spectrally similar anatomic sites. Next, we develop diagnostic algorithms to
distinguish healthy mucosa from lesions or subsets of lesions. Finally, we develop
spectral algorithms to distinguish benign lesions from dysplastic/malignant lesions.
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6.1 Motivation and Goals
Biopsy, the current gold standard for the detection of oral cancer, is limited by
the fact that it is invasive, and the final diagnosis is based on a qualitative assessment
of the tissue morphology'. In contrast, optical spectroscopy can provide quantitative
information about tissue morphology and biochemistry, and may therefore non-
invasively reveal changes in the properties of the tissue as it is altered by the disease
process. A spectroscopic tool could potentially enable the physician to assess a lesion
area over time without repeated biopsies, confirm the need for biopsy and the most
appropriate area to be biopsied for a patient with a suspicious lesion, and permit
several regions of a lesion to be evaluated beyond what may be typically biopsied.
The goal of the patient study is to develop spectroscopic diagnostic algorithms
with which we can distinguish healthy mucosa from lesions (clinically abnormal
mucosa), and benign lesions from dysplastic/malignant lesions. Four types of
comparisons were performed in our analysis: 1) Healthy mucosa versus benign
lesions, 2) Healthy mucosa versus dysplastic/malignant lesions, 3) Healthy mucosa
versus all lesions (benign, dysplastic, malignant), and 4) Benign lesions versus
dysplastic/malignant lesions.
The distinction of healthy mucosa from lesions is not of major clinical
importance; however, we take advantage of the relatively large numbers of samples
within each category to test whether certain anatomic sites which are spectrally
similar can be combined and preserve or even improve diagnostic performance as
compared to when all sites are combined. Because differences between healthy
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mucosa and lesions are visible by eye, we would expect excellent performance for the
diagnostic algorithms. Distinguishing dysplastic/malignant lesions from benign
lesions has considerable clinical significance, as the former group is more likely to
result in intervention. For this separation, we also compare the results for the case in
which all anatomic sites were combined, a single anatomic site was examined, or
spectrally similar anatomic sites were combined. For each comparison, we also
examined the trends in the extracted physical parameters with the development of
dysplasia/malignancy.
6.2 Materials and Methods
6.2.1 In Vivo Data Collection
Subjects were recruited from Boston Medical Center (BMC). The protocol for
in vivo data collection was approved by the institutional review board at BMC and the
Committee on the Use of Humans as Experimental Subjects at the Massachusetts
Institute of Technology. Subjects enrolled in the study included patients with
suspicious lesions undergoing biopsy in the clinic or operating room, and patients
undergoing surgical resection of known lesions. Written informed consent was
obtained from all participants to indicate their willingness to participate in the study.
Relevant background information was obtained from each patient, including their
smoking and alcohol consumption, history of oral or upper aerodigestive tract lesions,
and if relevant, any treatment received. Following collection of the spectral data the
physician used a small punch biopsy (1.5 or 2 mm in diameter) to score the exact area
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in which the probe was placed. The tissue sample was subsequently removed (biopsy)
with a larger punch biopsy (3.5 mm diameter), and sent for pathological evaluation.
In some cases a scalpel biopsy was performed because of the lesion architecture or
location. A microscopic assessment of each sample was performed by 3 pathologists
and the consensus diagnosis was considered to be the final diagnosis. The samples
were classified as either benign, dysplastic, malignant, or indefinite.
The set of 710 spectra collected from the healthy volunteers (HV) (Chapter 5)
were additionally used in the present study, as will be described, to represent healthy
mucosa.
6.2.2 Model-based Analysis
The spectra were calibrated and the modeled fit obtained as detailed in
Chapters 3.3 and 4.2, in the same manner as for the HV data. The diffuse reflectance
spectra were fit over the range of 380-700 nm. From the reflectance spectra we
derived 7 parameters: A, B, C, concentration of hemoglobin (cHb), the oxygen
saturation (a), effective vessel radius, and concentration of 13-carotene (cl3C). Because
the results from the HV study showed that the area-normalization of the fluorescence
spectra yielded parameter distributions with smaller relative standard deviations, all
fluorescence parameters were extracted following this pre-processing step (Section
5.2.2). Analysis of the area-normalized intrinsic fluorescence, as before, yielded 6
parameters: Tryptophan (308 nm), Collagen (308 nm), NADH (308 nm), NADH
(340 nm), Co11401 (340 nm), and Co11427 (340 nm). The number in parentheses
indicates the excitation wavelength. In order to be able to apply the findings from
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health volunteer study to the patient data, the 308 nm and 340 nm fluorescence
excitations were used for this analysis.
6.2.3 Identifying Spectrally Similar Anatomic Sites
Because of the limited numbers of samples in each lesion category (benign,
dysplastic, malignant, or indefinite) for a given anatomic site, we used the HV data to
determine if data collected from certain anatomic sites could be combined. We used
two methods to test whether specific sites were similar enough in their spectral profile
(i.e. parameter distributions), such that they could be combined into a single group
and anatomy would not influence the performance of the spectral algorithms. Both
methods were applied to the HV data after the interquartile range exclusion criteria
had been applied. The first method was a multiple comparison test of the mean values
for each parameter for each site. Using this method, the mean values for two sites
were considered statistically different if the p-value was <0.05. The Tukey-Kramer
correction was applied to compensate for multiple comparisons. The second method
used to compare the distributions for the sites was the Kruskal-Wallis test, a
generalization of the Wilcoxon rank sum test to allow greater than two samples to be
compared. This test is a nonparametric alternative to ANOVA and in contrast to the
previous method, does not assume that the parameters follow a specific type of
distribution (i.e. normal distribution)2. Using this method we test whether the medians
of the distributions for two samples are identical. Following this step, a multiple
comparison test was performed of the ranks for the groups using the Tukey-Kramer
correction. Both tests were performed at the 5% significance level.
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For each method we calculated a "similarity score" which represents the total
number of instances two sites were found not to be significantly different when their
distributions for each of the 13 parameters were compared. Perfect correspondence
between the parameters for two sites would be indicated by a similarity score of 13.
6.2.4 Spectral Diagnostic Algorithm Development
The details of the statistical methods used in the process of developing the
diagnostic algorithms are described in Chapter 4.3. Diagnostic algorithms were
developed for distinguishing specific subsets of data using logistic regression.
Spectral parameters with the greatest diagnostic potential for the comparison of
interest were identified using the log likelihood ratio (LLR) test. The fewest
parameters necessary to achieve the maximum ROC-AUC for a comparison were
retained. To prevent overtraining the data, we imposed an additional criterion on the
maximum number of parameters that could be included in the model. At least 5
training samples per class were required for each spectral parameter included in the
model. For example, for a comparison of 13 healthy mucosa samples versus 25 lesion
samples, the minimum number of samples in a class is 13 therefore a maximum of 2
diagnostic parameters were used in the model. Ideally, the ratio should be at least 10
parameters per training samples in the class, however this was not practical given the
limited number of samples in our data3. The discriminatory power of each algorithm
was evaluated by performing leave-one-out cross-validation (LCV) and calculating
the area under the receiver operator characteristic curve (ROC-AUC). The sensitivity
and specificity were additionally determined.
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6.3 Results and Discussion
6.3.1 General Description of the Data
A total of 79 subjects were recruited in the study. Of the 114 spectra collected
from these subjects, 13 spectra had to be excluded due to an error noted during data
collection, a broken probe, the poor quality of the biopsy specimen, or the pathology
being unavailable. Data were collected from the following sites in the oral cavity:
buccal mucosa (BM), dorsal surface of the tongue (DT), floor of the mouth (FM),
gingiva (GI), hard palate (HP), lateral surface of the tongue (LT), retromolar trigone
(RT), soft palate (SP), and ventral surface of the tongue (VT), tonsils (TL), base of
tongue (BT), lips (IL), and larynx (LX). Because we did not have comparable data
from healthy volunteers, the 12 spectra collected from the TL, BT, IL, and LX were
excluded from the analysis. Two additional samples, a lesion which turned out to be a
lymphoma, and a sample classified as indefinite, were also excluded. A total of 87
spectra collected from 67 subjects were included in the analysis. A summary of the
number of spectra measured from the subjects by disease category and site is shown
in Table 6.2. The frequency of lesions among the various sites in our data is
consistent with the well known high risk sites for oral cancer, which include the
tongue and floor of the mouth4. The average age (+ standard deviation) for the
subjects was 56±16 years. The HV data used in the analysis in this chapter are
summarized in Table 5.1. Specific comparisons involving a single anatomic site were
made in the subsequent analysis for the BM, LT, FM, SP, and VT. These groups
consisted of 100, 112, 112, 43, and 74 spectra, respectively.
147
CHAPTER 6: In Vivo Clinical Study: Patients
Site Malignant Dysplastic Benign Indefinite Total
Buccal mucosa 2 0 11 1 14
Dorsal tongue 0 0 4 0 4
Floor of mouth 2 11 3 0 16
Gingiva 0 1 0 0 1
Hard palate 1 1 2 0 4
Lateral tongue 4 9 12 0 25
Retromolar trigone 0 1 3 0 4
Soft palate 4 0 5 0 9
Ventral tongue 1 3 7 0 11
Total 14 26 47 1 88
Table 6.1 Summary of the number of spectra measured from each anatomic site
and the consensus pathological classification.
6.3.2 Identifying Spectrally Similar Anatomic Sites
From the results of the HV study, we found that anatomy strongly influences
the spectral parameters. However, if we identify which anatomic sites are spectrally
similar, lesions from these sites may be able to be combined without compromising
diagnostic performance. The results for the similarity score (the total number of
parameters for which two sites were not statistically different) based on the multiple
comparison test and Kruskal-Wallis test are shown in Tables 6.2 an 6.3, respectively.
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Site
BM
DT
FM
GI
HP
LT
RT
SP
VT
Table 6.2 Table listing the total number of instances in which the
mean values of a parameter for a pair of sites were characterized as
statistically similar (not significantly different), according to a
multiple comparison test performed for each of the 13 parameters.
Perfect correspondence between two sites would yield a score of
Site
BM
DT
FM
GI
HP
LT
RT
SP
VT
Table 6.3 Table listing the total number of instances in which the
median values of a parameter for a pair of sites were characterized
as statistically similar (not significantly different), according to a
Kruskal-Wallis test performed for each of the 13 parameters.
Perfect correspondence between two sites would yield a score of
13.
The scores and trends are fairly similar for both methods. Both tests
demonstrate that the various anatomic sites demonstrate pronounced spectral
differences. For the multiple comparison test, 26 of the 36 comparisons (72%)
produced a similarity score of <7. Similarly, 24 of the 36 comparisons (67%) for the
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Kruskal-Wallis test yielded scores <7. For each site, we identified which of the
remaining sites with which it demonstrated the highest score. We identified 4 groups
of sites with similar spectral properties (albeit to different degrees) which were
common to both methods: 1) BM and SP, 2) FM and VT, 3) DT and RT, and 4) GI
and HP.
In order to benefit from the ability to combine spectrally similar sites and
improve our ability to create spectral diagnostic algorithms despite limited numbers
of lesion samples, there are two important considerations. First, the total number of
samples for the combined set sites must be sufficient for further analysis. Second, the
number of samples in each category to be compared must be sufficient. In our case
the categories of particular interest are benign lesions versus dysplastic/malignant
lesions. Table 6.4 lists the number of samples in each of the lesion categories for the
spectrally similar sites. Two of the four groups of spectrally similar sites met these
criteria. Even by combining the GI and HP or DT and RT, the number of samples was
not substantially increased and therefore we did not perform any of the comparisons
described in the subsequent sections for these specific groups.
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Similarity Score Spectrally Similar Malignant Dysplastic Total Benign Total
Multiple Comparison Sites
test/ Kruskal-Wallis
test
9 / 10 Buccal mucosa 2 0 6 11 16
Soft palate 4 0 5
Floor of the mouth 2 11 3
10 / 12 Ventral surface of 1 3 17 7 10
the tongue
Dorsal surface of the 0 0 4
9/9 tongue 1 8
Retromolar trigone 0 1 4
11 / 6 Gingiva 0 1 0 2
Hard palate 1 1 2
Table 6.4 Spectrally similar anatomic sites as determined by the consensus of the results for the
multiple comparison test and Kruskal-Wallis test. The number of dysplastic/malignant, and benign
sample subtotals and totals are shown for each group.
6.3.3 Distinguishing Healthy Mucosa from Lesions, Subsets of Lesions
In Tables 6.5 and 6.6 we compare clinically normal mucosa (from healthy
volunteers) to clinically abnormal mucosa (from patients). For each of the three
comparisons listed, the ROC-AUC value for the combination of all 9 sites, the
combination of all sites except the GI and HP (combination of 7 sites), individual
sites, and spectrally similar sites are shown. We considered the combination of all
sites except the GI and HP (combination of 7 sites) because the k-means clustering
results from the HV study (Chapter 5) clearly demonstrate that the GI and HP were
spectrally distinct from most other sites for a number of parameters. For comparison,
we also list the results for the combination of 2 spectrally dissimilar anatomic sites,
LT/BM (similarity scores of 4 and 5 for the multiple comparison test and Kruskal-
Wallis test, respectively).
The combination of the 9 sites yielded 710 healthy mucosa samples, 47
benign samples, and 40 dysplastic/malignant samples. The combined group of 7 sites
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consisted of 598 healthy mucosa samples, 45 benign lesions, and 37
dysplastic/malignant samples. For some comparisons, the number of samples in one
or both categories was too few to be analyzed reliably.
Healthy Mucosa vs. Healthy Mucosa vs. Healthy Mucosa vs.
Lesions Dysplastic/Malignant Benign Lesions
Lesions
Group Maximum ROC-AUC
9 Sites Combined 0.83 0.85 0.81
7 Sites Combined 0.84 0.88 0.84
LT 0.95 0.97 0.95
FM 0.94 0.95 ---
BM* 0.94 --- 0.96
VT 0.95 --- ---
FM/VT 0.97 0.97 0.94
BM/SP* 0.91 --- 0.90
LT/BM 0.92 --- 0.91
Table 6.5 Summary of the maximum ROC-AUC values obtained for three different separations for the
combination of all sites, individual sites, and the combination of spectrally similar sites. *No
dysplastic samples.
The diagnostic performance of the spectral algorithms was poorest for the
group in which all 9 sites were combined. Only a slight increase in the ROC-AUC
was produced by omitting these sites as compared to the combination of 9 sites,
however, the combined number of GI and HP lesion samples was very small (5
samples total). A similar finding was observed in a study by Muller et al., in which
they examined the diagnostic performance of their spectral diagnostic algorithms for
distinguishing lesions from healthy/benign tissue, and dysplasia from malignant
tissue. They found that the best sensitivity and specificity was obtained when samples
from 4 non-keratinized anatomic sites (BM, FM, SP, VT) were analyzed separately
from keratinized anatomic sites (DT, GI, HP). Furthermore, when they combined
these two groups the overall sensitivity and specificity for the separations decreased.
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When we examined the same 4 keratinized sites, 4 parameters were found to be
statistically significant for separating healthy mucosa from lesions (in order of
decreasing significance): clc, Co11308, cHb, and Tryptophan (308 nm). For the first
two parameters all 4 sites are statistically similar according to both the multiple
comparison and Kruskal-Wallis tests. An ROC-AUC value of 0.92 was obtained.
Most investigations examining the potential of spectroscopy to non-invasively
identify oral cancer attempt to distinguish healthy mucosa from visible lesions
(dysplastic/malignant lesions or malignant lesions only). Benign lesions are
frequently excluded from the analysis for reasons which are not specified58 .
Approximately 80% of leukoplakias, the most frequently encountered lesion of the
oral cavity, prove to be benign upon pathological evaluation 9. Therefore, it is
important to consider this lesion category. The distinction between clinically
abnormal and clinically normal tissue is easily appreciated by eye and it would be
expected that spectroscopy would also easily appreciate the differences between these
two groups. The results in Table 6.5 indicate that excellent separation between these
two groups is possible using spectroscopy, particularly in the cases where the
diagnostic algorithms are developed and applied to individual sites, or spectrally
similar sites. The excellent separations achieved for the three comparisons are likely
due to the influence of keratinization, ulceration, and other abnormal mucosal
changes associated with the lesions, which are not directly linked to malignancy. This
is supported by the fact that the comparison of healthy mucosa versus benign lesions
yields both similar ROC-AUC values and diagnostic parameters as for the
comparison against dysplastic/malignant lesions alone. The decreased accuracy of the
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algorithms when applied to the combination of 9 is most likely due to the influence of
anatomic differences. Although many studies obtain excellent results while
combining all sites, usually the total number of samples (or patients) is small and/or
the majority of the lesion samples are derived from a few anatomic sites l0-12
Comparisons of healthy mucosa versus subsets of lesions may be particularly affected
by anatomic differences, as some sites are more represented than others in the
different lesion categories. As shown in Table 6.1, almost all the BM lesions are
benign, while the majority of the FM lesions are dysplastic/malignant. These
differences could falsely increase the diagnostic accuracy, if the sites in the two
categories to be compared are spectrally distinct.
Figure 6.1 shows examples of the ROC curves obtained for the separation of
healthy mucosa versus all lesions for the combination of 9 sites, LT, and FM/VT.
Figure 6.1. Examples of ROC
curves obtained for the separation
of healthy mucosa from lesions for
the combination of nine sites
(dotted line), LT (dashed line), and
the FM/VT (solid line). The thin
blue line represents the ROC curve
that would result due to random
chance.
s
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The diagnostic parameters which were combined to yield the ROC-AUC
values shown in Table 6.5 are shown in Table 6.6. The parameters are listed in order
of decreasing significance based on the results of the log likelihood ratio test. As
shown in the table, 2-4 parameters were found to be significant between the two
categories for all the comparisons shown in Table 6.6.
For the comparison of healthy mucosa versus all lesions, 6 parameters were
frequently noted as being significant as shown in Table 6.6: c3C, Tryptophan (308
nm), NADH (340 nm), cHb, Co11427 (340 nm), and a. The effective vessel radius, A
and C parameters were never among the diagnostic parameters. For the LT, the B
parameter was most significant, a parameter which was not significant for any other
separation. NADH (308 nm) was important for the BM as an individual site. In
examining the combination of spectrally dissimilar sites, LT/BM, NADH (308 nm)
and cOC, were both parameters for which the two sites were spectrally similar, which
may explain the high ROC-AUC values.
Healthy Mucosa vs. Healthy Mucosa vs. Healthy Mucosa vs.
Lesions Dysplastic/Malignant Benign Lesions
Lesions
Group Diagnostic Parameters
9 Sites Combined NADH340, cHb, a NADH340, cHb Co11427, cHb
7 Sites Combined NADH340, a, cHb NADH340, cOC, cHb NADH340, Trp308, a
LT B, Trp308, a Co11401, B,Trp308 B, Trp308, NADH340
FM Trp308, c3C Trp308, Co11427 ---
BM* NADH340, NADH308 --- NADH340, NADH308
VT Co11427, c3C --- ---
FM/VT Co11427, Trp308, c3C Co11427, a Col1427, cOC
BM/SP* cHb, cC, NADH340 --- NADH340, cpC
LT/BM NADH340, NADH308 cPC --- NADH340, NADH308,
c3C
Table 6.6 Summary of the significant diagnostic parameters determined for three comparisons. The
parameters are written in order of diagnostic significance. Trp308 (Tryptophan (308 nm)), Co11308 (Collagen
(308 nm)), NADH308 (NADH (308 nm)), NADH340 (NADH (340 nm)), Coll401 (Coll401 (340 nm)),
Coll427 (Co11427 (340 nm)) *No dysplastic samples.
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For all the comparisons, the order of significance of these parameters is also
relatively consistent. Therefore, the difference in the diagnostic accuracy for the
combination of 7 and 9 sites versus the individual and spectrally similar groups is
most likely related to the fact that the threshold for the combined sites is not as
optimal. For the Co11427 (340 nm) contribution, the combination of 9 sites, VT and
FMNT groups had similar relative standard deviations (RSDs) for their respective
healthy mucosa samples and lesion samples (range 13-20% and 36-41%,
respectively). The upper limits of the ranges were for the combined group. However,
the ratios of the means for the healthy mucosa compared to the lesions for the three
groups were considerably different: 1.29, 1.63, and 1.62, respectively. This suggests
that in combining numerous sites spectral contrast is diminished.
In Table 6.7, we list the trends in the parameters for lesions as compared to
healthy mucosa and compare the trends in the parameters for the GI and HP
(keratinized sites) relative to that of the other anatomic sites. We use the latter
comparison as a surrogate marker for the impact of keratin, although this is not a
perfect comparison because other mucosal features specific to these 2 sites may
contribute to the trends. All the trends in the parameters for the GI and HP relative to
the other anatomic sites were statistically significant except for Co11427 (340 nm).
The trends in each parameter when lesions or subsets of lesions were compared to
healthy mucosa were found to be independent of the specific comparison (i.e. versus
lesions, dysplastic/malignant lesions, or benign lesions).
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Group GI/HP Lesions
A Decrease
B Increase Increase
C Decrease --
cHb Decrease Increase
a Increase Increase
Effective vessel radius Decrease ---
cl3C Decrease Decrease
Tryptophan (308 nm) Increase Increase
Collagen (308 nm) Decrease ---
NADH (308 nnm) Decrease Decrease
NADH (340 nm) Increase Increase
Coll401 (340 nm) Decrease Decrease
Coll427 (340 nm) NSD Decrease
Table 6.7 Changes in the parameters that occur with the presence of keratin (as
determined by a comparison of the GI/HP to the other 7 anatomic sites) and for
visible lesions relative to healthy mucosa. NSD: not significantly different
As is shown in the table, the trends in the parameters for both groups are
identical for 7 of the 9 parameters. The trends were reversed for cHb. The Coll427
(340 nm) contribution decreased for the lesions compared to healthy mucosa, but was
not statistically different for the keratinized sites as compared to the other sites. The
strong parallel in the trends for the GI/HP and lesions provide added support that
keratin may be a key contributing factor in the differences between lesions and
healthy mucosa.
A study by Amelink et al. investigated the use of differential path length
spectroscopy to distinguish healthy mucosa from malignant lesions using a model-
based approach that incorporated vessel packaging13. They also found that malignant
lesions demonstrated a significant decrease in the hemoglobin oxygenation, increase
in the blood content, and increase in the scattering slope (B parameter). A significant
decrease in scattering amplitude (A parameter) was also observed, which was not
found in our analysis. A study by Muller et al. similarly found that for fluorescence
excited at 340 nm, the contribution of NADH increased and collagen decreased with
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disease progression1o. Muller et al. combined intrinsic fluorescence spectroscopy and
diffuse reflectance spectroscopy to evaluate the oral lesions.
The increase in the B parameter is most likely due to the scattering from
keratin present on leukoplakias. In addition to the impact of keratin, the increased
cHb may be due to angiogenesis or the vascular dilation seen in erythroplakias
(Section 2.2,2). The decreased collagen is consistent with degradation of the
extracellular matrix by matrix metalloproteinases (Section 3.1). The increase in
NADH at 340 nm excitation may result from increased metabolic activity.
6.3.4 Distinguishing Benign Lesions from Dysplastic/Malignant Lesions
In order to determine whether the reflectance and fluorescence parameters can
be used to identify the most severe lesions, we developed diagnostic algorithms to be
applied to clinically abnormal lesions. This distinction has considerable clinical
significance, as the differences in the two categories cannot be appreciated by
observation alone. Spectral algorithms designed to distinguish benign lesions from
dysplastic/malignant lesions were developed for the 5 groups with sufficient numbers
of samples in the two lesion categories: 9 sites combined, 7 sites combined, LT,
FMNT, and BM/SP.
The ROC-AUC value, sensitivity, and specificity for the comparisons between
benign lesions and dysplastic/malignant lesions are shown in Table 6.8. Unlike the
comparisons involving healthy mucosa, the diagnostic performance is considerably
poorer. The highest ROC-AUC value was obtained for the LT and the lowest value
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for the combination of 9 sites. While the diagnostic performance for the FM/VT
group is considerably better than that of the combination of 7 sites or 9 sites, the
results for the BM/SP group is comparable.
Group Benign Lesions vs. Dysplastic/Malignant Sensitivity/ Specificity 1%]
Lesions
Maximum ROC-AUC
9 Sites Combined 0.60 55.0 / 61.7
7 Sites Combined 0.63 56.8 / 64.4
LT 0.75 92.3 / 66.7
FM/VT 0.71 94.1 /60.0
BM/SP* 0.63 83.3 / 56.2
Table 6.8 Summary of the maximum ROC-AUC values obtained for the separation of benign lesions
from dysplastic/malignant lesions. *No dysplastic samples.
Figure 6.2 shows examples of the ROC curves obtained for the separation of benign
lesions from dysplastic/malignant lesions for the combination of 9 sites, LT, FM/VT,
and the BM/SP.
-- --------- -- F o- X.X
.......... .....
----- LT
* *I. I..;.1 * mCombination of 9 site!
.k - FM/VT
........ BM/SP
B'.. ~
Figure 6.2. Examples of ROC
curves obtained for the separation
of benign lesions from
dysplastic/malignant lesions for the
combination of 9 sites ( thick
dashed line), LT (dashed line),
FM/VT (solid line), and the BM/SP
(dotted line). The thin blue line
represents the ROC curve that
would result due to random chance.
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The diagnostic parameters that were combined to yield the ROC-AUC values
shown in Table 6.8 are listed in Table 6.9.
Group Benign Lesions vs. Dysplastic/Malignant Lesions
Diagnostic Parameters
9 Sites Combined C, Co11401, coC
7 Sites Combined C, cpC, Coll401
LT cOC, Co11401
FM/VT Coll427, C, cHb
BM/SP* A
Table 6.9 Summary of the significant diagnostic parameters for separating benign
lesions from dysplastic/malignant lesions. *No dysplastic samples. Coll401 (Coll401
(340 nm)), Coll427 (Coll427 (340 nm))
The important parameters for this comparison are almost entirely different
than those which were important for the separation between healthy mucosa and
lesions. While the C parameter was never a diagnostic parameter for distinguishing
healthy mucosa from lesions or subsets of lesions, it played a significant role in
separating benign lesions versus dysplastic/malignant lesions for 3 of the 5 groups.
This was also the case for the Coll401 (340 nm) parameter. This parameter was
important for 3 of the 5 groups for identifying dysplastic/malignant lesions, while
only important in 2 instances for the comparisons against healthy mucosa. Just as for
the comparisons against healthy mucosa, the clC continued to be a diagnostic
parameter. The consistency of the diagnostic performance among 4 of the 5 groups
suggests that the parameters are not being influenced by anatomy, but intrinsic
differences between the two lesion categories. In the case of the BM/SP group, most
of the benign cases are from the BM and the malignant cases from the SP (there are
no dysplastic lesions for this group), therefore anatomic differences likely play a role
in the separation. This is supported by the fact that the HV data shows that the two
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sites are significantly different from one another in their distributions for the A
parameter.
The dysplastic/malignant lesion sites are characterized by an increased C
parameter and cHb, and decreased cOC, Co11401 and Co11427. This trend in the C
parameter is consistent with increased scattering by small particles as may occur with
increased epithelial proliferation. The increased cHb may be the result of vascular
dilation and inflammation as seen in erythroplakias or with ulceration, features which
are more likely to be associated with dysplasia/malignancy than white lesions
(Section 2.2.2). The decreased collagen fluorescence may reflect disruption of the
basement membrane by the invading malignant cells and decreased stromal collagen
as a result of the action of matrix metalloproteinases.
The decrease in the c3C is more difficult to explain. p-carotene, which is
found at high concentrations in orange vegetables, is an antioxidant (protects against
free radical damage). p-carotene can also be metabolized to vitamin A, which is
involved in the differentiation of normal epithelial cells' 4. Supplementation with 3-
carotene has been explored as a chemopreventive strategy in a number of studies of
oral cancer (and other cancers), but shown limited or no success in large trials in
humans15,16. Interestingly, a case-control study of 6832 men of Japanese ancestry
found that over the 20 years in which they were followed, those who developed
esophageal, laryngeal, and oropharyngeal cancer demonstrated significantly reduced
f-carotene levels as compared to controls after adjusting for cigarette smoking and
alcohol intake 7.
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Because 3 parameters, C, cpC and Co11401 (340 nm) were found to be most
significant for distinguishing the two classes of lesions, we examined whether there
were certain groups of sites which were spectrally similar for all three of these
parameters. These sites could potentially be combined without reducing the
diagnostic performance, as seen for the combination of 9 sites. A single pair of sites
was found to be similar for all three parameters based on the consensus results for the
multiple comparison test and Kruskal-Wallis test: the FM and VT. According to the
multiple comparison test, the GI and HP were similar for all 3 parameters, but only
for 2 of the 3 parameters by the Kruskal-Wallis test. The BM and SP were identified
as similar for all 3 parameters by the Kruskal-Wallis test, but only for 2 parameters by
the multiple comparison test. We tested the performance of a diagnostic algorithm for
distinguishing benign lesions from dysplastic/malignant lesions for the combination
of the FM, LT, and VT. Both tests grouped these sites together for 2 of the three
parameters (C, c3C). An ROC-AUC value of 0.61 was obtained using these
parameters, which is worse than for the LT alone or the FM/VT combination. This is
consistent with the overall low similarity score (based on all 13 parameters) obtained
for the FM and LT.
Few investigators have attempted to distinguish benign lesions from
dysplastic/malignant lesions, and in most cases several anatomic sites are combined.
In a study by de Veld et al. using reflectance and fluorescence spectroscopy, they
analyzed 115 spectra from 11 anatomic sites (the DT and lip were excluded) and used
principal component analysis in combination with various normalization and
classifier methods 18. They report a maximum ROC-AUC value of 0.73 using the
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combination of the two methods when they combined all 11 sites. A study by van
Staveren et al. using fluorescence spectroscopy achieved a sensitivity and specificity
of 31% and 67%, respectively, using an artificial neural network 12. In the present
study, when all 9 sites were combined a sensitivity and specificity of 55% and 62%,
respectively, was achieved.
Consistent with our findings, greater success has been achieved for classifying
lesions when the sites included in the analysis is limited. Wang et al. performed an in
vivo fluorescence study of patients with lesions located only on the buccal mucosa'9.
They were able to obtain a sensitivity and specificity of 81% and 96%, respectively,
for distinguishing benign from dysplastic/malignant lesions. We obtained a sensitivity
and specificity of 92.3% and 66.7% for the LT site. A study by Mallia et al.
investigated the use of fluorescence at 404 nm excitation to discriminate grades of
oral cancer20. The authors found that they needed to exclude lesions samples from the
vermilion border of the lip, dorsal and lateral surfaces of the tongue in order to
develop successful diagnostic algorithms.
6.3.5 Spectroscopic Studies in the Literature
In Table 6.10 we provide a summary of fluorescence and reflectance studies
in the literature which have been performed in vivo in humans. We list our own
results from two of the common comparisons in the literature, healthy mucosa versus
malignant lesions, and healthy mucosa versus dysplastic/malignant lesions, as well as
for benign lesions versus dysplastic/malignant lesions. Several important
considerations in these studies should be noted, in particular when comparing our
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results to those of other investigators. First, many studies use visibly healthy mucosa
in patients with lesions as the source of healthy mucosa. Second, many studies
involve very few patients or lesions, and the lesions are derived from only a few
anatomic sites. Only the study by de Veld et al. and our study involve more than 25
patients18 . Inter-patient variability can contribute to the spread in the extracted
parameters and potentially reduce diagnostic performance, whereas when numerous
samples are taken from the same patient this effect is reduced. Third, as mentioned
earlier, many studies exclude benign lesions. This may reduce the heterogeneity
among the lesions and potentially increase the diagnostic performance in comparisons
of healthy mucosa versus visible lesions. Fourth, many of the studies listed (e.g.
Mallia et al., Tsai et al., and Gillenwater et al.) provide a sensitivity and specificity
which were not calculated using cross-validation, but by applying a threshold to the
data. Finally, most investigators compare clinically normal mucosa to visible lesions,
which is not the most clinically relevant distinction.
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Source Sens./Spec. ROC- Diagnostic Healthy Lesions: Details
[%] AUC Method Tissue: # Spectra
Comparison # Spectra (# Pts.)
(# people) Path.
Present Work DRS 710 (79 87 (67 Pts) Results are for 9
380 -700 nm em HVs) 14 Ca anatomic sites
Nml vs. Ca 85.7 / 84.6 0.88 IFS 26 Dys combined
308,340 nm ex 47 Be
Nml vs. Dys/Ca 77.5 / 85.6 0.85 370-600 nm em
Nml vs. Be/Dys/Ca 78.2 / 76.5
0.83
Be vs. Dys/Ca
55.0/ 61.7 0.60
Heintzelman, DL et --- F1 Ratio Calibration Calibration No benign sites
al., 2000 350,400 nm ex 35 (9 HVs) 10 (9 Pts)
472 nm em 17 (11 Pts) 4 Dys
Nml/Be vs. Dys/Ca Validation 6 Ca
100/98 274 (53 Validation
HVs) 2 (3 Pts)
4 (3 Pts) 2 Dys
2Ca
Wang CY et al., Partial least 15 HVs 13 Ca All lesions were
2003 squares, from buccal
artificial neural mucosa
Be vs. Dys/Ca 81/96 --- network
330 nm ex
340-601 nm em
van Staveren HJ et Artificial neural 6 (2 HVs) 22(21 Pts) Only studied
al., 2000 network 9 Be leukoplakias
420 nm ex 13 Dys
Nml vs. Be/Dys 86/100 --- 465-650 nm em
Majumder SK et al., PCA + logistic 82 (25 Pts) 126 (25 Pts) Limited lesions
2000 regression 126 Ca to those which
337 nm ex were suspicious
Nml vs. Ca 86 / 63 --- 350-700nm em for SCC
Did not perform
cross-validation
Majumder SK et al., Relevance 153 83 (16 Pts)
2005 vector machines (13HVs) 83 Ca
(RVM) 88 (16 Pts)
Nml vs. Ca 85-91/95-97 --- Support vector
(RVM) machines
87-93/95-96 (SVM)
(SVM) 337 nm ex
375-700 nm em
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Source Sens./Spec. ROC- Diagnostic Healthy Lesions: Details
[%] AUC Method: Tissue: # Spectra
Comparison Fl. Ex # Spectra (# Pts.)
Fl. Em (# people) Path.
53 (15 Pts)Muller M et al., NADH, collagen 38 (15 HVs) 2253 (15 Pts) Used TMS
2003 contribution +91.2 / 96.4* logistic 19 Dys
Nml/Be vs. Dys/ Ca all sites logistic 12 Ca
regression
94.4 / 96.6* 337, 358 nm ex
nonker sites 350-650 nm em
Dys vs. Ca 67.9 / 85.7
all sites
72.7 / 90.0
nonker sites
33( 12 Pts)Gillenwater et al., Fluor. ratio 95 (8 HVs) after Did not perform cross-
1998 337 nm ex exclusions validation
Nml vs. LesionsNm vs. Lesions 635 nm em/(455-(unspecified) 82 / 100 490 nm em490 nm) em
104
Tsai et al., 2003 --- 330 nm ex 20 Ca Only buccal mucosa
lesions in study dataBe vs. Dys/Ca 81 / 87 480/360 nm em 27 Dys
ratio 57 Be Did not perform cross-
validation
115 (155de Veld et al., 2005 DRS, Fl, PCA, 581 (70 HVs) Pts.) Excluded sites where
NN, multiple 88 Be diagnosis clearNml vs. Ca 94/94 0.98 classifiers 88 Be
Nmclassifiers 11 Dys 11 anatomic sites,Nml vs. Be/Dys/Ca 83 / 86 0.90 366-450 nm ex 16 Ca excluded lip, DT
Be vs. Dys/Ca 
._. <0.70 455-867 nm em
Calibration:Mallia et al., 2008. Fluor. ratio: 35 (35 HVs) 36 (20 Pts) Excluded vermillion
500/685nm em border lip, LT, DTNml vs. Be 100/100 m em Calibration: 18 Ca border lip, LT, DT
(hyperplastic) 404 nm ex 4 Nml (4 Pts) 9 Dys (algorithm did not work)
9 Be Biopsies taken only forBe vs. Dys 100/100 420-720 nm em Validation:
__. portion of measured
Dys vs. Ca 100/100 4 Nml (4 Pts) Validation: area
--- 21 (17 Pts)
6 Ca Did not perform cross-
5 Dys validation
7 Be
Table 6.10 Summary of in vivo spectroscopic studies of the oral cavity in which diagnostic performance was
evaluated using either sensitivity, specificity, and/or ROC-AUC. Nml: normal, NN: neural network, Pts: patients,
Be: benign, Dys: dysplastic, em: emission, ex: excitation HVs: healthy volunteers, PCA: principal component
analysis
Further improvement in the diagnostic algorithms for distinguishing benign
lesions from dysplastic/malignant lesions may be possible with a larger data set. For
this comparison the log likelihood ratio test identified very few parameters as
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statistically significant in the diagnostic model and higher p-values were obtained
when comparing the means between spectral parameters for these two classes, thus
indicating low spectral contrast. The heterogeneity of the lesions within each class
also contributes to the challenge of separating the two groups. For example, some
malignant lesions had small foci of invasion in a large area of relatively normal
epithelium, while others demonstrated more diffuse disease throughout the entire
specimen.
6.3.6 Application of Spectral Algorithms in Clinical Practice
Because of the low prevalence of oral cancer even among smokers, a
spectroscopic screening tool would be beneficial if it demonstrated a reasonably high
NPV (Section 4.3.3), and provided a quick, and easy means of isolating those at high
risk for disease. The high NPV is important because most of the population which is
screened will be negative for disease and the test should not frequently indicate the
need for further evaluation unnecessarily. If a patient tested positive, they could then
be referred to an otolaryngologist for further evaluation (a more thorough oral exam,
biopsy, etc.)21-23. As another possible application, we can consider using the spectral
diagnostic methods to distinguish benign lesions from dysplastic/malignant lesions in
the setting of a patient presenting with a previously identified suspicious lesion.
If we consider leukoplakia only, (as the prevalence of erythroplakia is <1%),
one study of 3256 leukoplakias found that 42.9% of biopsied FM lesions and 24.2%
of tongue lesions showed dysplasia/malignancy9 . The percentage of the 3256 cases of
leukoplakia which were located at these sites was 6.8% and 8.6%, respectively. Given
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that our most successful diagnostic algorithms represent a combination of the tongue
and FM (LT and FMNT), if we consider 1000 patients with leukoplakia of the
tongue/FM, a total of 442 FM cases and 558 tongue cases would be expected based
on the relative frequency of leukoplakia at these two sites. Of the 1000 cases, 32.5%
would be expected to show dysplasia/malignancy (42.9% of FM lesions and 24.2%
tongue lesions). Given that our sensitivities and specificities for the LT and FM/VT
sites are similar, we use the average values of 93.2% and 63.3% as the sensitivity and
specificity, respectively, of our spectral diagnostic test. Based on these values and the
aforementioned prevalence estimates for diseased lesions, we can calculate the PPV
and NPV (Section 4.3.3) for our test: 55.0% and 95.0%, respectively. These results
indicate that the spectral diagnostic algorithms would be useful in distinguishing
lesions that do not require biopsy (or further evaluation) from those that do.
Therefore, spectroscopy, may serve to reduce the number of unnecessary biopsies for
patients presenting with suspicious lesions. Spectroscopy could be used as a rapid
screening tool to indicate whether a person being seen by a dentist needs further
evaluation.
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6.4 Conclusions
The goal of this work was to use physical parameters derived from reflectance
and fluorescence spectra to create spectral diagnostic algorithms for two types of
applications. The first algorithms were designed to distinguish visible lesions from
visibly healthy mucosa. The second set was designed to distinguish benign lesions
from dysplastic/malignant lesions. The data and findings from the HV study were
incorporated into the analysis and used to address the spectral variations due to
anatomy. Based on the spectral parameters we extracted from healthy volunteers, the
following groups of sites were identified as the most spectrally similar: 1) BM and
SP, 2) FM and VT, 3) DT and RT, and GI and HP.
Distinctions between clinically normal and clinically abnormal tissue areas
can easily be distinguished based on spectral parameters, particularly for algorithms
developed from and applied to individual sites or spectrally similar sites. In addition,
the distinction between healthy mucosa and visible lesions is independent of the
presence of disease. This was shown by the fact that the results for healthy mucosa
versus benign lesions were comparable to those for healthy mucosa versus
dysplastic/malignant lesions.
The more clinically relevant separation of determining whether a clinically
abnormal site is benign or dysplastic/malignant, was considerably more challenging.
Just as for the first type of comparison, diagnostic algorithms for distinguishing
benign lesions from dysplastic/malignant lesions were generally more successful
when developed for a specific anatomic site or group of spectrally similar sites.
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We have demonstrated that the spectral differences among anatomic sites can
impact the performance of both types of diagnostic algorithms and presented a
strategy for overcoming this limitation based on the concept of spectrally similar
sites. Furthermore, we demonstrate that comparisons between healthy mucosa and
lesions are not a reliable means of assessing the potential of spectroscopy to
distinguish benign from dysplastic/malignant lesions because the diagnostic
parameters are almost completely different for the two types of comparisons. These
results emphasize the need to treat clinically abnormal and clinically normal mucosa
as separate entities and to develop separate diagnostic algorithms for each case. Our
results indicate the spectral diagnostic algorithms which we have developed and
applied to specific sites can reduce the number of unnecessary biopsies, and thus
serve as a screening tool, and test for ruling out the need for biopsy when a patient
presents with a suspicious lesion in the clinic.
Future work should focus on high risk sites for oral cancer, such as the tongue
(especially LT and VT), floor of the mouth, and soft palate. Since lesions are most
likely to be encountered at these sites, successful diagnostic algorithms developed
specifically for these sites may provide a significant clinical benefit.
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CHAPTER 7
Discussion and Conclusions
In this chapter, we begin by discussing our progress towards the initial goals, and
conclude with a statement on the major achievements of this work.
173
CHAPTER 7: Discussion and Conclusions
7.1 Accomplishments of this Thesis
The goal of this project was to use reflectance and fluorescence spectroscopy
to non-invasively and quantitatively identify pre-cancerous or cancerous changes in
the oral cavity. In Chapter 1 we presented the four objectives for the investigation,
which were as follows:
1) To advance the instrumentation for spectral data collection
2) To develop spectral models for the accurate modeling of reflectance and
fluorescence spectra from oral tissue and the reliable extraction of
parameters relating to tissue morphology and biochemistry
3) To collect in vivo reflectance and fluorescence spectra from healthy oral
tissue in healthy volunteers, and relate the extracted physical parameters to
tissue anatomy
4) To collect in vivo reflectance and fluorescence spectra from patients with
lesions and develop spectral diagnostic algorithms for identifying and
categorizing oral lesions
Here we discuss our accomplishments and progress towards these objectives.
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7.1.1 Advances in Instrumentation
In Chapter 4 we described the advances in instrumentation made as a result of
the elucidation of the source of an artifact in the measured reflectance. Through a
series of experiments with phantoms we identified second order light as the cause of
an increase in the reflectance measured by the instrument at longer wavelengths
(>-550 nm) as a result of a change to grade UV optics. A method to correct the
artifact was then developed which permitted data previously collected to be recover.
Furthermore, we were able to implement a change in the FastEEM hardware to ensure
accurate detection of future data, by collecting an unfiltered and filtered reflectance
spectrum during each set of measurements.
7.1.2 Spectral Model Development
There were several additions to the basic models developed by our laboratory
to model the reflectance and fluorescence spectra. One of the critical improvements in
the application of the reflectance model, was to take vessel packaging into account
when fitting the hemoglobin absorption features. Before this addition, significant
deviations between the data and modeled fit were frequently noted. This addition also
provided the extraction of a new reflectance parameter, the effective vessel radius.
Before this work, optical spectroscopic studies performed by our laboratory
and by other investigators had not recognized 1-carotene as a significant absorber in
oral tissue. The discovery of this new absorber was the second major improvement in
our modeling of the reflectance data. This finding was made in large part because of
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the large data sets collected and analyzed in the present work. Whereas small
deviations in the quality of the fit that appear in smaller data sets may not be fully
appreciated, the systematic nature of these differences can become evident over the
course of examining hundreds of spectra. In a similar manner, we discovered that the
fluorescence spectra collected at 340 nm excitation was best modeled as a
combination of three fluorophores rather than two. This permitted accurate modeling
of the fluorescence emission at this excitation for all the samples. We attribute the
two absorbers to two different types of collagens.
7.1.3 In Vivo Collection of Spectral Data from Healthy Volunteers
Oral tissue exhibits a range of architectural characteristics among the various
anatomic sites. One notable example is that while most of the oral cavity is non-
keratinized, the GI, HP and some regions of the DT are keratinized. Other key
differences include the thickness of the epithelium (i.e. BM>>FM), the composition
of the submucosa (i.e. bone, muscle), the density and size of the vessels, as well as
the presence of other unique features such as glands (i.e. BM,HP,SP) and papillae
(DT). We expect these variations to also be reflected in the spectral information we
collect from the tissue.
In the healthy volunteer study we used reflectance and fluorescence
spectroscopy to identify and characterize 9 different anatomic sites in the oral cavity.
The morphological and biochemical information provided by the extracted spectral
parameters were then related to the physical properties of the tissue. For the majority
of the spectral parameters, certain sites or groups of sites were observed to exhibit
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distinct values from one another. K-means clustering analysis was performed to
identify sites or groups of sites which showed similar features and revealed that sites
which are normally keratinized, most notably the hard palate and gingiva, were
distinct from non-keratinized sites for most parameters and clustered together. We
also tested whether the 95% confidence interval for the distribution of each
parameter, extracted from a subset of the normal tissue data, could correctly
characterize a second validation data set. Excellent classification accuracy was
demonstrated. Our results revealed that intrinsic differences among sites exist.
Furthermore, differences in anatomy are reflected in the extracted spectral
parameters, and can produce separations among sites. The results of the study
provided strong evidence that a robust and accurate spectroscopic-based diagnostic
algorithm for oral cancer will need to be applied in a site specific manner to improve
the diagnostic capability, and to ensure accurate evaluation of malignancy while
avoid the confounding effects of anatomic properties.
7.1.4 In Vivo Collection of Spectral Data from Patients
The goal of the patient study was to develop spectroscopic diagnostic
algorithms with which we can non-invasively distinguish healthy mucosa from
lesions (clinically abnormal mucosa), and benign lesions from dysplastic/malignant
lesions. Furthermore, we tested the concept of developing and applying the diagnostic
algorithms specifically for spectrally similar sites, and to compare the performance.
We compared the performance of the algorithms using this approach to that obtained
when all sites were combined, or only individual sites were examined.
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Our findings demonstrated clear spectral differences between clinically
normal tissue and lesions. For this comparison, the ROC-AUC values were highest
(>0.90) for diagnostic algorithms developed and applied either to a single anatomic
site or to spectrally similar sites. Spectral diagnostic algorithms developed to
distinguish between benign lesions and dysplastic/malignant lesions were not as
successful, as for comparisons between healthy mucosa and lesions. ROC-AUC
values between 0.60 and 0.75 were obtained. The most successful algorithms were
developed for the LT and the combination of the FM and VT. Furthermore, the
diagnostic parameters for this comparison were substantially different from those
used to distinguish healthy mucosa from lesions.
Once again, anatomy had a strong impact on the results of the analysis. We
demonstrated that the spectral differences among anatomic sites can impact the
performance of both types of diagnostic algorithms. From the data we conclude that
the approach of developing and applying spectral diagnostic algorithms to individual
or spectrally similar sites improves diagnostic performance, while overcoming the
challenge of limited sample numbers.
7.2 Conclusions
In this thesis we have presented our investigation on the use of reflectance and
fluorescence spectroscopy for the detection of oral dysplasia/malignancy. Our goal
was to use these non-invasive techniques to evaluate both the structural and
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biochemical properties of the tissue and to identify a spectroscopic "signature" for
dysplasia/malignancy.
In this investigation we have taken preliminary steps towards this goal by
examining the impact of tissue anatomy and exploring the optimal means of
diagnostic algorithm development. We have investigated the impact of tissue
anatomy for 9 sites in the oral cavity and have fully characterized the spectral profile
of these sites. We can successfully distinguish healthy mucosa from clinically
abnormal mucosa using the spectral parameters. Finally, we have successfully created
diagnostic algorithms to distinguish benign lesions from dsyplastic/malignant lesions
for the LT, and the FM/VT.
This work has highlighted the complexity and challenges of using
spectroscopic approaches to identify pathology in the oral cavity as a result of the
innate heterogeneity in the anatomy of this site and we have suggested some
approaches for how to realize a successful diagnostic technology. Nevertheless, the
findings we have presented show significant progress towards this goal, and serve as
an important guide for how to realize a successful spectral diagnostic technology.
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CHAPTER 8
Future Directions
In this final chapter of the thesis, we propose some future directions for subsequent
investigations on the spectroscopic detection of oral cancer.
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8.1 Future Directions
8.1.1 Clinical Studies
Based on the results presented in this thesis, the next step in this project would
be to test the diagnostic algorithms developed for specific sites in Chapter 6
prospectively in a large scale clinical study. We could test the ability of spectroscopy
to indicate whether a biopsy is not needed (benign lesion), when a patient presents
with a suspicious lesion, thus reducing the number of unnecessary biopsies.
In addition to evaluating visible lesions, the margins of excised lesions could
also be assessed for invisible disease, by comparing the parameters extracted to those
obtained for healthy mucosa (HV data). Another database of spectral data and
correlated biopsies collected from clinically normal mucosa with benign, dysplastic,
or malignant changes according to pathology would be needed to create spectral
diagnostic algorithms to distinguish benign from dysplastic/malignant lesions.
Evaluating the margins of excised lesions for invisible disease can also be performed
efficiently for a large area of tissue using a wide-scale imaging device, as described in
Section 8.1.3.
We may further improve upon the work described here by including
additional excitation wavelengths, developing a normalization procedure to reduce
inter-patient variability, such as normalizing data by the contralateral site in the
patient, and developing the software to enable real-time diagnosis.
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8.1.2 Probe Design
The diffuse reflectance and fluorescence spectra measured by the FastEEM
reflect not only the tissue architecture and biochemistry, but a number of other
factors. In particular, since the excitation light is delivered and collected via an
optical fiber, the measured signal is impacted by the geometry of the delivery and
collection fibers"12, including the numerical aperture (NA), diameter of the fibers,
spacing between the delivery and collection fibers, and collection efficiency3. A
number of probe designs have been explored in order to optimize the collection of
light returning from a specific depth within the tissue or differentiate the signal
returned from various layers4-9. Common approaches include varying the separation
between the source and detector fibers and using an angled delivery/collection fiber.
One can then isolate light emitted from the structures/regions of interest, or from
layers (e.g. epithelial layer, stroma) in which the contrast in the spectral signal
between normal and malignant tissue is greatest, leading to a enhanced sensitivity to
disease-related changes. The work presented in this thesis was carried out using a
single probe design. It is possible that with some of the modifications described
above, we may be able to enhance our sensitivity to disease, and even filter out the
effect of keratin.
8.1.3 Quantitative Spectroscopy Imaging (QSI) Instrument
Despite the detailed information and relative technical simplicity of the point
probe technology, an imaging device offers several advantages for the detection of
early disease: 1) A wide area of tissue can be inspected including both lesions and
182
CHAPTER 8: Future Directions
margins of excised lesions 2) It would facilitate the clinician's ability to monitor a
particular site for disease development with time, thus avoiding the need for
unnecessary biopsies 3) Variability introduced into the measured signal due to the
effect of probe pressure is no longer an issue.
A non-contact wide-scale imaging device, known as the quantitative
spectroscopy imaging (QSI) instrument, has been designed for early cancer detection
in the oral cavity and cervix. The instrument was designed based on the concept of a
"virtual probe", in which 1 mm spots of the excitation light are raster scanned along
an approximately 2 cm by 2 cm area of tissue. Figure 8.1 shows examples of
parameter maps for 1 cm by 1cm area of tissue obtained after applying the spectral
A
High Figure 8.1 Examples of parameter mapsgenerated from modeling data collected by
the QSI instrument from an oral lesion on
the ventral surface of the tongue. The units
are shown in millimeters (a) A map of the
A parameter (b) A map of the ratio of
collagen to NADH (reduced nicotinamide
adenine dinucleotide)
2 4 6 1 10 [1
CCOICMDfI
Low
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models to in vivo image data collected from an area of leukoplakia on the ventral
surface of the tongue. Each spot is analogous to a single measurement collected by an
optical fiber probe, therefore the knowledge and experience gained from the FastEEM
clinical instrument and the DRS and IFS modeling strategies can be applied to the
analysis of the measured data.
The first generation instrument is currently being re-designed as an
endoscopic system based on an imaging fiber bundle. The fiber bundle could be
advanced through the accessory channel of an endoscope and additional sites along
the upper aerodigestive tract, including the pharynx and larynx, are accessible to
examination.
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List of Abbreviations
a Oxygen saturation
SExtinction coefficient
AUC Area under the curve
BM Buccal mucosa
BT Base of the tongue
cpC Concentration of P-carotene
cHb Concentration of hemoglobin
C.I. Confidence interval
CIS Cancer in situ
CRM Confocal reflectance microscopy
DRS Diffuse reflectance spectroscopy
DT Dorsal surface of the tongue
FAD Flavin adenine dinucleotide
FastEEM Fast excitation emission matrix
FM Floor of the mouth
FWHM Full width at half-maximum
GI Gingiva
Hb Deoxyhemoglobin
HbO 2  Oxyhemoglobin
H&E Hemotoxylin and eosin
HP Hard palate
HV Healthy volunteer
IFS Intrinsic fluorescence spectroscopy
IL Lips
IQR Interquartile range
LCV Leave-one-out cross-validation
LLR Log-likelihood ratio test
LSS Light scattering spectroscopy
LT Lateral surface of the tongue
LX Larynx
MCR Multivariate curve resolution
MLE Maximum likelihood estimation
MPM Multi-photon microscopy
NA Numerical aperture
NADH Nicotinamide adenine dinucleotide (reduced)
NPV Negative predictive value
PCA Principal component analysis
PPIX Protoporphyrin IX
PPV Positive predictive value
ROC Receiver operator characteristic
RSD Relative standard deviation
RT Retromolar trigone
SCC Squamous cell carcinoma
SNR Signal-to-noise ratio
SP Soft palate
TL Tonsils
TMS Tri-modal spectroscopy
VT Ventral surface of the tongue
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